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ABSTRACT 
Since the chance discovery, in 1967, of the anti-tumour activity of cisplatin, 
cis-dichlorodiammineplatinum(ll), research has focussed on studying the reactions of 
this and other related complexes in an effort to elucidate the nature of the biological 
activity. This thesis presents a study of the aqueous solution chemistry of some 
platinum(ll) and platinum(N) complexes in order to extend what is known about the 
simple chemistry of this biologically important class of compounds. 
The chloride ion anation of diaqua (cis-[Pt(OH2) 2(N)2f+) complexes is 
investigated as is the bromide ion anation of the bromoaqua (cis-[PtBr(OH2)(Nht) 
and diaqua (cis-[Pt(OH2) 2(N)2] 2+) species, all in 1.0 M HC104. The kinetics are 
studied using UV/Vis spectroscopic methods- both conventional and stopped-flow. 
High-pressure stopped-flow is used for selected reactions to determine the effect of 
pressure on the anation process. The collective data are used to calculate activation 
parameters from which conclusions are drawn as to the mechanism of the reaction. 
The redox kinetics of the platinum(ll)/platinum(N) couple are investigated 
using a variety of redox agents. These data provide a basis on which to form 
mechanistic interpretations for both the oxidation and reduction processes. 
Extrapolations are made to the biological system for the reduction of anti-tumour 
active platinum(N) drugs. 
Platinum(N) complexes are known to be very inert. An investigation into the 
base hydrolysis of platinurn(N) complexes is presented and a mechanism proposed. 
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CHAPTERl 
INTRODUCTION 
1.1 INTRODUCTION 
The discovery, in 1965, that a platinum coordination complex, cis-
diamminedichloro-platinum(II) (cisplatin, cis-DDP), was an anti-tumour agent led to 
a resurgence of interest into the chemistry of platinum complexes. Cisplatin is 
currently one of the most widely used anti-cancer drugs in the USA with 30,000 
patients undergoing successful treatment each year [1]. It is used mainly for treating 
testicular and ovarian cancer but tumours of the bladder, head, neck and lungs are 
also sensitive to treatment [2 - 3]. The advent of cisplatin has increased the long 
term survival rate (defined as the cancer not returning within 5 years) for men 
suffering from testicular cancer to greater than 85% [4]. 
0 
H3N"" /Cl 
OAc 
H3N"" /0 H3N"-._ I /Cl 
Pt Pt o- Pt 
H3N/ "'Cl H3N/ "b N/ I ~Cl Hz OAc 
0 
cisplatin carboplatin JM-216 
Figure 1.1: Platinum-based anticancer drugs. 
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1.2 DISCOVERY OF CISPLATIN 
The first indication that platinum-based coordination compounds could be 
used in cancer chemotherapy came from a chance discovery by Barnett Rosenberg in 
1965 [5]. He was investigating the effects of an electric field on growth processes in 
bacteria, specifically Escherichia coli, by passing an electric current through 
platinum electrodes immersed in a nutrient medium consisting of NH4Cl, Na2HP04, 
KH2P04, NaCl, MgCh and Na2S04 ('C' medium). As a result, bacteria formed long 
filaments up to 300 times their normal size implying that although cell growth was 
not affected, cell division was inhibited. Further experiments showed that it was not 
the current causing bacterial elongation, but rather a new long-lived chemical species 
produced when the 'inert' platinum electrode dissolved electrolytically in the nutrient 
medium [6]. Analysis of the solution showed that the platinum species formed in 
solution was [PtC16f which acting as a bactericide, inhibited cell growth at 
concentrations of 10 ppm. It was later observed by van Camp that aged solutions of 
(NH4)z[PtC16] (2 - 3 days old) produced filamentous bacteria at very low platinum 
concentrations [7]. Further investigation showed that the platinum-containing 
components in solution could undergo a photochemical reaction to produce 
[PtCls(NH3)r. This species neither affected cell growth nor cell division but it 
readily converted to the more stable neutral [PtC14(NH3)2] complex, which was a 
potent inhibitor of cell division whilst having little effect on bacterial growth [7]. 
This platinum(IV) compound exists in two isomeric forms, cis- and trans-
[PtCl4(NH3)z], but testing of the two isomers showed that while the cis form had 
biological activity, the trans form had little effect on cell division. At the same time 
the corresponding platinum(II) complexes were synthesised and again, the cis form 
was active and the trans form inactive. These platinum(ll) species are produced, in 
small quantities, from the spontaneous thermal reduction of the corresponding 
[PtCl4(NH3)z] isomers [8]. 
Another aspect of the bacterial activity was reported by Reslova et al [9]. 
They found that lysogenic strains of E. coli can be induced by the platinum 
compounds, to develop partial or complete viruses leading to destruction (lysis) of 
the cell. This effect can also be caused by other agents such as UV, X-rays and 
chemicals such as nitrogen mustards and other anti-tumour agents [10]. 
3 
It was subsequently suggested that these platinum compounds be tested for 
anti-tumour activity due to their ability to inhibit cell division but not cell growth. 
This suggestion was further reinforced by the fact that other anti-tumour agents, 
including alkylating agents and actinomycin D, were also observed to cause 
elongation and lysis in lysogenic bacteria [8]. Initially four compounds were tested 
against Sarcoma 180 in the ICR strain of mice: cis-[Ptrv Cl4(NH3)2], 
cis-[PtnC}z(NH3)z], [PtnC}z(en)] and [PtrvC14(en)]. All four were found to be 
effective in inhibiting tumour growth [11] but the corresponding trans isomers were 
ineffective, as predicted by the bacteriological results. Further testing showed cis-
[PtnC}z(NH3)z] to be the most potent of the four complexes tested initially [12] and it 
was submitted (1971) for subsequent screening to the National Cancer Institute of 
America. 
Cis-[PtC}z(NH3) 2], cis-diamminedichloroplatinum(II), cisplatin or cis-DDP, 
was not a new compound. It had been first synthesised in 1845 and was known as 
'Peyrones Chloride' [13]. The existence of the cis and trans isomers had been 
established by Werner in 1890 [14] and the crystal structure of the cis isomer was 
determined by Milburn in 1966 [ 15]. 
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Phase 1 clinical trials of cisplatin began in 1971 [2] and despite having a 
broad range of toxic side-effects it showed marked activity against advanced 
testicular and ovarian cancer [16]. The dose-limiting side-effect was nephrotoxicity 
but patients also experienced very intense nausea and vomiting. In addition to these, 
loss of hearing and neurotoxicity were also observed in some patients. In 1973 
doubts were expressed as to whether cisplatin would ever be used as an anti-tumour 
agent due to its extreme toxicity [17]. A major breakthrough came in 1977 with the 
technique of hydrating the patient before and after treatment using D-mannitol, an 
osmotic diuretic agent [18]. This minimised the concentration of the complex in the 
kidneys and allowed higher doses to be given (up to 300 % greater) while decreasing 
the kidney toxicity. Other advances came by introducing anti-emetics such as S-HT3 
antagonists to reduce the intense nausea and vomiting [17] and by infusing the drug 
slowly over 6- 8 hours to keep the concentration of cisplatin in the kidneys to a 
minimum [19]. 
During this same period in the 1970's, studies showed that when cisplatin 
was combined with other anti-tumour agents a substantial improvement in the 
effectiveness of the treatment was seen [20- 21]. Two such drugs are bleomycin and 
vinblastine. These combinations proved extremely successful in treating cancers of 
the genito-urinary type (testicular and ovarian) [19, 22] and marketing approval for 
cisplatin was obtained in the USA for its sale under the trade name 'Platinol' in 
1978. International registration of the drug followed with approval in the UK in 
1978 and in Japan in 1984 [17]. 
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1.3 DEVELOPMENT OF PLATINUM-BASED ANALOGUES 
Although cisplatin was seen as a 'wonder drug' it had limitations due mainly 
to its side-effects. It was also not effective in the treatment of colorectal (bowel) and 
breast tumours - two of the most prevalent types of cancer. This lead to a search for 
platinum-based analogues with similar or better clinical activity and lower toxicity, 
as well as a broader spectrum of activity. Many thousands of platinum(ll) and 
platinum(IV) compounds have been synthesised and tested for anti-tumour activity 
and from this certain structural requirements were elucidated in the 1970's [23 - 26]. 
• The complex should be electrically neutral even though the active form may 
be charged after undergoing ligand-exchange processes. The drug must be 
neutral in order to pass across biological membranes [9]. Charged species 
may also be quite toxic [27]. 
• Two cis monodentate leaving groups are required. 
• The leaving groups, usually anions, should have groups with intermediate 
binding strength to platinum(II) (eg. chloride). Labile complexes will react 
too rapidly and indiscriminately thus preventing the drug from reaching the 
tumour site. Inert complexes will not react significantly enough to elicit a 
response. 
• The amine ligands, either monodentate ( eg. NH3) or bidentate 
(eg. ethylenediamine) should have a cis configuration, be relatively inert and 
have at least one N-H group. All complexes tested not containing this 
functionality were inactive [4, 28] and it is thought that this N-H moiety may 
be important in the interaction of cisplatin with DNA. 
Most of the initial platinum complexes that have proven to be anti-tumour 
active have had platinum in the +II oxidation state. However, Tobe et al 
found that the oxidation state was not critical [29] and indeed, the initial 
platinum complex found to be active was cis-[Pt1vC14(NH3) 2] [7]. 
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These requirements hold in many cases but, as with most things, there are exceptions 
to the rules and so the above criteria need not be valid for every platinum drug 
available. Indeed, the more recent analogues defy all the structure-activity 
relationships with trans drugs showing activity when platinum is coordinated to a 
large ligand eg. pyridine. However, these drugs may interact with DNA in a 
different manner to cisplatin [118]. 
There are also certain requirements that were thought necessary in the design 
of new anti-tumour drugs in order to improve their efficiency. 
• Activity in tumours that are resistant to cisplatin and improved activity in 
cancers that respond to cisplatin. 
• Reduced toxicity, and treatable side-effects. 
• Improved physical properties such as greater aqueous solubility, 
solution stability and longer lasting action. 
The development of these structure-activity relationships resulted in the 
synthesis of an extraordinary number of platinum compounds all of which were 
tested for their anti-tumour activity. From the complexes tested, 23 were found to be 
suitable for clinical trials. Only one of these second-generation platinum drugs, 
carboplatin, is now being routinely used for treatment of tumours [ 17]. 
Carboplatin, 1, 1-cyclobutanedicarboxylatodiammineplatinum(ll) (Figure 
1.1 ), has a similar clinical activity to cisplatin with minimal toxicity to the kidneys, 
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hearing, nervous and gastrointestinal systems. The dose-limiting feature of 
carboplatin is myelosuppression (suppression of bone marrow production) which can 
be muted using haematopoietic growth factors. These growth factors promote the 
production of the white blood cells necessary for the immune system to function. 
The slower hydrolysis of the cyclobutanedicarboxylate ligand results in the lower 
toxicity of carboplatin [21, 30, 145]. Car bop latin is limited in that it shows cross-
resistance with cisplatin and thus it also has a limited spectrum of cancers against 
which it is active. 
Further analogues of cisplatin currently under clinical testing fall into two 
main categories. Firstly there are the 1,2-diaminocyclohexane (dach, chxn) 
derivatives (ormaplatin, tetraplatin, oxaliplatin, L-NDDP) whose development has 
been based on their non-cross-resistance in cisplatin resistant murine leukemias. The 
second category is carboplatin analogues (zeniplatin, enloplatin, lobaplatin) with 
either cyclobutanecarboxylate or other oxygen-containing leaving groups [31]. 
Burchenal et al [32- 33] originally observed that a series of analogues 
containing a diaminocyclohexane moiety had activity against a cisplatin-resistant cell 
line. They found that the in vitro activity of these chxn derivatives was independent 
of the leaving group. Ormaplatin [21] is a 1,2-chxn complex that is of interest due to 
its broad spectrum of activity and ability to overcome cisplatin resistance. It has 
associated with it strong neurotoxicity which may be overcome by use of agents such 
as Org-2766, a protectant against cisplatin neurotoxicity. 
Tetraplatin (Figure 1.2) is a racemic mixture of [PtC14 { (±)-trans-chxn}]. 
This platinum(IV) complex is rapidly reduced in tissue cultures and in vivo to the 
platinum(II) species [PtC}z { (±)-trans-chxn}] [34]. Tetraplatin has a similar spectrum 
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of activity to cisplatin with the exception of the lack of cross-resistance to the L1210 
and P388 leukemias. Emesis and myelosuppression have been reported but these 
are less severe. Hydration therapy must still be used and the main side-effect appears 
to be peripheral sensory neuropathy. 
tetraplatin iproplatin 
0 
H2 0 H2 QN'- /0 HOXN 0 ""-/ Pt Pt /""" /""" N 0 HO NH2 0 
H2 0 
0 
oxaliplatin zeniplatin 
H QN~+~rl /Pt o-c-T-R 2 N R" 
H2 
NDDP 
Figure 1.2: Platinum anti-cancer drug analogues. 
Oxaliplatin was first synthesised in 1978 and has an oxygen-containing 
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leaving group in the form of oxalate, while the other coordination sites contain 1,2-
chxn. Although active in many murine tumours including cisplatin-resistant lines, 
this drug causes severe emesis and neurological problems. Some patients 
experienced acute paralysis of the extremities and lips beginning during the treatment 
and continuing for several days. Severe nausea was experienced by 50 % of those 
treated. Symptoms regressed over a six-month period with no permanent 
neurological damage. It has now been registered for use as a chemotherapeutic agent 
in France [35] with positive results. 
It was thought that these chxn complexes would overtake cisplatin as perfect 
candidates for new improved drugs overcoming the cross-resistance problem with 
cisplatin and carboplatin. However, Phase I and II clinical trials have shown that 
chemical instability, poor solubility and high toxicity limited their clinical potential. 
An alternative approach in using these compounds has been to entrap them in 
liposomes [36] eg. L-NDDP (liposome-entrapped cis-bis-neodecanato-trans-R,R-
1 ,2-diaminocyclohexane platinum(II) ). Entrapment lowers toxicity by reducing the 
bioavailability of the platinum drug and thus allowing use of complexes containing 
the non-cross-resistant chxn group [21]. It can also facilitate the use of drugs with 
poor solubility such as the above cyclohexanediamines. However, continuing drug 
instability and poor entrapment efficiency has hampered development. 
The second category of analogues was based on carboplatin. It was thought 
that the oxygen-containing leaving group would provide both good water solubility 
and stability. Zeniplatin was more active than cisplatin but showed cross-resistance 
to many cell lines. It also gave rise to severe emesis, neurotoxicity and 
nephrotoxicity, with one patient dying of acute renal failure. Enloplatin gave a 
similar spectrum of effects to zeniplatin. These are not favourable and therefore no 
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therapeutic advantage is found over cisplatin and carboplatin. 
Another cisplatin analogue entered into clinical trials was iproplatin (CHIP, 
JM-9) (Figure 1.2) [21, 30] (cis, trans, cis-[PtrvCh(OH)z(C3H7NH2) 2]) which has the 
platinum in the +IV oxidation state. Randomised clinical trials showed that 
compared to carboplatin it offers no advantages in terms of either reduced toxicity or 
improved activity. It was not active in tumours that displayed resistance to cisplatin 
and carboplatin and it caused more severe gastrointestinal and haematological 
toxicity. 
Most of the platinum drug discovery initiatives focused on circumventing 
cisplatin resistance. Research showed that there were no other drugs offering 
improvements over cisplatin and carboplatin. Work therefore began to identify a 
platinum complex that would produce a different array of adducts on DNA, thereby 
overcoming the problem of resistance. It was also noted that an orally active drug 
would be clinically advantageous with no hospitalisation required. This is important 
for the psychological well-being of the patient and also reduces financial costs. The 
third generation platinum complexes were developed to improve upon these ideas 
[31, 36]. 
JM-216 (bisacetatoamminedichlorocyclohexylamineplatinum(IV)) (Figure 
1.1) [21, 37] entered clinical trials in 1992. It shows activity in cell lines resistant to 
cisplatin and carboplatin with a substantial amount being absorbed after oral 
administration. The toxicity of this complex is mainly limited to delayed-onset 
vomiting and minimal thrombocytopenia. No nephrotoxicity or neurotoxicity have 
been seen. This drug has the platinum in oxidation state +IV and in a similar fashion 
to other platinum(IV) drugs [38], it will probably be reduced in vivo to produce the 
corresponding platinum(II) complex. 
Despite the lack of success in finding a new improved platinum anti-cancer 
drug, research is continuing to find a non-toxic drug that is orally active and non-
cross resistant with cisplatin. 
1.4 RESISTANCE TO CISPLATIN 
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Although the discovery of cisplatin was serendipitous, drug resistance is now 
proving to be a major impediment to the clinical success of the drug. Resistance may 
either be intrinsic (present at the onset of treatment) or acquired during successive 
treatments after an initial response to the drug. The quest to overcome this 
resistance, whether inherent or induced, has become the basis for a large proportion 
of research into platinum drug therapy [39- 41]. 
There are three possible mechanisms for cellular resistance. The first is 
reduced drug accumulation in the cell. The mechanism for the transport of cisplatin 
into the cell is not well understood but it is most likely to be a combination of passive 
diffusion across the cell membrane and an energy-dependent gated channel. This 
may include Ca2+-dependent protein kinase activity, cyclic AMP-dependent activity 
and Na+, K+-ATPase activity. The Na+, K+-ATPase inhibitor ouabain reduces 
accumulation of cisplatin in cells which can induce resistance to cisplatin. This also 
indicates that Na+, K+-ATPase plays a role in the delivery of cisplatin from the 
plasma into the cell. Any modifications of these mechanisms or changes in the cell 
membrane may result in reduced drug influx. 
A second resistance mechanism involves induction of increased cellular 
levels of GSH (y-glutamyl-cysteinyl-glycine). This reacts chemically with cisplatin 
via the free thiol group. It may either (i) form an inactive conjugate; (ii) react with 
Pt-DNA mono-adducts to prevent cross-linking to adjacent purines; or (iii) assist 
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enzymes that repair cisplatin-induced DNA damage. Metallothionein is a family of 
cysteine-rich proteins that bind strongly to heavy metals. It binds to cisplatin both 
intra- and extracellularly and can scavenge cisplatin even more efficiently than GSH. 
High levels of metallothionein have been observed in testicular tumours that are 
resistant to cisplatin [ 41]. 
A third possibility is an increase in the cellular capacity to repair or remove 
cisplatin-DNA adducts. This may be induced by platinum exposure, with patients on 
long courses of cisplatin treatment developing resistance to the drug. Several 
preliminary studies investigating tumour tissue have supported the theory that an 
increase in DNA repair is the key feature of cisplatin resistance [36]. Patients treated 
with cisplatin had an inverse relationship between clinical response and levels of 
repair in the leukocytes [36]. This means that the higher the response to the drug the 
lower the level of repair. Another experiment showed a three-fold increase in DNA 
repair following failed treatment with cisplatin when compared to the repair level 
before treatment [36]. 
It is now known that HMG-domain proteins can recognise DNA structural 
elements such as the bends in cisplatin-modified DNA. Models have been proposed 
to explain the association of the proteins with cisplatin-resistant DNA. Two of these 
models propose that they influence the repair of cisplatin-DNA adducts [42]. The 
'damage-recognition' model suggests that the HMG-domain proteins bind to DNA 
adducts and serve as recognition elements for repair complexes. However, the 
'repair-shielding' mechanism proposes that the HMG proteins bind tightly to the 
platinum-DNA adducts and prevent the repair complex getting to the place of 
damage on the DNA strand. Present evidence points toward this latter explanation 
being correct, as a desensitisation of cells to cisplatin was observed when the gene 
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encoding the HMG-domain protein IXR1 was interrupted [42]. 
By whatever mechanism cells become resistant to cisplatin it is a major 
problem, as previously responsive tumours are now unable to be treated. This means 
that researchers must find an alternative platinum based-drug that operates in a 
different manner to cisplatin. 
1.5 THE HYDROLYSIS KINETICS OF CISPLATIN 
In the earliest biological experiments with cisplatin it was noted that there 
was an initial insensitivity to the drug lasting about two hours. It was suggested that 
cisplatin was converted, over time, to the actual 'active' form of the drug. Studies on 
the aqueous chemistry of cisplatin can help to explain this phenonomen. In aqueous 
solution the labile chloride ligands are displaced in a step-wise manner by water 
molecules as shown in equations (1.1) and (1.2). 
(1.1) 
(1.2) 
In addition to these two solvolyses there are many other hydrolysis reactions that 
may occur. 
cis-[PtC12(NH3)z] + Olf 
k 11 
OH • cis-[PtCl(OH)(NH3)z] + cr (1.3) 
koH 12 
cis-[PtCl(OH)(NH3)z] + Olf cis-[Pt(OHMNH3)2] + cr (1.4) 
cis-[PtCl(OH)(NH3)z] + H20 
k3 
cis-[Pt(OH)(OH2)(NH3)2t + cr (1.5) k_3 
cis-[PtCl(OH2)(NH3ht cis-[PtCl(OH)(NH3)2] + H+ pKa=6.85 (1.6) 
cis-[Pt(OH2)2(NH3)z]2+ cis-[Pt(OH2)(0H)(NH3)zt + H+ pKa=5.93 (1.7) 
cis-[Pt(OH2)(0H)(NH3)zt cis-[Pt(OHMNH3)z] + H+ pKa=7.87 (1.8) 
At equilibrium the relative amounts of all these platinum species vary as a function 
of the chloride ion concentration and pH. 
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In blood plasma the high chloride ion concentration (1 04 mM) stabilises 
cisplatin as the dichloro complex. After entering the cell by an unknown mechanism 
(thought to be a combination of passive diffusion and a gated channel) cisplatin can 
hydrolyse due to the low (4 mM) chloride ion concentration. 
The reactive species in vivo are thought to be those containing a coordinated 
water molecule such as cis-[PtCl(OH2)(NH3)2t. In contrast to coordinated chloride 
and hydroxide, water is easily substituted by other molecules. Inert hydroxo species 
may be formed (Equations (1.3)- (1.8)) and at very high concentrations these can 
dimerise and trimerise [43] however, this is generally considered unlikely under 
biological conditions. 
As water is a much better leaving group than either chloride or hydroxide, the 
chloroaqua species will be the most likely reactive form of cisplatin in vivo and so 
hydrolysis will be the rate-limiting step in the reaction of cisplatin with biomolecules 
such as DNA. Miller and House et al [44- 51] have accurately determined the 
kinetic parameters for most of the hydrolysis reactions ((1.1)- (1.5)) and concluded 
that the acid hydrolysis of cisplatin in vivo is unlikely to proceed beyond cis-
[PtCl(OH2)(NH3ht. 195Pt NMR work by Bancroft et al also suggests that cis-
[PtCl(OH2)(NH3)2t is the predominant complex that reacts with biomolecules [52]. 
As well as the work of Miller and House [ 44 - 51], the rate of hydrolysis of 
platinum(II) complexes has been studied numerous times [25, 52 -71] by many 
different workers and the results are summarised in reference [44]. Knowledge of 
the fundamental reaction chemistry of cisplatin and other platinum(II) complexes in 
solution can provide important information for the design of new platinum drugs. 
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1.6 MODELS FOR THE INTERACTION OF CISPLATIN WITH DNA 
It is generally agreed that the anti-tumour activity of cisplatin arises from the 
ability of its hydrolysis products to bind to DNA and thus inhibit cell replication. 
Each DNA strand has a backbone consisting of repeating deoxyribose 
phosphadiester units attached through the sugar moiety to the N9 atoms of the purine 
bases adenine (A) and guanine (G) or the N7 atoms of the pyrimidines cytosine (C) 
and thymine (T). The ordering of the bases from 5' to 3' on the DNA strand defines 
the sequence of that strand. Complementary strands of DNA are stabilised by 
hydrogen bonds between guanine and cytosine (G-C) and between adenine and 
thymine (A-T), called 'Watson-Crick' base pairs. The complementary strands are 
aligned in anti-parallel fashion to form a double helix which is also stabilised by 
stacking interactions between the parallel bases. The DNA double helix offers an 
electrostatic potential that attracts the positively charged platinum hydrolysis 
products thought to be responsible for the anti-tumour activity [43]. DNA has a large 
range of potential binding sites for platinum(II) due to its size and chemical 
complexity. Platinum(II) behaves as a 'class B' (soft) metal and so can form stable 
compounds preferentially with S (but also with N) donor atoms thus will react with 
N atoms of the DNA nucleobases. Metal binding to a nucleobase (such as guanine) 
can be affected by a variety of factors including basicity of the donor, steric effects, 
interligand interactions and the charge on the metal. 
Coordination of these platinum species to DNA takes place in two steps. The 
first involves the formation of a monofunctional adduct, mainly at the N7 position of 
a guanine or adenine residue. The monofunctional adducts react further, mostly at 
the N7 of nearby guanines and to a smaller extent adenine, forming bifunctional 
adducts. If the coordinated nucleobases are on the same strand of DNA an 
intrastrand cross-link is formed; if on different strands an interstrand cross-link 
forms. Platinum has also been shown to link DNA and proteins [72]. 
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It is now generally accepted that the moderately labile monoaqua platinum 
species produced in vivo binds via an intrastrand cross-link to the N7 position on two 
guanine nucleobases. The first evidence for the interaction of cisplatin with DNA 
came from Rosenberg's early work when he observed filamentous growth in E. coli, 
that is inhibition of cell division but not cell growth [5]. Biochemical studies 
measuring the uptake of radiolabelled precursors for proteins and nucleic acids in 
human A V 3 cells in vitro and in Ehrlich ascites cells in vivo, showed inhibition of 
DNA synthesis with hardly any effect on RNA or protein synthesis [72]. Further 
evidence that cisplatin interacts with DNA is that DNA repair-deficient cells are 
more sensitive to cisplatin than DNA repair-proficient cell lines. A prophage 
induction study showed that biologically active platinum complexes induce lysis in 
lysogenic bacteria and that there is a good correlation between anti-tumour activity 
and prophage induction [73- 74]. 
After the initial hydrolysis (see Section 1.5), binding of the cisplatin 
hydrolysis product to DNA occurs as follows [43]: 
• Bifunctional binding to the N7 position of two adjacent guanine bases on one 
DNA strand ie. an intrastrand cross-link. This is the most prevalent binding 
mode and is responsible for ~ 60 % of the binding of cisplatin to DNA. 
• Bifunctional binding to an adenine and a guanine on the same strand (~25 %). 
Bifunctional binding to two guanines on two different strands - an interstrand 
cross link (10 %). 
Monofunctional binding to a single guanine base (2- 3 % ). 
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Bifunctional binding to two guanines separated by a third nucleobase. 
DNA-protein cross-linking ( < 1 % ). 
The two major adducts formed by cisplatin are cis-[Pt(NH3) 2 { d(pGpG)}] and 
cis-[Pt(NH3h { d(pApG)}]. These adducts are responsible for the inhibition of cell 
division. The cis-[Pt(NH3) 2{ d(pGpG)}] adduct is very stable and only strong 
nucleophiles such as cyanide or thiourea can break the DNA-Pt bond. One of the 
many possible explanations for the large stability of the Pt-GN7 bond may be due to 
the intrinsic basicity of the G-N7 and an additional stabilisation through hydrogen 
bond interactions with G-06 [74]. 
There have been many crystallographic and NMR studies on the interaction 
of cisplatin with various single (ss) and double (ds) stranded oligonucleotides in 
order to model the events that occur when cisplatin binds to DNA [43, 72, 75- 79]. 
In ss DNA chains with AG and GG adducts, the two bases are coordinated through 
N7 in a 'head to head' orientation. The interaction with the 5' -phosphate group in 
the GG chelated DNA seems to be important as it is involved in a hydrogen bond 
with an NH3 ligand of the platinum complex. This could account for the observation 
that active platinum drugs of this type require an acidic N-H group [73]. The 
phosphate-ammonia interaction may well induce and/or stabilise DNA distortions 
thereby interfering with the replication process. 
Upon binding to cisplatin the double helix of the oligonucleotides is distorted 
to a kinked structure. Changes in the UV and CD spectra reflect a loss in normal 
base stacking within the helix. The melting temperature of DNA decreases and 
increasing amounts of cisplatin can unwind the double helical structure [74]. Gel 
electrophoresis has shown that the reaction of cisplatin with DNA results in a 35° 
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bend in the double helix at the intrastrand GG-N7N7 cross-link [74]. This altered 
structure may influence the protein-DNA interactions with DNA polymerases being 
blocked by the adducts formed by cisplatin and thus interfering with the replication 
process and inhibiting cell division [74]. 
Recently Lippard et al [75, 80] have determined the first X-ray structure of 
duplex DNA containing the major adduct of cisplatin (Figure 1.3). The structure 
shows that when cisplatin binds to adjacent guanine residues on the duplex DNA it 
severely distorts the double helix by causing a bend toward the major groove and a 
widening and flattening of the minor groove. The overall structure of the double 
helix remains intact and most of the distortion is absorbed by conformational 
changes in the sugar-phosphate backbone ie. the phosphate groups on the backbone 
move closer together at the site of the platinum binding. This structure reveals that 
DNA is a flexible molecule as it can accommodate an intrastrand cross-link by 
adopting an unusual structural conformation. 
Stereochemical differences in the adducts formed by cis- and trans-platinum 
complexes imply that the anti-tumour activity is due to the formation of a specific 
structural motif on DNA which can trigger a cellular response leading to cell death. 
To investigate this, attempts have been made to identify cellular proteins that 
recognise cisplatin-DNA interactions with the ultimate goal of understanding how 
such an interaction may lead to the selective toxicity of the drug to tumour cells. 
South Western Blot analyses have revealed the existence of two classes of 
proteins that recognise cisplatin-damaged DNA. One of these has been identified as 
HMG1 (high mobility group). This protein recognises d(GpG) and d(ApG) 1,2-
intrastrand cross-links which comprise 85 %of the cisplatin adducts in vivo. 
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Figure 1.3: Stereoview of a ball and stick model of the duplex DNA, 
d(CCunrCTG*G*TCTCC).(GGAGACCAGAGG), where -G*G*- is 
modified by cis-{Pt-(NH3)z}2+ [80]. 
These adducts bend the helix by 34 o in the direction of the major groove and 
unwind it by 13 o providing a signal for HMG 1 binding. Other inactive platinum 
complexes unwind DNA to different degrees and these are not recognised by HMG 1. 
Thus the degree to which DNA is unwound is an important determinant for HMG 1 
binding. HMG 1 binds more strongly to DNA damaged by cisplatin than to 
unplatinated B-form DNA or to DNA modified with therapeutically inactive 
platinum analogues. The biological role of HMG 1 is not known at present. Binding 
of it to platinum-modified DNA may prevent recognition of the adducts by cellular 
repair mechanisms. It is interesting to note that other investigators have observed 
lower levels of a protein of similar size to HMG 1 found in cisplatin-resistant cell 
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lines [81]. Alternatively HMG 1 may be required for active transcript in rapidly 
dividing cells and therefore removal of it by reaction with platinum drugs may cause 
cell death [81]. 
Another feature of cisplatin-DNA interactions is the speculative proposal that 
the platinum drug may be able to move along the DNA backbone. One model 
presented [82] is that the reaction of the drug with guanine is random but that the 
subsequent evolution of Pt-DNA cross-links may result in the breaking of the initial 
complexes, ie. the drug can 'walk' along the helix or 'jump' across helices. This 
effect has not been observed in ss DNA suggesting that it is not possible for the drug 
to jump over to another helix but in ds DNA it may walk down a helix by a 
mechanism that is dependent on the tertiary structure of the double helix. 
During a physico-chemical study of cross-link modified DNA, Perez, Leng 
and Malinge [83] noticed that interstrand cross-links were not stable. Subsequent 
experiments showed that under physiological conditions, the bonds between 
platinum and N7 of guanine residues at the d(GC/GC) site are cleaved leading to the 
formation of monofunctional adducts. These can react further to form bifunctional 
intrastrand cross-links within the double-stranded DNA. This may account for the 
observation that more intrastrand cross-links are seen than are theoretically predicted. 
In the thirty years since the discovery of the anti-tumour activity of cisplatin 
it is still not decisively known how the drug operates in vivo. However, with the use 
of X -ray studies and other techniques the picture is now becoming much clearer and 
hopefully within the next few years, the definitive pattern will emerge. 
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1.7 REDOX REACTIONS OF PLATINUM(II) AND PLATINUM(IV) 
1. 7.1 Reduction 
Renewed interest into the redox chemistry of platinum(II)/(IV) began with 
the discovery of drugs such as JM-216 [21] where the platinum is in the +IV 
oxidation state. These drugs were developed in the search for an orally active 
complex as the toxicity of platinum(II) complexes limited their use to high hydration 
therapy. The derivatives prepared were either of the form cis-[PtC14(am)2] or cis, 
trans, cis-[PtCh(OH)2(am)2]. The hydroxo derivatives, synthesised by the oxidation 
of the corresponding platinum(II) complex with hydrogen peroxide, are generally 
more soluble than the tetrachloro derivatives. 
Most evidence suggests that platinum(IV) complexes undergo ligand 
exchange processes very slowly and must be activated by reduction to the 
platinum(II) product prior to reaction with DNA [84 - 86]. Only those platinum(IV) 
complexes with active reduction products are biologically active. Thiol containing 
biomolecules such as cysteine and ascorbic acid appear to be the most likely 
intracellular reducing agents. Research by Pendyala et al [87] has shown that 
iproplatin (Figure 1.2) is partially converted to the platinum(II) complex trans-
[PtCh(NH2CH(CH3)2h] (ie. a reduction product) in the blood and urine of patients 
receiving the drug. Eastman [38] showed that the reaction between tetraplatin and 
DNA requires the presence of glutathione in vitro and he postulated that the 
tetraplatin is activated in vivo by glutathione or other intracellular reducing agents. 
Gibbons [34] studied the rapid reduction of tetraplatin in tissue culture medium and 
found that the tetraplatin was reduced to PtCh(chxn) with a half life of 5 to 15 
minutes depending on the level of protein sulfhydryl in the medium. However, a 
second explanation for the anti-tumour activity of platinum(IV) complexes may lie in 
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the observation that the complex trans, cis, cis-[Pt(OH)zCh(NH2Pri)z] (CHIP, JM-9) 
can cleave DNA. Mong et al showed that the incubation of PM2 DNA with CHIP 
results in the formation of intrastrand cross-links and the appearance of DNA 
breakage. They speculated that, similar to bleomycin, the compound can produce 
hydroxyl or superoxide radicals which can cleave DNA. 
Recent work on the reduction of platinum(IV) complexes comes from Biding 
et al [89]. They demonstrated that their model compound trans-[PtiVCh(CN)4f is 
rapidly reduced by thioglycolic acid, L-cysteine, DL-penicillamine and glutathione 
and that the thiolate anions are the most reactive species at physiological pH. This 
implies that reduction of platinum(IV) anti-tumour drugs by thiol-containing 
molecules may occur before interaction with DNA. They did similar work using L-
methionine as the reducing agent [90]. The less reactive thioether-containing amino 
acid was able to be studied over a much broader pH range. In contrast to glutathione, 
there was only a small change in reaction rate within the pH range 0- 12. Biding et 
al concluded that in neutral solution methionine-containing biomolecules will only 
compete for the reduction of platinum(IV) species when in the presence of low thiol 
concentrations. However, in acidic solution both species will be equally competitive. 
Other very recent work involves the reduction of platinum(IV) by ascorbic 
acid [91]. Bose and Weaver proposed that ascorbate reductions proceed through a 
platinum(IV)-ascorbate intermediate whose formation is catalysed by platinum(II). 
They commented that the reactions were complex and difficult to interpret. This is in 
agreement with the more recent work of House [92] who was able to cleanly study 
the ascorbic acid reduction of a range of platinum(IV) complexes. They found 
standard first-order kinetics were followed when all solutions were oxygen free and 
BDTA was added to the solution to prevent interference from trace metal ions. 
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Ascorbic acid reduction has earlier been studied by Evans and Green [93] and 
Mehrotra et al [94]. The latter workers found a non-linear dependence on ascorbic 
acid which was attributed to the formation of an outer-sphere encounter complex 
prior to electron transfer. Similar effects were found by Sen Gupta et al when using 
hydroxylamine as a reducing agent [95]. 
Sen Gutpa et al also studied the reduction of platinum(IV) by sulfite [96]. 
They found the reaction to be a two-electron transfer which they confirmed by the 
lack of polymerisation of acrylamide when added to the reaction mixture. If radicals 
were present then it was expected that polymerisation would be observed. 
Reedijk et al found that trans, trans, trans-[Pt(NH3)(e6H11NHz)eh(OH)z] 
would only react with 5' -GMP, a biomolecule, in the presence of glutathione. A 
major product from this reaction was the reduced trans-platinum(II) complex [97]. 
ehandayot studied the base-promoted reduction of platinum(IV) and the reduction of 
trans-[PtX2(eN)4] 2- by inorganic anions including SeN-, eN-, sol- in aqueous 
solution [98 - 99]. 
Peloso has published a large amount of work in the area of platinum redox 
kinetics. He has used such reductants as iodide [100- 101], Fe(II) [100- 101] and 
platinum(II) [100- 102] to reduce a range of platinum(IV) complexes. This has been 
used to investigate aspects such as ligand size (hence steric hindrance) on the rates of 
reduction. In most cases he found the reactions to obey second- or third-order rate 
laws and the reactions were sensitive to steric hindrance and cr-donor ability. 
Moodley and Nicol [103] studied the reduction of platinum(IV) by Sn(II) and 
eu(I). In the case of Sn(II) they found the reaction to proceed via one two-electron 
transfer step but for eu(I) a non-complementary one-electron transfer occured 
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involving the formation of platinum(III) as an intermediate. 
Sykes et al reported kinetic data for the platinum(IV) reduction by V2+ and 
[Ru(NH3)6f+ [ 104]. These reactions also involve the formation of platinum(III) as a 
transient intermediate and were found to occur via an outer-sphere mechanism. 
The reduction of platinum(IV) can proceed by two pathways; one two-
electron transfer step or two one-electron transfer steps [1 05]. Complimentary 
reduction reactions (one two-electron transfer step) involving platinum(IV) are the 
most well documented. Reactions belonging to this type of reduction usually occur 
via an inner-sphere transfer process where a bridged intermediate is formed between 
the two reactants prior to electron transfer. One such two-electron reductant is 
platinum(II) and thus it is possible to get reversible platinum(II)/platinum(IV) 
reactions. Non-complimentary processes are also known to occur and involve two 
one-electron transfer steps. This will result in the formation of platinum(III) which is 
an unstable oxidation state of platinum and produces short-lived intermediate 
species. These reaction types (complementary and non-complementary) also apply 
to the oxidation reactions discussed below. 
1.7.2 Oxidation 
The oxidation of platinum(II) is the most common route for the synthesis of 
platinum(IV) complexes. This is usually effected using hydrogen peroxide as an 
oxidising agent. Dunham et al used NMR and X-ray crystallographic techniques to 
study the oxidation of platinum(II) complexes by hydrogen peroxide. They found 
that the products produced were the trans-dihydroxyplatinum(IV) species, where the 
H20 2 added into one of the two vacant coordination sites and a water from solution 
adding into the other [106- 107]. Harrigan and Johnson monitored the kinetics of 
the H20 2 oxidation of [Pt(en)2] 2+ and [Pt(NH3)4f+ and found that the reactions 
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occurred by one two-electron transfer step [105]. They also studied the oxidation of 
these same complexes by peroxydisulfate and found the reaction occurred via two 
one-electron transfer steps. Drougge and Biding followed the oxidation of 
[Pt(CN)4]2- by chlorine and hypochlorous acid using stopped-flow spectrometry 
[108]. Halpern and Pribanic [109] postulated the intermediate formation of Pt(III) in 
the oxidation of Pt(II) complexes by hexachloroiridate indicating two one-electron 
transfer steps. Peloso has also investigated the oxidation of platinum(ll) complexes 
by hexachloroiridate [110- 111] and found the oxidation to be chloride dependent. 
He studied the kinetics of the oxidation of Pt(II) complexes by tetrachloroaurate [88, 
112] and found the reactions to be third-order for trans complexes but more complex 
for cis isomers. He has also used platinum(IV) complexes as oxidising agents [113] 
to give a third-order rate law dependent on Pt(II), Pt(IV) and cr. This has also been 
observed by Mason [114]. Mason used bromine as an oxidising agent [115] in a 
two-step process. The first step was rapid producing a bromoaqua complex and the 
second slower step produced the dibromo complex. Zemskov considered possible 
oxidation reaction mechanisms including that for the oxidation of Pt(ll) by 
permanganate and cerium(IV) [116]. 
1.8 THE TRANS EFFECT IN PLATINUM(II) CHEMISTRY 
The trans effect has been defined as 'the effect of a coordinated group upon 
the rate of substitution reactions of ligands diagonally opposite to it in a metal 
complex'. Considering a ligand L, that means the oppositely-placed group will be an 
important factor in determining the reaction chemistry of L. 
The chemistry of platinum(II) complexes is full of examples of the role the 
trans effect plays in synthesis and reaction chemistry and the extensive research that 
went into this field has provided qualitative information on the trans-directing 
influence of various ligands. The approximate order of decreasing trans effect is: 
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This is an empirical order and it is concerned only with the rates of competing 
reactions. Kinetically the effect can be very large with a factor of 106 (or more) often 
being the difference in rate between a good trans labilising ligand and a ligand low in 
the trans series. It is generally accepted that the strong trans directing influence of 
CN- is associated with its 1t accepting character. 
The trans effect can be useful when synthesising isomeric platinum(ll) 
complexes. For example, the cis and trans isomers of [PtCh(N02)(NH3)r can be 
made by reversing the order of introduction of groups into [PtC14] 2-. It can also be 
used to determine which chloride ion will be hydrolysed first in complexes such as 
[PtCb(NH3)t. Due to the stronger trans effect of cr over NH3 the chloride 
diagonally opposite to another chloride will hydrolyse first. 
Therefore the trans effect plays a major role in the substitution chemistry of 
platinum(ll) complexes and in the design of synthetic reaction schemes. One 
application of this is the difference in reactivity between cisplatin and transplatin as 
discussed in Section 1.9. 
1.9 CISPLATIN VERSUS TRANSPLATIN 
Much research has focussed on trying to discover the differences between the 
activity of cisplatin and transplatin [52, 117]. In the solid state, these complexes 
differ only in geometry, but as is the case for many drugs, only one isomer has the 
required effect. Without going into great detail, the main points of interest regarding 
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the two isomers will be summarised. 
Both cisplatin and transplatin are thought to interact with DNA even though 
the effects are less pronounced for transplatin. When interacting with DNA cisplatin 
forms mainly intrastrand cross-links and these are thought to be the main interactions 
necessary for anti-tumour activity. On the other hand, transplatin is unable to form 
intrastrand cross-links due to geometrical constraints, but it does form interstrand 
cross-links and also cross-links between DNA and proteins. Cisplatin-DNA adducts 
lead to thermal destabilisation but transplatin-DNA links seem to be of greater 
variability and cause thermal stabilisation or destabilisation. For cross-links of the 
type purine-X-purine, the intervening base, X, seems to be important with regard to 
activity. 
Higher doses of transplatin are required in living cells to bind an equal 
number of platinum atoms per nucleotide, but bifunctional DNA adducts of either 
isomer inhibit DNA replication to the same extent. This has been interpreted as each 
isomer having a different repair mechanism. 
The water molecule in aquated transplatin is kinetically more reactive than 
that for cisplatin (ie. k_lcis = 64.6 X w-4 M-IS-I [49], k_/'"ans = 160 X w-4 M-ls-1) in 
agreement with the trans effect series (Cr > NH3). However, the reactivity can be 
'tuned' [118] by introducing a sterically hindering non-leaving group which slows 
the reactivity by retarding the formation of the five-coordinate intermediate (see 
Chapter 2). Such ligands include pyridine, thiazole and quinoline. Also, if equal 
amounts of cisplatin and transplatin are taken, the amount of aquated product at 
equilibrium will be less for the trans isomer than for the cis isomer due to the 
difference in equilibrium constants for equation (1.1) (pKc1cis = 2.17, pKc1trans = 2.92, 
25 oc, I= 1.0 M). 
Transplatin is less water-soluble than cisplatin. This may be problematic 
when infusing the drug into the bloodstream, but, at physiological concentrations, 
this will not be of great concern. 
Although transplatin shows biological activity, it is quite toxic and not as 
active as the cis isomer due to the different array of adducts it forms with DNA. It 
has been found that certain trans isomers do inhibit tumour growth but they tend to 
be very individual complexes that defy all previous structure-activity relationships 
[119]. 
1.10 INTRODUCTION TO THE CURRENT RESEARCH 
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The initial investigations presented here follow on from the work of Miller 
and House et al [ 44 - 51] studying the aquation and anation of platinum(ll) amine 
complexes. They studied the aquation of cisplatin and the chloride ion anation of the 
monochloro (cis-[PtCl(OH2)(NH3)zt) species (Equation (1.1)). This work aims to 
complete the chloride ion dependence by measuring the chloride ion anation of the 
diaqua (cis-[Pt(OH2) 2(NH3)z]2+) complex using UVNis spectrometry (Equation 
(1.2)) and by indirectly measuring the aquation (k2) of the monochloro species by 
free chloride ion titration. A further extension was to study the bromide ion anation 
of both the bromoaqua and diaqua platinum(II) complexes and to measure the effect 
of pressure on reaction rates for a selection of chloride and bromide anation 
reactions. 
In light of the newer analogues of cisplatin containing platinum in the +IV 
oxidation state, it was decided to study the reduction of platinum(IV) complexes with 
a range of biological and abiological reducing agents. Ascorbic acid was selected as 
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it is thought to be one of the most likely in vivo reducing agents. Other reductants 
(Sn(II), Fe(II), S20t, hydroxylamine) were chosen because of their chemical 
significance in an effort to elucidate the underlying redox mechanisms. The 
preparation of these platinum(IV) complexes usually involves the oxidation of 
platinum(II) by hydrogen peroxide. Very little work has been done on the kinetics 
and mechanisms of the oxidation process so it was felt worthwhile to investigate the 
kinetics of platinum(II) oxidation. 
In comparison with the lability of platinum(II), platinum(IV) is very inert to 
substitution and thus little has been done in way of kinetic studies, with complexes in 
this oxidation state. A starting point for investigating the chemical reactivity of d6 
platinum(IV) chloroammines is base hydrolysis, and work on this reaction is 
presented here. 
This thesis therefore describes investigations of the solution chemistry of the 
anti-cancer drug cisplatin, various platinum(II) amines and their hydrolysis products, 
as well as some redox reactions of platinum(II)/(IV) complexes and the base 
hydrolysis of some platinum(IV) ammine complexes. 
CHAPTER2 
EXPERIMENTAL 
2.1 INTRODUCTION 
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The work in this thesis measures the rates of reaction for various platinum 
complexes undergoing a range of reactions. The main technique used for these 
measurements was UV/Vis spectroscopy, coupled with a high-pressure stopped-flow 
technique for certain reactions. 195Pt NMR spectroscopy has been used for some 
product characterisation and X-ray crystallography was used to determine the 
stmctures of three platinum complexes synthesised during the course of this research. 
This chapter gives a brief introduction of the techniques used, with more 
detailed information given in subsequent chapters. 
2.2 UV !VIS SPECTROSCOPY 
Conventional mixing spectroscopy (for reactions complete in greater than 10 
minutes) and stopped-flow spectroscopy (reactions complete in under 5 minutes) 
were used to collect the data presented in this thesis. 
2.2.1 Conventional mixing spectroscopy 
The majority of data were obtained using the conventional mixing technique 
with a Perkin Elmer 'A-2 Recording Spectrometer (Figure 2.1). 
The general technique involved mixing two temperature equilibrated 
solutions (each containing a different reactant) or dissolving a small amount of solid 
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(- 1 mg) in a solution at the appropriate temperature. 
Figure 2.1: The Perkin Elmer A.-2 Spectrophotometer. 
All solutions were thermally equilibrated in a water bath prior to reaction. 
Once mixed (or dissolved) the resulting solution was transferred by syringe to a cell 
in either an electrically heated cell-holder or to a water-cooled jacketed cell system. 
Solution temperature in the electrically heated cell was maintained using a 
thermostat, and the accuracy of the temperature gauge was confirmed using a Fluke 
52 K/J platinum-resistance digital thermometer. For this experimental configuration, 
a 4 em pathlength cell was used. For the water-cooled system, a small pump 
continually circulated water from the thermostatted bath through a water-jacketed 
cell (5 em pathlength). The change in temperature during the 'dead-time', when the 
water passes from the bath to the cell, was not significant ( < 0.1 °C). This 
configuration was used for reactions being studied at temperatures 10:::;; T:::;; 30 oc. 
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Measurements at temperatures below 10 oc were not possible due to fogging of the 
cell window. The electrically heated cell-holder was used for higher temperatures 
(30 ~ T ~ 60 °C). 
2.2.2 Stopped-flow spectroscopy 
Stopped-flow apparatus was required for studying rapid reactions. Data were 
obtained using an Applied Photo-Physics SX-18MV Biosequential Reaction 
Analyser. Reactions studied on this equipment were performed at the University of 
Erlangen-Niirnberg. Reactants were prepared and placed in two syringes. These 
syringes were connected to the top of the stopped-flow apparatus and the contents 
used to fill the internal syringes (Figure 2.2). 
Filling syringes 
Figure 2.2: Representation of a stopped-flow apparatus. 
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A computer was used to set necessary parameters ( eg. wavelength, scantime, 
time base) before the reaction was started. Each reaction was measured 14 times and 
the rate constant evaluated using the Applied Photo-Physics software [120]. There 
were minimal differences between runs (± 2 %) and an average of the data collected 
was used in calculating the final rate constant. 
2.2.3 Data collection 
Where conventional mixing was used, absorption spectra of the individual 
reactants were initially run to determine if there was a 'window' in which to monitor 
any absorption changes (ie. an area where only one of the reactants absorbed). A 
repeat scan was then run. This involved measuring the complete absorption 
spectrum of the mixture ( ~ 200 nm to ~ 600 nm), at appropriate concentrations and 
time intervals to establish if there were any changes in absorption by which the 
reaction could be monitored. To successfully study a reaction this absorbance 
difference (~A) must be at least 0.1 absorbance unit. If there is sufficient change the 
reaction may then be studied at a fixed wavelength, following the decrease (or 
increase) in absorbance of either a reactant or product. Under pseudo-first-order 
conditions and from the final absorbance versus time scan, the observed rate constant 
can be calculated. Reactions were followed for 6 - 8 half lives (until constant 
absorbance was reached) and data were collected at various temperatures, allowing 
calculation of the activation parameters - activation enthalpy (~H#) and activation 
entropy (.1S#). 
34 
2.3 HIGH-PRESSURE STOPPED-FLOW SPECTROSCOPY 
High-pressure stopped-flow instrumentation was used to study selected 
kinetics of anation reactions at elevated pressure. The high-pressure stopped-flow 
instrument consisted of a cell block which is placed inside a water-jacketed 
pressurising vessel. This allowed constant temperature to be maintained via an 
external water reticulation system. The cell block (constructed out of teflon) was 
composed of two reactant syringes, a mixing/optical block and a receiver syringe 
(Figure 2.3). The reactants are placed in the syringes and mounted onto the block. 
The receiver syringe is fully depressed allowing the waste solution to flow into it. 
The entire block is then placed into the pressurising vessel and the system sealed. 
n-Heptane was used as the pressurising medium. A switch connected to the data 
collection system activated a step-motor (incorporated into the pressurising vessel). 
This motor depressed the two reactant syringes and a small portion of each reactant 
passed into the mixing chamber (a 'shot') and past the sapphire window. 
sapphire 
window 
reactant solutions 
mixing chamber 
waste syringe 
Figure 2.3: Schematic diagram of the high-pressure stopped-flow 
apparatus. 
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The reaction was monitored by UV/Vis spectroscopy. The reactant solution is then 
driven into the receiver syringe and the cycle repeated. Approximately twenty 
'shots' can be used from one filling of the syringes. 
As before, reactions were followed for 6 - 8 half-lives and pseudo-first-order 
([X]:?: lO[Pt(ll)]) rate constants evaluated using the KINFIT kinetic software 
package (On Line Instrument System (OLIS)). Mathematical manipulation (see 
2.6.2) of the rate constant data allowed calculation of the activation volume (Ll V#). 
2.4 195Pt NMR SPECTROSCOPY 
13C and 1H NMR spectroscopy have been widely used for structural 
identification of organic compounds for many years. More recently other nuclei (eg. 
15N, 19F, 31P, 195Pt) have been used in structure determination. 195Pt NMR was used 
in some of this work as an aid in identifying reaction products. 
The 195Pt NMR spectral data in this work were collected on a Unity XL300, 
referenced to H2[PtC16] (0 ppm). This instrument is not ideal due to the large 
( ~ -3000 to ~ 3000 ppm) chemical shift range. It is necessary to do four individual 
scans to cover the entire spectral range and so it can be a time consuming process to 
find a peak. The low concentrations of platinum (10-3 M) exacerbated this problem 
as longer acquisition times were needed to have a sufficiently large signal to noise 
ratio. 
2.5 X-RAY CRYSTALLOGRAPHY 
Three X-ray structures are presented in this thesis. The data were collected 
on a Siemens P4 instrument and refined using a full matrix least-squares method on 
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F2. There was no refinement of H-atoms. Full details of the structures and selected 
parameters are given in the relevant sections of this thesis (Table A3.6, Table A6.3). 
Crystallographers from the Chemistry Department X-Ray Laboratory performed the 
structural analyses. 
2.6 NUMERICAL ANALYSIS 
2.6.1 Calculation of rate constants and activation parameters 
Within this work two types of reactions were observed; those following 
pseudo-zero-order kinetics and those following pseudo-first-order kinetics. The 
absorbance vs time spectra for zero-order reactions show a linear increase (or 
decrease) in absorbance before a sharp levelling off (Figure 2.4(A)). For this type of 
reaction the rate constant is simply the slope of the line. A first-order reaction 
produces an exponentially shaped plot (Figure 2.4(B)) (with exponential decrease 
also possible) and rate constants must be calculated (see equation (3.3), page 46). 
A B 
Q) Q) 
(.) § § 
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Time Time 
Figure 2.4: Schematic representations of absorbance vs time plots for (A) a 
zero-order reaction and (B) a first-order reaction. 
About 30 data points (at fixed time intervals) are extracted from the absorbance vs 
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time output and entered into a computer programme specifically written for 
calculation of the rate constants ('SIAN'). The rate constants at a range of 
temperatures are then used to calculate the activation parameters L1H#, L1S#, and the 
rate constant at 25 oc using another specifically written programme 'BACT'. Errors 
for the calculation of rate constants are taken as ± one standard deviation. In all 
cases these errors are less than 5 %. Error parameters in L1W are calculated 
automatically by the computer programme using a linear least-squares analysis. 
Errors in L1S# are assumed to be three times those for L1W. 
The variation of rate constant with temperature was first quantified by 
Arrhenius who proposed equation (2.1) [121]. This states that as the temperature 
increases, the reaction rate will also increase. 
k = PZexp(-EafRT) (2.1) 
In equation (2.1) k is a general rate constant, Ea is the activation energy, T is the 
absolute temperature, R is the gas constant, Z is the collision rate between reactant 
molecules and P is a probability factor inserted to allow for the disparity between 
calculated and observed values of k. The logarithmic form of this equation 
Ink = lnPZ - Ea!R T (2.2) 
when plotted as Ink vs liT is linear with a slope of -Ea!R and a vertical intercept of 
lnPZ. 
Ea and PZ can be determined directly if there is a range of known rate 
constants at known temperatures. Once determined they can be used to calculate the 
activation enthalpy (L1H#) and activation entropy (l1S#). If equation (2.2) is 
integrated between the limits k = k1 at T = T1 and k = k2 at T = T2 then 
38 
(2.3) 
and, if two values of k at two different temperatures are known Ea can be calculated. 
Alternatively when Ea and k (at one temperature) are known, kat a second 
temperature can be calculated. This second method is used (by the BACT 
programme) to calculate the rate constant at 25 °C. 
An alternative approach to reaction kinetics is transition state theory [122]. 
This theory postulates that before undergoing a reaction an activated complex must 
form. The activated complex is in equilibrium with the reactants and the rate of 
reaction is controlled by the concentration of this complex present at any instant. 
The activated complex is assumed to have the properties of an ordinary molecule and 
to possess some inherent temporary stability. On the basis of these ideas, 
k = (RT/Nh)exp(-~G#/RT) (2.4) 
where N is Avogadro's number, his Planck's constant and ~G# is the free energy of 
activation. Since the activated complex is in equilibrium with the reactants, standard 
thermodynamics can be applied giving 
and 
Since ~H# can be related to activation energy (~W = Ea- RT) then 
PZ = (RT/Nh)exp(~S#/R) 
(2.5) 
(2.6) 
(2.7) 
Thus from the determination of rate constants over a range of temperatures, the 
parameters Ea, lnPZ, ~W, ~S#, and k (at a second temperature) can be calculated. 
Activation entropy is a measure of the total entropy change taking place in 
the reactants and the solvent on the formation of the activated complex. Its sign and 
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magnitude are determined mainly by the charge of the activated complex relative to 
the charge of the reactants. For reactions between oppositely charged ions, the 
activated complex will have a lower charge than the reactants and thus will be less 
solvated (ie. less ordered). As formation of the activated complex is therefore 
accompanied by an increase in disorder, the activation entropy is positive. For a 
reaction between ions of like charge this theory predicts that LlS# will be negative. 
Where one reactant is neutral and the other charged, LlS# is predicted to be close to 
zero. 
2.6.2 Theory behind activation volume 
This section gives a simple derivation of the equation used to calculate 
activation volume from rate and pressure data, and a brief description of the theory 
behind the technique. A more complex derivation involving chemical potential may 
be found in Appendix 1. 
ll V# can be obtained from a plot of Ink vs P where the slope= -ll V#/RT. 
Three possibilities can arise: 
(i) k increases with an increase in p giving a negative ll v#. 
(ii) k decreases with an increase in p giving a positive ll v#. 
(iii) k is independent of P (ie. no volume change from initial state, IS, to 
transition state, TS). 
Now ll V# = VTs- Vrs, and if ll V# is positive then the transition state is of larger 
volume than the initial state. Conversely if ll V# is negative, the transition state is of 
smaller volume than the initial state. 
One method to derive the expression 'slope= -~V#/RT', considers the 
standard equilibrium reaction 
X + y XY (2.8) 
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where K = k,dk_ 1 is the equilibrium constant for the reaction. 
Standard thermodynamics gives 
V = ( -aG/()P)T (2.9) 
so ~ V = ( -a~G/()P)T (2.10) 
and since ~G# = -RT1nk (2.11) 
so (()lnk/()P)T = -~V/RT (2.12) 
as required. 
The most common unit of pressure used is MPa. In most cases experimental 
pressures ranged from 10 to 200 MPa. In aqueous solutions the extent of 
compression is 10- 20% and so the risk of explosion is negligible (note: 1 bar= 105 
Pa = 0.1 MPa = 0.986 atm = 14.5 psi). 
2.7 THE MECHANISTIC INTERPRETATION OF ~S# AND ~V# 
It is possible to propose certain reaction mechanisms for the substitution of 
square-planar complexes by considering the activation entropy (~S#) and volume 
(~ V#) [123]. 
There are three main types of mechanism for ligand substitution reactions: 
associative, dissociative or interchange. A dissociative mechanism involves a step 
where an intermediate of reduced coordination number forms before being converted 
into the product. An associative mechanism involves a step where an intermediate of 
higher coordination number is formed. An interchange mechanism occurs in one 
step ie. the leaving and entering groups exchange in a single step by forming an 
activated complex, but not a true intermediate. This last mechanism is probably the 
most common pathway for substitution reactions of square-planar complexes. 
Activation volume is a measure of the difference in molar volume between 
the reactants and the activated complex. Information about the volume change 
experienced by the complex and entering ligand is a good guide to the reaction 
mechanism. A small ( < 10 cm3mor1) positive 11 y# indicates a dissociative-
interchange reaction and in contrast, a small negative 11 y# points to an associative-
interchange mechanism. 
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An important feature affecting the entropy of activation is the effect of a 
change in charge that occurs when an activated complex forms. If two ions of like 
charge form the activated complex (ie. charge density increases), the solvent 
molecules around the complex will become more ordered. This decreases the 
entropy and hence 11S# is negative. If the reaction leads to a charge reduction in the 
activated complex (ie. two oppositely charged ions combine), the solvent molecules 
around the complex become more disordered and /1S# is positive. 
A large negative value of 11S# points to an associative-interchange mechanism 
whilst a large positive entropy indicates a dissociative-interchange mechanism. 
In their simplest forms, these interpretations predict that if a substitution 
process is observed to have both 11 V# and /1S# negative then an associative-
interchange mechanism is the most likely. 
CHAPTER3 
HYDROLYSIS KINETICS OF 
PLATINUM(II)-AMINE COMPLEXES 
3.1 INTRODUCTION 
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A knowledge of the reaction chemistry of cisplatin and other related 
complexes in aqueous solution is very important if the mode of action of cisplatin in 
vivo is to be understood. It is now agreed that in plasma, cisplatin remains in the 
dichloro form ([PtCiz(NH3)2]) for the first few hours, due to the high chloride ion 
concentration. Once the drug is transported across the cell membrane (by a 
mechanism which is not yet fully understood) it can undergo hydrolysis reactions 
(eg. Equation (3.1)), due to the large drop in chloride ion concentration (104 mM to 4 
mM). One product from these reactions is the chloroaqua species, 
[PtCl(NH3) 2(0H2)t, which is thought to be responsible for the anti-tumour activity 
of cisplatin. A further possible hydrolysis reaction may occur giving the diaqua 
product ([Pt(NH3)2(0H2)2]2+) (Equation (3.2)). This species is easily generated in the 
laboratory and provides an entry into the chemistry of the chloroaqua complex, but is 
unlikely to exist in the biological situation [52]. 
While it is generally agreed that DNA is the primary target of cisplatin (or, 
more specifically, hydrolysis products of cisplatin), it is important to establish the 
simple kinetic and equilibrium properties of such complexes. Miller and House et al 
have recently [44- 51] described a complete speciation profile for cisplatin in 
aqueous solution over a wide pH range and, along with others [124, 125] this 
information is being extended to further [Pt(N)2X2] (X= cr, B{) systems [49, 51]. 
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A large quantity of work has studied the interaction of cisplatin (and its hydrolysis 
products) with DNA and other biomolecules. These molecules include simple amino 
acids, DNA substituents (ie. guanine, adenine, cytidine, histidine) and other 
molecules including 5'-GMP and purines [62, 126- 143]. 
[PtX2(NH3)2] 
kl 
k_l 
[PtX(OH2)(NH3h]+ + x- (3.1) 
[PtX(OH2)(NH3)2t k2 [Pt(OH2h(NH3hf+ + x- (3.2) 
k_2 
It should be remembered that there are several other reactions involving the 
aqua/hydroxy equilibrium (See Chapter 1, Section 1.3), but under biological 
conditions, starting with [PtCh(N)2], the predominant species within the cell will be 
the chloroaqua!chlorohydroxo complexes in equilibrium [52]. 
In this chapter the kinetics and equilibria associated with reaction (3.2) for 
chloride ion anation are examined. These data complete the chloride dependent rate 
constant and equilibrium constant information associated with Scheme 3.1 
(excepting K3, see page 68) for (Nh =cis-(py)2, en, chxn, tn, Me2tn and trans-(NH3)2. 
Similar information is reported for the equivalent bromide ion anation reactions for 
the calculation of k_2, k1, k-1 and K1 (Equations (3.1) and (3.2)). The effect of 
pressure on selected anation reactions is also discussed. 
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3.2 EXPERIMENTAL 
3.2.1 Materials 
The platinum(Il) complexes were either commercially available (cis-(NH3) 2, 
cis-(py)2, trans-(NH3)2, chxn; Strem) or synthesised (en, tn, Me2tn) as described by 
Miller et al [49]. The chloride (NaCl) and bromide (NaBr) ion solutions were 
prepared from AnalaR reagents (BDH). A background ionic strength of 1.0 M 
(HC104) was used for all standard kinetic experiments, while I= 0.1 M (HC104) was 
used for the high-pressure studies. 
3.2.1.1 Chloride ion anation (k_2) 
Solutions of [Pt(OH)iN)2] were generated by base hydrolysis of the 
corresponding dichloro complex [49]. For all complexes except cis-(pyh, 50 mg of 
complex was dissolved in 50 mL 0.01 M NaOH and the solution heated on a steam 
bath for 3 - 5 hours before being left to cool overnight [ 49]. To simulate dark 
conditions the glassware was wrapped in aluminium foil. Concentrations of these 
solutions were: cis-(NH3h 3.33 mM, trans-(NH3)2 3.33 mM, en 3.07 mM, tn 2.96 
mM, chxn 2.63 mM and Me2tn 2.73 mM. To confirm completeness of base 
hydrolysis, acidified solutions were titrated with standard Hg2+ solution. 
Diphenylcarbazone (phenylazoformic acid 2-phenylhydrazide), dissolved in 
isopropanol, was used as an indicator [144a]. The titrations gave Pt: free chloride 
ion ratios of 1:2.0 ± 0.2 in all cases indicating hydrolysis was complete. There was 
no evidence to suggest the formation of any polymeric ~-hydroxo platinum(II) 
species [45]. Trans-[PtCh(NH2)2] (50 mg) required about 14 days in 50 mL 0.01 M 
NaOH at room temperature for complete hydrolysis, but complete chloride release 
was also achieved by heating the solution at 80 oc (steam bath) for 5 hours (in the 
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dark) followed by overnight cooling at room temperature. For the hydrolysis of cis-
(py)2, 5 mg was dissolved in 100 mL of 0.1 M NaOH ([cis-(py)2] = 0.12 mM) and 
treated as above. 
Upon acidification the dihydroxo complex is immediately converted to the 
diaqua species which, in the presence of halide ion, undergoes the two anation steps 
(Equations (3.1) and (3.2)). Because k.2 ~ k_1 the two reactions can be followed 
separately at isosbestic points characteristic of the reaction not under study. 
3.2.1.2 Bromide ion anation (kr, k.r, k.2) 
The bromide ion anation of platinum(II) diaqua (k.2) complexes was studied 
using stopped-flow techniques. In these cases the platinum(II) solutions were 
prepared as for chloride ion anation (see 3 .2.1.1 ), but using 50 mg of complex 
dissolved in 100 mL 0.01 M NaOH. This resulted in concentrations of: cis-(NH3)2 
1.67 mM, trans-(NH3h 1.67 mM, en 1.53 mM, tn 1.48 mM, chxn 1.32 mM and 
Me2tn 1.37 mM. 
Platinum(II) solutions for the bromide ion anation of the bromoaqua and 
aquation of dibromo (k. 1 and k1) were prepared as for the chloride anation of the 
diaqua (ie. 50 mg of complex per 50 mL of solution). Concentrations of these 
solutions were: cis-(NH3)2 3.33 mM, trans-(NH3h 3.33 mM, en 3.07 mM, tn 2.96 
mM, chxn 2.63 mM and Me2tn 2.73 mM. 
3.2.2 Kinetics 
In both the chloride ion anation of the diaqua and the bromide ion anation of 
the bromoaqua, aliquots (5 mL) of the base hydrolysed solutions ( ~3 mM in Pt(II) 
and 6 mM in Cr) were added to 5 mL of 2.0 M HC104 containing 30 - 80 mM 
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dissolved NaCl or NaBr, both at the appropriate temperature. These solutions were 
thermostatted in a water bath to ensure temperature equilibration prior to reaction. 
The newly acidic solution was quickly transferred to a temperature controlled 
spectrophotometer cell ( 4 or 5 em pathlength) and the change in absorbance 
monitored at fixed wavelength using a A.-2 Perkin Elmer Recording 
Spectrophotometer. For the chloride anation of the diaqua the actual wavelengths 
used correspond to an isosbestic point for reaction (3.1) (cis-(NH3)2 245 nm, trans-
(NH3)z 235 nm, en 283 nm, tn 270.2 nm, chxn 283 nm, Me2tn 269.8 nm, py 230 nm) 
to minimise interference from this step. 
The chloride ion anation reactions were followed for 6- 8 half-lives and 
pseudo-first-order ([Cr] ~ 10[Pt(II)]) rate constants (kobs) were calculated from the 
usual absorbance vs time expression (3.3). 
kobst = ln {(A, - Ao)/(A, - At)} (3.3) 
Plots of kobs vs [Cr] were linear with slope= k_2 and zero intercept (within 
experimental error), indicating k2 < 5 x 10-4 s-1 at 25 °C. Thus k_2 = kobs[ClT1, and 
the variation of k_2 with temperature allows the calculation of the activation 
parameters listed in Table 3.1. Full details of kobs, [Cr], temperature and lc2 are 
given in Table A3 .1. The variation of k_2 with ionic strength (I) is given in Table 
A3.2. 
Similar procedures were used for the bromide ion anation of the bromoaqua 
complex [PtBr(N)z(OHz)t. In this case, the rate of the first anation step 
(corresponding to the reverse of Equation (3.2)) was sufficiently rapid (Figure 3.1) as 
to be complete in the time of mixing (except for (N)z = cis-(py)z). The rate of the 
second step (Equation (3.1), x-= B() was measured at an appropriate wavelength 
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(cis-(NH3)2 260 nm, trans-(NH3) 2 335 nm, en 332 nm, tn 300 nm, chxrt 243 nm, 
Me2tn 300 nm, cis-(py)2 281 nm) corresponding to an isosbestic point for reaction 
(3.2). In these cases, plots of kobs vs [Br-] were linear with positive intercepts: the 
slope corresponding to k-1 (M-1s-1) and the intercept to k 1 (s-1) ie. kobs = k 1 + k-1 [Bf]. 
Activation parameters are listed in Tables 3.3 (k_1) and 3.4 (k1). Full details of kobs 
(calculated using Equation (3.3)), [Bf] and temperature are given in Table A3.3 and 
A3.4. 
The bromide anation of the diaqua species, [Pt(N)2(0H2)2]2+, was measured 
using a Biosequential SX-18MV Stopped-Flow Reaction Analyser (Applied Photo-
Physics). Reactions were again followed for 6- 8 half-lives and the pseudo-first-
order ([B{] ;::: lO[Pt(II)]) rate constants (kobs) calculated by the Applied Photo-
Physics software package [120]. The reactions were monitored at fixed wavelengths 
(cis-(NH3)2 275 nm, trans-(NH3)2 330 nm, en 290 nm, tn 280 nm, chxn 290 nm, 
Me2tn 280 nm). Preliminary experiments to determine these wavelengths were 
performed on a Shimadzu UV-2101 PC UV/Vis Scanning Spectrometer. Plots of kobs 
vs [Br-] were linear with slope= k_2 and zero intercept (within experimental error). 
Raw data are presented in Table A3.5. 
The variation of k_2 (Br-) with temperature allows the calculation of the 
activation parameters ~H# and ~S# (Table 3.6). 
3.2.3 Equilibrium constants for reaction (3.2) 
Solutions of [Pt(OH)2(N)2] + 2Cl- (generated by base hydrolysis of the dichloro 
complex as described above), were acidified with HC104 and the systems allowed to 
reach equilibrium by heating for 4 hours at 80 oc in the dark followed by 24 hours at 
25 oc. The free chloride ion concentration (T) was determined by Hg2+ titration 
[144a] and the equilibrium constant K2 (Equation (3.2)) was calculated from the 
expression (3.4) (derived in Appendix 2) [156]. 
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(3.4) 
where a= [Pt]initial and K1 (= k1/k_1) is the previously determined [49] equilibrium 
constant for Equation (3.1). Using the values for k_2 obtained, values for k2 (Equation 
(3.2)) can be estimated from the expression k2 = k_2K2. These data are listed in Table 
3.4. 
3.2.4 Synthesis of [PtBr4(N)z] complexes 
Residue solutions from the bromide ion anation of [PtBr(N)z(OH2)t were 
allowed to evaporate at room temperature in open beakers. After several weeks 
orange crystals were deposited ((N)2 =en, tn), which proved suitable for single 
crystal X-ray analysis. Similar orange platinum(IV) products were deposited for 
(N)z = chxn and Meztn, but these were unsuitable for X-ray analysis. 195Pt NMR 
chemical shifts (relative to H2PtC16) for [PtBr4(N)2] dissolved in DMF are (N)2 = en -
1473 ppm, chxn -1431, tn -1307, Me2tn -1364. Variations in ()Pt are usually 
considered to be caused mainly by variations in the paramagnetic contribution to the 
shielding thus for a similar range of complexes such as these only a small variation in 
chemical shift is expected. 
3.2.5 Crystal Structures 
The single crystal X-ray structures of [PtBr4(en)] and [PtBr4(tn)] were 
determined on a Siemens P4 spectrometer using Mo radiation by Professor M. 
Turnbull. Table A3.6lists the crystal characteristics, X-ray data collection 
parameters, and solution and refinement procedures for [PtBr4(en)] (I) and 
[PtBr4(tn)] (II). 
3.2.6 Effect of pressure on selected anation reactions 
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High-pressure stopped-flow instrumentation was used to study the kinetics at 
elevated pressure for some anation reactions in order to calculate the activation 
volume (L~.V#). To calculate~ V#, the reactions must be studied with all variables 
except pressure, fixed ie. constant wavelength, concentration and ionic strength. All 
reactions were studied with a background ionic strength of 0.1 M (HCl04). 
Rate constants for the anation of the diaqua (k_2) may be obtained under these 
conditions. ~ V#_2 can then be calculated from the slope of the lnk_2 vs P plots (as 
described in Chapter 2 of this thesis). For these reactions [X-] (ie. concentration of 
anating ligand) was fixed at 0.05 M. 
Both k1 and k_1 (and hence~ V_1 and~ V 1) can be calculated from the same 
experimental data but both the concentration (of anating ligand) and the pressure 
must be varied. To effect this, the reactions were studied at four concentrations (0.5, 
0.75, 1.0, 1.25 M) and up to six pressures. Plots of lnkobs vs [X-] (where X= cr or 
Br-) were plotted for each pressure to give k1 from the intercept and k_1 from the 
slope of these plots for each P. ~ V# was then obtained as above for both kx (ie. ~ V#-1 
and ~V#1 ). Data for k1 were not used (and hence ~V#1 was not calculated) as the 
errors in determining the intercepts were too large. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Chloride ion anation 
The rates of chloride anation (k_2 , Equation (3.2)) for several [Pt(Nh(OH2)2]2+ 
complexes were measured in acidic solution over a 15 - 20 oc temperature range. 
The raw data are presented in Table A3.1. As expected for a reaction between ions 
of opposite sign, a negative salt effect is observed (Table A3.2) for (N)2 = cis-(NH3)2, 
and an effect of similar magnitude is assumed for the other (N)2 complexes. 
The rate of anation of the cis-diaqua ions is 14 times greater than that of the 
monoaqua, (cis-[PtCl(NH3h(OH2)t, k_t = 6.46 x 10-4 M-ts-t [49] and 
k_2 = 9.27 x 10-2 M-ts-t), but this ratio increases to 94 for anation of trans-
[Pt(NH3)2(0H2)2]2+ relative to trans-[PtCl(NH3)2(0H2)t (k_t = 160 x 10-4 M-ts-t and 
k-2 = 151 x 10-2 M-ts-t). 
It should also be noted that the water molecules in both the trans-diaqua and 
trans-monoaqua are more labile than in the corresponding cis isomer, but the effect 
is more marked for the trans-diaqua. This is mainly due to a significant decrease in 
activation enthalpy associated with k_2 (~H#cis = 66.3 kJ mort, ~H#trans = 50.6 kJ 
mort, Table 3.1). 
The trans effect (Section 1.8) can be used to explain the difference in aquation 
and anation rates between transplatin and cisplatin. For aquation, the trans effect of 
cr is greater than that of NH3 and so substitution reactions will take place 
preferentially trans to cr. Transplatin has both the chloride atoms trans to each 
other and thus hydrolysis (substitution of a cr by H20) will occur at a faster rate 
than in cisplatin which has both chlorides trans to an NH3 group. However, this is 
not observed in this work or in work by Miller et al [ 49]. With regard to anation, for 
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transplatin substitution trans to a chloride will be faster than the corresponding 
cisplatin anation where anation will be opposite an arnrnine ligand which has a less 
strong trans effect. This is the observed order (ie. trans> cis) for the anation 
process. 
Table 3.1: Activation parameters for the first step in the chloride anation of 
some [Pt(N)z(OH2)z]2+ complexes (I= 1.0 M 3 ). 
(N)2 l02k_2 ~H# ~s# 
(M-ls-1) (kJ rnor1) (JK1 rnor1) 
cis-(NH3)2 9.27 b 66±2 -42± 6 
9.45c 66±4 -44 ± 12 
9.39d 65±2 -44±6 
8.9e 
- -
cis-(pyh 20.0b 72±2 -17 ± 6 
en 3lf 37 ± 12 -130 ± 36 
24.5b 59± 1 -59± 3 
R1-en 32.2g 67 ± 1 -28 ± 3 
chxn 21.4 b 66±2 -36 ± 6 
32.2h 67 ± 1 -28 ± 3 
tn 34.4 b 67 ± 3 -28 ± 9 
Me2tn 33.2 b 57± 3 -61 ± 9 
trans-(NH3)2 151 b 50± 1 -72±4 
a See Table A3 .1 for the effect of ionic strength on k_2• b This research. c Recalculated from the data 
in Ref. [45]. d Data from this research and Ref. [45] combined. e Ref. [145], ionic strength not stated. 
f Ref. [124]. g R1-en is a bicycloalkyl-substituted 1,2-diaminoethane ligand [124], I= 0.04 M. 11 Ref. 
[ 49] measured spectropolarmetrically. 
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Despite the fact that the cis-[Pt(NH3)2(0H2) 2] 2+ ion is at insignificantly low 
concentrations under biological conditions [46], anation reactions involving this 
species and biologically relevant nucleophiles have been widely investigated [69, 
128, 133- 135, 140, 146- 155]. Some of these nucleophiles (eg. 5'GpG [151 - 152] 
or DNA [155]) react with cis-[Pt(NH3)2(0H2)] 2+ up to 30 times faster than cr, 
pointing to a very efficient platinum(II) capture process. This information is of 
prime importance when considering the biological interaction of cisplatin with DNA, 
as it is the binding of cisplatin to the mononucleotide guanine and to a lesser extent 
adenine, that disrupts the DNA helix. Competition with unproductive scavengers (ie. 
other biological nucleophiles) may lead to wastage of the drug as it can react with 
these components prior to reaction with the DNA in the tumour cells. It is these 
extraneous reactions that may be responsible for some of the side-effects caused by 
cisplatin chemotherapy. 
The equilibrium constants K2 (at 25 °C) associated with reaction (3.2), have 
been determined for various (N)2. Using these values, together with k_2 data, 
estimates of k2 have been obtained (Table3.2). There have been very few direct k2 
measurements made [124], but the titrimetric method used here [156] gives estimates 
in good agreement with those obtained from a spectrophotometric procedure 
described previously [ 45]. The values obtained for k2 are of the order of 10-5 s-1, 
which are similar to those values for k1 [49]. This indicates that the aquation 
processes of both the dichloro and monoaqua species are slow. The slow aquation 
time has been expressed as one of the reasons why cisplatin is the platinum(II) drug 
of preference. The change in chloride ion concentration across the cell membrane 
promotes formation of the chloroaqua species. The unfavourable equilibrium 
constant, K2, for the second hydrolysis reaction means that formation of the diaqua is 
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unfavourable in the biological situation. The chloroaqua may react (in terms of 
ease/speed of reaction) with biological nucleophiles rather than aquate to the diaqua 
species. Other non-biologically active platinum(II) complexes have been shown to 
aquate at much faster rates and thus the inertness of cisplatin may be important in its 
clinical activity. 
Table 3.2: Values of Kh K 2, k.2, k2 estimated for the reaction between 
[Pt(Nh(0Hzh]2+ and Cr at 25 oc (I = 1.0 M). 
(N)z [Pt]i [CrJrree u 103Ktb 104Kz0 102k.z 105kz 
(mM) (mM) (M-ts-1) (s-1) 
cis-(NH3)z 1.67 1.595 6.42 2.94d 9.3 2.75d 
en 0.767 0.742 1.50 3.21 25 8.0 
chxn 0.658 0.569 1.81 3.98 21 2.2 
tn 0.740 0.677 1.62 1.88 34 6.4 
Meztn 0.683 0.643 3.22 2.85 33 2.7 
trans-(NH3)z 0.833 0.600 1.19e 3.86 151 5.8 
a Measured by [Hg2+] titration of an equilibrium solution. b I= 0.1 M [49]. c Calculated using 
equation (3.4). d Values of Kl 2.7 X 10"4 and k2 =: 2.5 X 10"5 s"1 have been previously estimated 
spectrophotometrically [49]. e This research. 
This now completes information on the chloride-ion-dependent equilibria 
outlined in Scheme 3.1 (see page 68), (apart from K3) for (N)2 = cis-(NH3) 2, en, 
chxn, tn, Me2tn and trans-(NH3)2 and partial data for cis-(py)2• Rate and equilibrium 
constants associated with Scheme 3.1 for other (N)z complexes are presented in 
Table 3.3. 
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Table 3.3: Rate and equilibrium constants (25 oc, 1=0.1 M) associated with 
Scheme 3.1. 
(Nh l05lq 103k_1 pK1 105k/ 102k_2a pK2a 
(s-1) (M-1s-1) (s-1) (M-1s-1) 
cis-(NH3)2b 4.15 6.46 2.17 2.75 9.27 3.53 
trans-(NH3)2c 1.90 16.0 2.92 5.8 151 4.41 
cis-(py)2 5.87 9.42 2.20 - 20.0 -
en 3.20 21.1 2.82 8.0 24.5 3.49 
R1-en d 3.20 44.0 3.14 7.8 67.0 3.93 
chxn 3.68 20.3 2.74 2.2 21.4 3.40 
tn 5.88 36.1 2.79 6.4 34.4 3.73 
Me2tn 8.40 26.1 2.49 2.7 33.2 3.55 
a I= 1.0 M. b pKa1 = 5.93, pKa2 = 7.87, pKa3 = 6.85 [157]. c pKa1 = 4.24, pKa2 = 7.22, pK/ = 5.63 
[157]. d Ref. [124]. 
There has been some controversy in the literature with regard to the rate of 
hydrolysis for the first step in the chloride release from trans-(NH3)2 relative to the 
cis isomer (lq in Equation (3.1)). Some estimates for lq (trans-(NH3)2) have been 
very indirect [158], but even the direct forward measurement is complicated by 
reversible first- and second-order kinetics [68]. The situation is made more difficult 
by the low aqueous solubility of transplatin. Arpalahti et al [158] found that k1 trans 
> k1 cis when studying the complexation of transplatin with inosine. As Miller and 
House [ 49] found the reverse it was decided to reinvestigate the reaction. Theory 
predicts that the stronger trans effect of cr over NH3 means trans > cis is the 
expected reaction order. 
The procedures adopted previously [ 49] have been repeated here and the rate of 
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chloride ion anation of trans-[PtCl(NH3)z(OH2)t remeasured (using a wider [Cl-] 
range), where kt (intercept) and k_1 (slope) are directly obtained from plots of kobs vs 
[Cl-] (Tables 3.4 and 3.5). 
Satisfactory agreement for k1 were obtained from the intercept (this work = 1.9 
X w-5 s-1' [49] = 1.9 X w-5 s-1 (25 °C)), but values for k_l (this work= 160 X w-4 M-1 
s-
1
' [49] = 305 X w-4 M-1 s-1 (25 °C)) from the slope differ by a factor of almost two. 
This, in turn, changes the value for Kl from 0.622 X 10-3 in [49] to 1.19 X 10-3 at 
25 ac and our new estimate has been used in all subsequent calculations (Table 3.4) 
and throughout this thesis (eg. pages 28, 50). Despite the changes in the absolute 
value of lc1, the activation parameters obtained for k1 and k_1 in both investigations 
are comparable within experimental error (Table 3.8). Results from this work still 
indicate that the hydrolysis of cisplatin is greater than that for transplatin by a factor 
of 2.76. A similar trend is also observed for the analogous bromide anation studies 
where lct is calculated indirectly from the intercept of the kobs vs [Bn plots (cis/trans 
= 22.4). Why this ordering (cis> trans) goes against the trans effect and other 
studies [158] is not understood. 
The trans-dibromo system gives a K1 value about ten times greater than the 
analogous chloride system (K1Br = (15.2 X 10-4 /12.6 X 10-2) = 12.1 X 10-3) which 
appears to be a normal trend when [PtBr2(Nh] systems are compared with 
[PtCh(Nh] (See Table 3.7). 
3.3.2 Bromide ion anation 
The reaction of bromide ion with [Pt(N)2(0H2)2]2+ is about five times faster 
than that of Cl- but the rates were too rapid to measure using the conventional mixing 
experimental conditions. These fast diaqua anation reactions were measured using 
stopped-flow techniques. It was possible however to measure the rate of the 
subsequent step (bromoaqua species, Equation (3.2)) once [PtBr(N)z(OH2)t had 
been generated. 
Figure 3.1: Repeat scans (180 s time interval) showing an increase in 
absorbance for the bromide ion anation of (N)z = tn. 
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The Br- anation rate of the bromoaqua (k_ 1) is again about 2- 5 times greater 
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than Cl- anation with relatively constant L~H# data within each series: ~H# =58± 2 
kJ mor1 for Bf (Table 3.4) and ~H#::::: 69 ± 4 kJ mor1 for cr [49], excluding the 
trans-(NH3)z data. 
Plots of kobs vs [Bn for reaction (3.2) were linear with positive intercepts and 
these were interpreted in terms of Equation (3.6) 
(3.6) 
Values for k1, the rate of bromide release from [PtBr2(N)z] at 25 oc, (Table 3 .5) 
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are rather more dependent on (Nh than their chloro analogues [ 49] and the activation 
parameters are more variable but in general, the loss of the first bromo ligand from 
[PtBr2CNh] is about ten times faster than the loss of the first chloro ligand. 
The trans effect theory can be used to partially explain why bromide ion 
anation is faster than chloride ion anation. Bromide has an even stronger trans effect 
than chloride and thus substitution is more favourable. It also has a greater overlap 
of the ligand orbital with the central platinum atom. It therefore implies that r 
reactions will be faster than Br- reactions. This has been qualitatively confirmed by 
preliminary experiments which showed that the first anation step (k_2) was not 
observable on the stopped-flow time scale while the second step was just observable 
using stopped-flow techniques. 
Table 3.4: Activation parameters for the bromide anation of 
[Pt Br(N)z (OH2)t (25 oc, I= 1.0 M HCI04, NaCI04, NaBr). 
(Nh 1 02/c1 L:lH# L:lS# k_J(Br)/ 
(M-Is-1) (kJ mor1) (JK1 mor1) lc1(Cl) 
cis-(NH3)2 1.99 57.8 ± 2 -84 ± 6 3.08 
cis-(pyh 2.10 57.2 ± 3 -85 ± 9 2.23 
en 6.40 63.5 ± 1 -55 ±4 3.03 
chxn 9.72 56.6 ± 4 -17 ± 10 4.79 
tn 9.25 52.9 ± 1 -87 ± 3 2.56 
Me2tn 8.70 54.8 ± 1 -62 ± 3 3.33 
trans-(NH3h 12.6 69.0 ± 5 -31 ± 15 4.13 
trans-(NH3)2 a 1.60 78.1 ± 4 -17 ± 12 -
a Data for the cr anation of trans-[PtCl(Nh(OH2)t (I= 0.1 M). 
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The rates of bromide anation (k_2, Equation (3.2)) for several [Pt11(N)2(0H2)2]2+ 
complexes have been measured on the stopped-flow time scale in acidic solution 
over a 20-25 oc temperature range (raw data are presented in Table A3.5). Plots of 
kobs vs [Bf] were linear with zero intercept indicating k2Br < 5 x 10-5 s-1. Comparison 
between the rate of anation (at 25 °C) for both chloride and bromide ions 
(k-2CBO/ k_2(Cr), Table 3.6) gives a constant ratio of 5.1 ± 0.4, excluding trans-
(NH3)2 data. For trans-(NH3h this ratio drops to 2.8. This rate increase may be due 
to the larger orbital overlap for the bromide system. 
Table 3.5: Activation parameters for the aquation of [PtBr2(N)z]3 (25 oc, I = 
1.0 M HCI04, NaCI04, NaBr). 
(N)2 104k1 ~H# ~s# k1(Br-)/ 
(s-1) (kJ mor1) (JK1 mor1) k1(Cr) 
cis-(NH3)2 4.25 87.0 ± 2 -17 ± 6 8.1 
cis-(py)2 15.8 38.5 ± 2 -93 ± 6 27 
en 5.12 70.0 ± 3 -73 ± 9 16 
chxn 17.4 53.3 ± 1 -42 ± 3 47 
tn 6.05 112 ± 5 +71 ± 15 10 
Me2tn 9.88 109 ±4 +141 ± 12 12 
trans-(NH3)2 15.2 45.7 ±4 -69 ± 12 10 
trans-(NH3)2 b 0.19 83.1 ± 5 -17 ± 15 80 
"These data were obtained from the intercept of kobs vs [Br-] plots. b Data for trans-[Pt(NhCh] (I= 
0.1 M). 
There is a relatively constant ~W within each series (~H#Br = 68 ± 2 kJ mor1, 
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~H# c1 = 64 ± 4 kJ mort) as was observed for the anation of the monoaqua (Table 
3.4). For all complexes the activation entropy is negative, indicating an associative-
interchange mechanism (as observed for the analogous chloride anation). The 
lability of the cis-diaqua ions is 10 - 20 times greater than that in the monoaqua 
([Pe1X(N)z(OH2)] +),but this increases to 33 for the trans-(NH3)z system (Table 3.6). 
As for the case of chloride anation, the trans-diaqua is more labile than the cis 
isomer due to a decrease in activation enthalpy (~H#cis = 68 kJmor1, ~H#tra11s =56 
Table 3.6: 
(N)z 
cis-(NH3)z 
en 
chxn 
tn 
Me2tn 
trans-(NH3)2 
Activation parameters for the bromide anation of 
[Pt(N)z(OH2)z]2+ (25 oc, I = 1.0 M HCI04). 
k_2 ~H# ~s# k-2(B{)/ 
(M-ts-t) (kJ mort) (JKt mort) k_2(Cr) 
0.446 67.6 ± 1 -25 ± 3 4.81 
1.29 70.9 ± 0.3 -5 ± 1 5.3 
1.13 69.9 ± 1 -9 ± 3 5.3 
1.86 67.9 ± 1 -12 ± 3 5.6 
1.53 64.9 ± 1 -24 ± 3 4.6 
4.23 56.4 ± 1 -44 ± 3 2.8 
k-2(Bf)/ 
k_t(Br-) 
22.4 
20.2 
11.6 
20.1 
17.6 
33.6 
It is interesting to note that the order for the rate of reaction at 25 oc is the 
same (trans> tn > Me2tn >en> chxn >cis) for both chloride ion and bromide ion 
anation of the diaqua although the spread is not large. We can suggest no reason for 
this order, other than unexplained steric factors. However note that for the diamines, 
a similar order has been observed for the aquation of trans-[CoCh(N)2t complexes 
[159]. 
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The temperature variation of K1 allows estimation of the quasi-thermodynamic 
parameters (non-standard state conditions) given in Table 3.7. Similar data are 
available for the chloride ion anation process [ 49] and the patterns based on the 
influence of (N)2 are similar (within a large experimental error) for both anating 
ligands. All free energy data are positive, but there is variability within the 
activation enthalpy and activation entropy data. 
Table 3.7: Quasi-thermodynamic parameters associated with the bromide 
anation of [Pt Br(N)z(OH2)t (25 ac, I= 1.0 M). 
(N)2 103K1Br ~G0_1 or 0 ~H -1 or ~S0-1 or 
-~G0-1 - ~H0-1 -~S0-1 
(kJ mor1) (kJ mor1) (JK1 mor1) 
cis-(NH3)2 21.3 (6.42)a 9.54 +29±4 +65 ± 12 
cis-(py)z 75.2 (6.31) 6.41 -19 ± 5 -85 ± 15 
en 8.0 (1.50) 12.0 +6.5 ±4 -18±12 
chxn 17.9 (1.81) 9.97 -3.2 ±4 -44 ± 12 
tn 6.54 (1.62) 12.5 +59±6 +156±18 
Me2tn 11.3 (3.22) 11.1 +54±5 +144 ± 15 
trans-(NH3)z 12.1 (1.19b) 10.9 -23 ± 9 -114 ± 27 
a Values in parentheses are 1 03K1 cJ data [ 49]. b This research. 
3.3.3 Equilibrium relationships 
If a platinum-containing compound is to be an effective anti-tumour agent then 
it is necessary for a reasonable concentration of the platinum-containing substitution-
labile complex to be available at the site of the replicating tumour. Neither cis-
[PtCh(NH3)2] nor [PtCl(OH)(NH3)2] are thought to react directly with DNA, but 
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both can provide a source of the 'active' [PtCl(NH3) 2(0H2)t. The amounts of these 
species present depends on the extent to which the equilibria represented by equation 
(3.7) occur ie. K1 (= kdk-1), and pKa3. 
~ pK,' (3.7) 
cis-[PtCl(OH)(NH3h] 
Considering this, it is interesting to see if variations of pKa3 or K1 have been 
reported for the types of dichloroplatinum(II) that are either inactive or active in 
cancer chemotherapy. 
The acid-base equilibrium constant Ka3 is difficult to measure due to the 
competing anation of the chloroaqua by chloride ion during any potentiometric 
titration. It is only recently that values of pKa3 = 6.85 (25 °C) for cisplatin and pKa3 
= 5.63 (25 °C) for transplatin have been determined [160- 161]. It is also possible 
to estimate pKa3 as being equal to the pH at the half equivalence point when adding 1 
mole of 1.0 M NaOH to a solution of the chloroaqua. This method gives a value of 
pKa3 = 7.25 at 45 oc (I= 0.2 M) [46]. For other complexes pKa3data are not 
available. Some workers have used the arithmetic mean of Ka 1 and Ka 2 (Scheme 3.1) 
as an estimate. The value for [PtCh(en)] of 6.7 (estimated in this way) [162] does 
not differ greatly from that for cisplatin (6.85). In the absence of more precise 
measurements it has been assumed that values for all other (N)2 complexes will be 
similar to 6.7. 
A pK} value of 6.7 means that at physiological pH (7.4) a chloroaqua solution 
will contain about 78 % chlorohydroxo but with pKa3 = 5.63 (the transplatin value) 
this proportion increases to 98 % [ 49]. Despite 78 % being a somewhat high 
percentage of inert chlorohydroxo it still remains an important source of active 
chloroaqua because, as the chloroaqua is removed from solution by complex 
formation, it will constantly be replaced from the 'store' of chlorohydroxo in 
proportions controlled by pKa3. 
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Consideration of K1 values for cisplatin and transplatin (ie. 6.42 x 10-3 [ 49] and 
1.19 x 1 o-3 , respectively) implies that there will be less of the chloroaqua species 
produced from transplatin than cisplatin. The unfavourable equilibrium 
concentration of trans-[PtCh(NH3)2] (relative to cisplatin), and its much lower pKa3 
value, prevent it from functioning as an effective anti-tumour drug under biological 
conditions. There is not enough trans-[PtC1(NH3) 2(0H2)t available to effectively 
inhibit DNA replication. However, if sufficient chloroaqua can be produced from 
transplatin then it will be anti-tumour active. Values for other platinum(II) amine 
complexes (Table 3.2) all have lower K1 values than cisplatin and using this rationale 
should be less effective anti-tumour agents. As none of these complexes have made it 
to clinical trials this may be an important point to consider when developing new 
anti-tumour drugs. 
K1 is the ratio of the forward (k1, aquation) and reverse (k_J, anation) rate 
constants of equation (3.1). The forward reaction, being between two neutral 
species, will proceed at a rate independent of ionic strength. The reverse reaction is 
however, a reaction between two singly charged species of the opposite sign. 
Because of this k_1 will decrease as the ionic strength increases. Consequently K1 
will also be ionic strength dependent with a value increasing with increasing I. 
Fortunately this dependence is not large, which means that the values of K1 found by 
Miller [ 49] are probably satisfactory for the biological situation where the blood 
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plasma has an ionic strength of~ 0.1 M. 
It is interesting to compare the equilibrium constant K1 for both chloride ion 
and bromide ion anation. K1Br is the larger value (K1Br = 21.3 x 10-3, K 1c1 = 6.42 x 
10-3) and this means that at equilibrium there will be more cis-[PtBr(NH3)z(OH2)t 
than cis-[PtCl(NH3)2(0H2)t. For a 1 mM solution of the dihalo complex there will 
be 88 % of the cis-chloroaqua and 96 % of the cis-bromoaqua complex. This may 
lead to the speculative thought that cis-[PtBr2(NH3)2] may be a more effective anti-
tumour drug than cisplatin as more of the anti-tumour active bromoaqua species is 
produced. However, the bromoaqua complex is more reactive than the equivalent 
chloride monoaqua and this may lead to it reacting indiscriminately with a wider 
range of nucleophiles and thus being less effective and causing more side-effects. 
It has not been measured during the course of this work but it should be 
possible to measure the rate of chloride ion anation of the bromoaqua species. The 
main problem associated with this will be the production of the bromoaqua complex 
independent of diaqua and dibromo species. Likewise the bromide ion anation of the 
chloroaqua complex should also be possible. One method for generating pure 
chloroaqua using column chromatography has been previously described by Miller et 
al [44]. 
3.3.4 Crystal structures 
In our work, it is general practice to retain the solutions from kinetic runs for 
platinum recycling after evaporation. Residues from the bromide ion anation studies 
were left in open beakers and after several weeks, small amounts of orange crystals 
deposited. These were assumed to be [PtBr2(N2)], and so to confirm this assumption 
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a single crystal structural analysis was performed on the (N)z =ethylenediamine (en) 
compound. It was somewhat surprising to find that spontaneous oxidation had 
occurred and the products were platinum(IV) complexes [PtBr4(N2)]. This oxidation 
is thought to occur via atmospheric oxidation or through bromine oxidation 
(produced by atmospheric oxidation of bromide in the residue beakers). An X-ray 
structural analysis of the (N)z = propanediamine (tn) compound gave a similar result 
and the structures of neutral [PtBr4(en)] (I) and [PtBr4(tn)] (II) complexes are shown 
in Figure 3 .2. 
While the synthesis of [PtC14(en)] has been reported [163], our work appears to 
be the first description of the tetrabromo complex. The average Pt(IV)-Br and 
Pt(IV)-N bond distances are 2.455(5) and 2.04(2) A, respectively. The latter are very 
similar to Pt(II)-N distances (2.00- 2.09 A) in cis-[PtCh(NH3)z] systems [47]. The 
five-membered ring torsion angle of 49.8° in [PtBr4(en)] indicates that the en ring is 
virtually strain-free [164]. 
3.3.5 Effect of pressure 
A high-pressure stopped-flow instrument [165] was used to measure the 
activation volumes for some anation reactions of platinum(II) amine complexes. The 
reactions studied were chosen to fit within the limitations of the instrument ( eg. 
wavelength). 
In all systems studied (Table A3.7) it was found that k increases with P 
resulting in a small, negative 1':!..V# ( -5 to -11 cm3mor1) (Table 3.8). This indicates an 
associative-interchange mechanism which is in agreement with that indicated by the 
thermal activation parameters (L1~ and L1S#) (Table 3.8). (See Chapter 2, Section 
2.7). 
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Br2 
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H1D 
Figure 3.2: X-ray crystal structures of [PtBr4(en)] (I) and [PtBr4(tn)] (H). 
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There was very little difference in the values for the activation volumes for the 
chloride and bromide anation of both the diaqua (cis-[Pt(N)z(OH2hf+) and 
monoaqua (cis-[PtX(N)z(OH2)t) (Table 3.8). Activation volume values for the 
aquation of the platinum(II) complexes (~ V#) are not presented as it was found that 
the errors in determining the intercept of the appropriate plots were too large. 
3.3.6 Comparison with palladium(II) 
Platinum(II) and palladium(II) have comparable ionic radii (60 ppm and 64 
ppm, respectively) and behave very similarly except for palladium(II) complexes 
being 105 more reactive than their platinum(II) analogues. This is mainly due to their 
kinetic lability and weaker Pd-X bond strengths. Both metals are soft Lewis acids 
and prefer N and S donor ligands. It is believed that high lability is one reason why 
palladium(II) complexes are ineffective anti-tumour agents. Although there is a 
large difference in reactivity between the two metals the overall equilibrium 
constants are similar and thus palladium(II) complexes can be used to model 
platinum(II) chemistry [166]. 
It was found that reported data for model palladium(II) complexes support the 
strong preference of platinum(II) drugs for the N7 position of guanine over other 
coordination sites of DNA [167]. There is also good correlation between the trends 
observed for palladium(II) and the analogous platinum(II) complexes, and therefore 
it is possible to extrapolate palladium(II) results to the biologically relevant 
platinum(II) situation. Excellent correlation between structure and reactivity are 
observed for the interaction of both metal centres with nucleic acid components 
[167]. 
3.4 CONCLUSIONS 
The work presented in this chapter adds to the kinetic and equilibrium data 
available for the reaction of cisplatin and its derivatives with small nucleophiles. 
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A complete list of data (rate, activation enthalpy, activation entropy and activation 
volume) are presented in Table 3.8. These activation parameters point towards the 
anation process occurring via an associative-interchange mechanism. This means 
that the reaction proceeds via the formation of a five coordinate transition state ie. 
both the entering group and leaving group are partially 'bound' to the central 
platinum atom and exchange by an interchange process. This is in agreement with 
other studies on the substitution of square-planar platinum(Il) complexes, which have 
been found to proceed in this way. 
The difference in reactivity across a range of platinum(II) amine complexes 
can be used to explain why cisplatin is the best (or most appropriate) anti-tumour 
active complex. Data for both the chloride and bromide anation/aquation show that 
cisplatin is the least reactive of all the complexes studied. This means that the dmg 
is more likely to remain intact as the dichloro complex before reaching the tumour 
site. Side reactions between the chloroaqua species (produced by aquation) and other 
biological complexes (eg. thiols in proteins) are thus minimised and the cis-
chloroaqua concentrations remain high, which therefore leads to a more effective 
chemotherapeutic dmg. 
Scheme 3.1 : Rate and equilibrium constants for 
the hydrolysis of trans-(NH3)2 
(I = 0.1 M, T = 25 °C). 
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Table 3.8: Activation parameters for the aquation and anation of some [PtX2(N)z]n+ complexes (1.0 M HC104). 
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(M-1s-1) 
4 10 k_1 
(M-1s-1) 
105k1 
(s-1) 
2 10 k_2 
(M-1s-1) 
ka 
X Mf 
(kJmor1) 
LiS# Ll y# I kxa 
(JK1mor1) (cm3mor1) 
cis-(NH3)1 
64.6b 76.9 ± 6b -29 ± 12 b - 160c 
4.15b 93.6 ± 8b -15 ± 16b -9.5 ± 1.2f 1.60c 
9.27d,e 66.3 ± 2d 
-42 ± 6d - 151d 
tn 
361b,c 65.3 ± 2b,c -53± 4b,c 
-
261 b,c 
5.88b 97±3b -1 ± 6b - 8.4b,c 
34.4d 67.2 ±3d -28 ± 9d -7.41 ± 0.3c 33.2d 
Mf 
(kJmor1) 
LiS# f1y# I kxa 
(JK-1mor1) (cm3mor1) 
X=Cl 
trans-(NH3)2 
78.1±4c -17 ± 12c - 211b 
83.1 ± 5c -17 ± 16c - 3.2b,c 
50.6 ± 1d -72 ±3d - 24.5d 
Me2tn 
72.1 ± 6b,c -33 ± 12 b,c 
-
203b,c 
82.6 ± 3b,c -46 ± 6b,c 
- 10.3b 
57.4 ±3d -61 ± 9d - 21.4d 
Mf 
(kJmor1) 
69.7 ± 3b 
97.1 ± 3b,c 
58.8 ± 1d 
69.5 ± 5b,c 
55.2 ±4b 
66±2d 
LiS# !lV# 
(JK-1mor1) (cm3mor1) 
en 
-43 ± 6b -9.4 ± 0.5c 
-5 ± 6b,c 
-9.2± 1f 
-59± 2d -5.27 ± 1c 
chxn 
-44 ± 10b,c 
-
-136 ± 8b -
-36 ± 6d -
0\ 
\0 
X=Br 
cis-(NH3)2 trans-(NH3)2 
102k_1 1.99d 57.8 ± 2.2d -84 ± 7d -10.2 ± 0.4c 12.6d 69.0 ± 5d -31 ± 15d 
(M-1s-1) 
104k1 4.25d 87 ± 2.3d -17 ± 7d - 15.2d 45.7 ±4d -69 ± 12d 
(s-1) 
k_2 
(M-1s-1) 0.45 67.6 ±0.7 -25 ± 2.1 -5.08 ± 0.6c 4.23 56.4 ± 1.3 -44 ± 3.9 
tn Me2tn 
102k-l 9.25d 52.9 ± 1d -87 ± 2d -10.4 ± 0.8c 8.7d 54.8 ± 1d -62 ±3d 
(M-Is-1) 
104k1 
(s-1) 6.05d 112 ± 5d +71 ± 15d - 9.88d 109 ±4d +141 ± 12d 
k_2 
(M-1s-1) 1.86 67.9 ± 0.7 -12 ± 2.1 -5.82 ± 1c 1.53 64.9 ± 1 -24±3 
a See Equations (3.1) and (3.2). b Ref. [49]. c 0.1 M HC104. ct Ref. [168]. e Ref. [45]. f Ref. [169]. 
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CHAPTER4 
THE REDUCTION OF PLATINUM(IV) 
COMPLEXES 
4.1 INTRODUCTION 
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One of the many early generalisations made regarding the structure-activity 
relationships of platinum anti-tumour agents was that the central metal must be in the 
+II oxidation state [23 - 26]. This is now known not to be a requirement for 
biological activity as there are currently platinum(IV) complexes which show 
particular promise as anti-tumour drugs. These include CHIP, cis, cis, trans-
[PtNC12(iPrNH2)2(0H)2] [85, 93], tetraplatin, [PtNC14(chxn)] [36, 21], oxaliplatin 
(Figure 1.2), a cyclohexanediamine containing complex [21], and JM-216, cis, trans, 
cis-[PtNC12(0Ac)2(NH3)(cyclohexylamine)] (Figure 1.1) [21, 170]. These drugs are 
thought to act as prodrugs for platinum(II) species, with the active platinum(II) 
complexes being produced by reduction within the plasma. Studies have shown that 
when platinum(IV) drugs are administered to patients, the main excreted complex is 
the platinum(II) reduction product [34]. 
Such results raise the question as to the nature of the oxidation state of 
platinum when the drug finally reaches the site of the replicating cancer cells [21, 
85], as platinum(IV) complexes are generally regarded as being substitutionally inert. 
Biological reduction of platinum(IV) to platinum(II) has been proposed [21], but 
further information on the rates of reduction of platinum(IV) species with both 
biological and abiological reducing agents is desirable. Recent information in this 
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area comes from the work of Peloso who used Fe(II) [171], ferrocene [100- 101], 
iodide ion [100- 101, 171] and platinum(II) complexes [100- 102, 172] as reducing 
agents and Elding who used glutathione, R-(+)-(L)-cysteine, penicillamine, L-
methionine and thioglycolic acid as reductants [89- 90]. 
Platinum(IV) complexes, as 'third generation' platinum drugs, may offer the 
advantage of being able to be taken in an oral form ie. a patient would be able to take 
a pill at home. This reduces cost and stress for the patient, factors which are also a 
consideration in the development of new drugs and improved treatment protocols. 
Side-effects have also shown to be reduced with the platinum(IV) drugs. One 
speculative model for the observed increase in side-effects when platinum(II) drugs 
are used, is that in this form the drug may react with other biological nucleophiles 
before reaching the tumour site. In the case of platinum(IV) drugs, they must 
initially be reduced to the active platinum(II) species. This means that the drug 
remains in the inert platinum(IV) form which reduces unwanted interactions of the 
platinum(II) complexes, and hence leads to fewer side-effects. 
Chapter 4 reports on the use of ascorbic acid [91, 93], hydroxylamine 
hydrochloride [95], iron(II), thiosulfate and Sn(II) [100] as potential electron transfer 
agents, with cis-[PtCl4(NH3)2], trans-[PtCl4(NH3) 2] and [PtC16]2- as model 
platinum(IV) systems. Ascorbic acid was selected as an example of a biological 
reducing agent, while the other reductants were chosen because of their chemical 
significance in an effort to elucidate the nature of the underlying redox mechanism. 
4.2 EXPERIMENTAL 
4.2.1 Materials 
The platinum(IV) complexes cis-[PtC14(NH3)2], trans-[PtCl4(NH3)2] and 
K2[PtC16] were commercially available (Strem Chemical Company) and used as 
supplied. All other chemicals were AnalaR or best reagent grade available. 
4.2.1.1 Sn(II) 
Solutions of the three platinum(IV) complexes were prepared in 1 M HCl 
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(5 mg/50 mL, cis-[PtCl4(NH3)2] 0.27 mM, trans-[PtCl4(NH3)2] 0.27 mM, K2[PtCl6] 
0.21 mM). Tin(II) solutions were freshly prepared from SnCh in 1 M HCl and 
concentrations determined iodometrically [ 144b]. 
4.2.1.2 Ascorbic acid 
Solutions of all three complexes were prepared in 0.1 M NaCl (5 mg/50 mL, 
cis-[PtCl4(NH3)2] 0.27 mM, trans-[PtCl4(NH3)2] 0.27 mM, K2[PtCl6] 0.21 mM). 
Ascorbic acid solutions were prepared in 0.1 M NaCl and the pH adjusted to 4.0 
using HC104. The concentration of ascorbic acid was determined by titration with 
iodine solution. 
4.2.1.3 Fe(II) 
Solutions of platinum(IV) complexes cis-[PtC14(NH3)2], trans-[PtCl4(NH3)2] 
(5 mg/50 mL 1 M HCl, 0.27 mM) and [PtC16f (5 mg/50 mL 1M HCl, 0.21 mM) 
were prepared. [PtC16] 2- solutions (5 mg/50 mL) were also prepared in 0.1 M HCl 
and 1.0 M HC104. Freshly made iron(II) solutions were prepared in the same media 
as the platinum(IV) complexes from (NH4)2Fe(S04)2.6H20. 
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4.2.1 A Hydroxylamine hydrochloride 
The platinum(IV) complexes (5 mg/50 mL, cis-[PtCl4(NH3)z] 0.27 mM, trans-
[PtC14(NH3)z] 0.27 mM, [PtC16]2- 0.21 mM) were dissolved in 0.1 M NaCl. 
Hydroxylamine hydrochloride solutions were also prepared in 0.1 M NaCI. 
All three platinum(IV) complexes were prepared in 0.1 M NaCl (25 mg/50 mL, 
cis-[PtCl4(NH3)z] 1.35 mM, trans-[PtCl4(NH3)z] 1.35 mM, [PtCI6f 1.03 mM). 
Sodium thiosulfate solutions were also prepared in 0.1 M NaCl. 
4.2.2 Reduction Kinetics 
Most reactions were monitored at fixed wavelengths using a Perkin Elmer 'A-2 
Recording Spectrophotometer, but the rapid reduction of both cis-[PtCl4(NH3)2] and 
trans-[PtC4(NH3)z] by sodium thiosulfate was studied using an Applied Photo-
Physics Biosequential SX-18MV Stopped-Flow Reaction Analyser. All reactions 
were followed for 6- 8 half-lives and the pseudo-first-order ([reducing agent] 2 
10[Pt(IV)]) rate constants (kobs) calculated using 20- 30 data points over this interval. 
The effect of temperature on the reaction rate was also determined and the 
appropriate activation parameters calculated from these data. 
4.2.2.1 Sn(II), Fe(II), Na2S203 as reducing agents 
Plots of kobs vs [reducing agent] were linear with zero intercept allowing 
calculation of the second order rate constant from the expression k2 = kobs[reducing 
agent]-1• 
75 
4.2.2.2 Ascorbic acid, hydroxylamine hydrochloride as reducing agents 
Plots of kobs vs [reducing agent] were non-linear and reached saturation values 
at high concentrations of reducing agent, but reciprocal plots (kobs-1 versus 
[reducing agentr1) were linear. Values of ket (the rate of electron transfer) and Kos 
(constant for the formation of the outer-sphere encounter complex) were calculated 
from these data using a non-linear least squares programme or from the slopes and 
intercepts of the reciprocal plots. Of these two methods the non-linear least-squares 
technique is the more accurate. For these calculations a spreadsheet programme 
(Microsoft Excel) was used to fit the raw experimental data to a non-linear equation. 
Double reciprocal plots weight low values very severely, often by a factor of one 
hundred which greatly magnifies any errors. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Tin(II) 
Preliminary investigations showed that in the presence of excess Sn(II) in 1.0 
M HCl, the absorption spectrum of the octahedral platinum(IV) complexes (also in 
1.0 M HCl), slowly changed to that of the corresponding square-planar platinum(Il) 
complex (Equation (4.1)). At longer times, further reduction or complexation 
occurred which produced absorption spectral changes consistent with the formation 
of colloidal precipitates (light scattering) [173]. 
Absorbance vs time data for the first reaction (Equation (4.1)), with Sn(II) in 
excess, followed first-order kinetics and plots of kobs (s-1) vs [Sn(II)] were linear with 
zero intercept (Figure 4.1). 
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Il m- -[Pt Cl2(N)2] + Sn(IV) + 2Cl (4.1) 
(where (N)2 is an ammine ligand or cr for [PtCI6t) 
The reactions were sufficiently fast to avoid any major loss of Sn(Il) by due to 
oxidation by dissolved molecular oxygen. Values of k2 (M-1s-1) were obtained from 
the expression k2 = kobs[Sn(II)f1 (Table 4.1). Raw data are presented in Table A4.1. 
Variation of [H+] (using HC104) and [CI-] (using NaCl), both at I= 1.0 M, 
showed that the reaction rate was independent of [H+] (0.1 - 1.0 M) but increased as 
the [Cl-] was increased. Plots of kobs vs [Cl-] were linear with a zero intercept 
suggesting the general rate law ( 4.2) with k3 = 0. 
-d[Pt(IV)]/dt = {k3 + k4[CI-]}[Pt(IV)][Sn(II)] (4.2) 
All subsequent measurements were made in 1.0 M HCI so that k2 ksn = k4[Cl-]. 
Figure 4.1: Plot of kobs vs [Sn(II)] for the reduction of cis-[PtCI4(NH3)z] 
by Sn(II). 
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The above observations are entirely consistent with an earlier investigation of 
the reaction between [PtN Cl6]2-and Sn(Il) [ 103] and the agreement between the 
reported kinetic parameters for this reaction and those obtained here, is most 
satisfactory (Table 4.1). When platinum(II) complexes are used as reducing agents 
for platinum(IV), a rate law similar to (4.2) is also observed, and for most of these 
reactions k3 ~ 0 [100]. 
Table 4.1: Activation parameters for the reduction of platinum(IV) 
complexes by Sn(II) (25 °C). 
Complex k2 L\H# L\S# 
(M-ls-1) (kJ mor1) (JK1 mor1) 
[PtC16]2- a 308 31.0 ± 1 -93 ± 3 
[PtC16f b 378 29 ± 1 -101 ± 3 
cis-[PtCl4(NH3)2] a 177 50±3 -35 ±9 
trans-[PtCl4(NH3)2] a 131 49± 1 -39±3 
a 1.0 M HCI. b Ref. [103], l.O M HCI. 
Of the three platinum(IV) complexes studied, the neutral cis- and 
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trans-[PtC14(NH3)2] were reduced at very similar rates (Table 4.1 ), at about half that 
observed for [PtCI6f. Large changes in stereochemistry are expected for both 
platinum(IV) and Sn(II) once the electron transfer has occurred, with octahedral 
platinum(IV) producing square-planar platinum(II), and trigonal pyramidal 
[SniiCh(OH2)2] [174- 175] producing octahedral [Sn1vClx(OH2)6-x](4-x)+ [176]. 
Although [SnChr shows little tendency to add additional ligands in the solid state 
[174] there is the possibility of an atom transfer redox process via a [LsPt-Cl-
SnCht- bridge in solution. 
The chloride ion dependence is reflected in the pre-equilibrium with added Cl-
increasing the amount of [SnChr [100]. This mechanistic scheme follows that 
proposed by Peloso for the platinum(II) reduction of platinum(IV) [100]. 
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[SnnC12(0H2hJ + cr 
K [SnnC13r + H20 (4.3) 
[SnnC13r + [L4CIPt1v Cl] kl .. [L4C1Pt1v ClSnnC13r (4.4) k_l 
[L4C1Pt1v ClSnnC13r ket • [L4Ptn] + [Sn1v Cl4(0H2hJ + Cf (4.5) 
-d[Pt(IV)]/dt 
= k1ket [SnnC13 -][Pt(IV)] ket + k_l 
= 
klketK [ Cl-] [ S n (II)-] [Pt(IV)] 
ket + k_l 
= ksn[Sn(II)][Pt(IV)] (4.6) 
where ksn = klketK [Cr] (4.7) 
ket + k_l 
4.3.2 Ascorbic acid 
Evans and Green [93] have investigated the kinetics of the reaction between 
CHIP and ascorbic acid. They found a linear dependence on ascorbic acid 
concentration and plots of [ascorbic acidh vs kobs (pH unspecified) had a positive 
intercept that was difficult to accommodate in any plausible mechanistic scheme. 
For the model platinum(IV) compounds used in this study, plots of kobs (s-1) vs 
[ascorbic acidh (in excess, at pH= 4.0, I= 0.1 M, NaCl) are curved. Raw data are 
presented in Table A4.2. 
There are three possible proton related reactants for the diprotic ascorbic acid 
(H2A) [36] namely H2A, HA- and A2- (Equations (4.8) and (4.9)), with 
dehydroascorbic acid as the reduction product [ 177]. 
HA +W K1 = 6.67 x w-5 
Kz = 2.69 X w-lZ 
(4.8) 
(4.9) 
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A general increase in kobs with increasing pH (pH= 4.0- 6.0, I= 0.1 M NaCl) 
is observed, suggesting A2- is the dominant reactant in this pH region. 
As the pK1 value of ascorbic acid is close to 4.0, the selected pH is in the 
ascorbic acid/ascorbate ion buffer region. HA- is often orders of magnitude more 
reactive than H2A and this may cause the rate constants to be extremely pH sensitive 
in this pH range. Normally one has to go to pH 6.0 to reach a plateau [178] where all 
the ascorbic acid is in the ascorbate anion form, but if A 2- is extremely reactive, the 
plateau is sometimes obscured. 
Increasing ionic strength and [Cl-] (varied independently at pH= 4.0) caused a 
decrease in the reaction rate, but both effects are rather weak. All the listed rate 
constants (kobs, s-1) were obtained at pH= 4.0, I= 0.1 M NaCI. 
The curvature in the kobs vs [ascorbic acidh plots can be analysed in terms of 
classical outer-sphere precursor formation, followed by rate-determining electron 
transfer (Equations (4.10) and (4.11)). 
Pt(IV) + HA-
{ Pt(IV) .HA-} 
with rate law (4.12) 
-d[Pt(IV) ]/ dt = 
Pt(ll) + A2-
Kosket [Pt(IV)][HA-] 
1 + K08[HA-] 
(4.10) 
(4.11) 
(4.12) 
Plots of kobs- 1 vs [ascorbic acidh-1 were linear ([HA-] is proportional to 
[ascorbic acid] Tat constant pH). ket-I can be obtained from the intercept and 
(ketK05r1 from the slope of these plots, or the data can be fitted using non-linear 
least-squares analysis (Table 4.2). 
Table 4.2: Activation parameters for the reduction of platinum(IV) 
complexes by ascorbic acid (0.1 M NaCI, 25 °C ). 
Complex ket Kos swa f1S#a 
(s-I) (kJmof1) (JK1mof1) 
[PtCI6f 0.172 . o.65 x w-3 78±2 2±5 
[PtCI6t b 0.673 - 70.8 -23 
cis-[PtCl4(NH3)2] 8.5 x w-3 4.18 x w-3 35.7 ± 0.4 -164 ± 1.5 
trans-[PtCI4(NH3)2] 10 x w-3 2.33 x w-3 35.7 ± 1 -164 ± 3 
"For ket· b Ref. [94], 0.12 M HCI, 35 oc. 
In strong acid, the K08[HA-] term in the denominator will become very small 
relative to 1 and rate law (4.12) simplifies to (4.13) 
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(4.13) 
as observed by Mehrotra et al [94] for the reduction of [PtC16]2- by ascorbic acid in 
0.12 M HCI (Table 4.2). The difference in activation enthalpy between the two 
neutral complexes and the negative hexachloroplatinate may point to different 
mechanisms. It was found for hexachloroplatinate that the reaction showed a 
positive salt effect, which suggests that the rate-determining step would involve two 
similarly charged ions interacting ie. HA- and [PtC16]2-. This would produce the 
ascorbate free radical. A mechanism for this could be: 
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slow 
This mechanism also leads to the same rate law ( 4.13) as above. In a redox 
process between a transition element and a reducing agent, the formation of a free 
radical or unstable intermediate, indicative of a one-electron transfer step, is likely to 
be a more endothermic process than the corresponding two-electron transfer [96]. 
This may mean that, as for the oxidation of platinum(II) by peroxydisulfate (see 
Chapter 5), electrostatics play an important role in determining the reaction 
mechanism. 
The effect of pH on the reduction of ascorbic acid, over the pH range (1.0-
8.0), was recently investigated by House et al [92]. The reaction was barely 
measurable (ie. slow) at pH< 3.0 but once past pH= 4.0, the reaction becomes very 
fast (ie. requiring stopped-flow techniques). Implications for the biological system 
mean that at the pH of plasma, ascorbic acid will react quickly with platinum(IV) 
complexes. As well as being extremely pH sensitive, the reactions needed to be 
studied in the absence of oxygen and the presence of EDTA to remove any trace 
metal catalysis. Once these conditions were satisfied the reactions obeyed normal 
first-order kinetics without 'saturation'. Bose and Weaver [91] have recently 
published a paper detailing the presence of an ascorbate radical anion being produced 
in the reaction. They were working in oxygen-free solutions without the presence of 
EDTA, and were getting very complicated kinetics. 
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4.3.3 Hydroxylamine hydrochloride 
Hydroxylamine is an unstable endoergic compound (AGf = +23 kJmor1). Its 
standard reduction potentials indicate that it can act as both an oxidising and 
reducing agent, but it more readily effects reduction reactions. This reaction does not 
produce N2, but instead N20 is produced in a mechanistically complex reaction. 
(4.14) 
The kinetics of the reduction of [PtC16] 2" by hydroxylamine hydrochloride have 
been studied by Sen Gupta et al [95]. Their work is reinvestigated here under 
differing pH conditions and with a wider hydroxylamine concentration range. Data 
for the reduction of cis- and trans-[PtC14(NH3)z] are also reported (Table 4.3). 
Repeat absorbance scans showed an overall decrease in absorbance (Figure 4.2). 
Figure 4.2: Repeat scans (180 s time interval) showing the decrease in 
absorbance for the reduction of trans-[PtCI4(NH3)z] by 
hydroxylamine (14 mM, 0.1 M NaCI, 40 °C). 
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In all cases plots of kobs vs [hydroxylamine] were curved (Figure 4.3), but 
reciprocal plots (llkobs vs 1/[hydroxylamine]) were linear with positive y-intercepts. 
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Raw data are presented in Table A4.3. As for ascorbic acid, these suggest a 
mechanism involving encounter complex formation prior to electron transfer. 
{Pt(IV).NH20H} Pt(II) + oxidation 
products 
(4.15) 
NH30H+ (4.16) 
Equations (4.15) and (4.16) give rise to the rate law (4.17) 
rate 
= (4.17) 
which shows the inhibitory effect of H+, suggesting that it is the unprotonated form 
of hydroxylamine that is the reactive species in solution. ket (the rate of electron 
transfer) and Kos (the constant for the formation of the outer-sphere encounter 
complex) can be calculated from the reciprocal plots (where ket = (interceptr1 and 
ketKos = (sloper1) or by non-linear least-squares analysis. 
Figure 4.3: Plot of kobs vs [hydroxylamine] for the reduction of 
cis-[PtC14(NH3) 2] by hydroxylamine. 
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An outer-sphere mechanism is favoured as the possibility of bridging in the transition 
state is unlikely. 
Table 4.3: Activation parameters for the reduction of platinum(IV) 
complexes by hydroxylamine (0.1 M NaCl, 25 °C). 
Complex ket Kos LiH#a LiS# a 
(s-1) (kJmor1) (JK-1mor1) 
[PtC16]2- 4.33 x w-4 155 64±2 -95 ± 6 
[PtC16t b - - 68.6 ± 2 -80±6 
cis-[PtCl4(NH3)2] 1.21 x w-4 47.5 72.8 ± 0.5 -76 ± 1.5 
trans- [PtCl4(NH3)2] 5.12 x w-4 55.8 48.1 ± 0.2 -147 ± 1 
"For ket· b Ref. [95], pH= 4.8, 35 °C. 
4.3.4 Iron(II) 
Iron is a trace metal found in the body. It is incorporated into haemoglobin, 
which is used for transporting oxygen around the body. It has two main oxidation 
states, Fe2+ and Fe3+. This opens up the area of redox chemistry - with iron being 
both a reductant (Fe2+) and oxidant (Fe3+). Peloso has done some research into 
platinum redox kinetics with Fe(II). He has concentrated on studying the role of 
steric hindrance on a range of reactions and has used iron(II) as a reducing agent in 
one major study [100]. In his work he used ferrocene in organic solvents as the 
reductant. This differs greatly from the research presented here which used ferrous 
ammonium sulfate in aqueous solution. In this research it was decided to study the 
reduction of platinum(IV) by iron(Il) to allow comparison with the biological 
reducing agent ascorbic acid, and to see if a one-electron reductant would have any 
effect on the reaction mechanism. 
85 
The reduction of [PtC16f was studied in three different media (1.0 M HCl, 
0.1 M HCl and 1.0 M HC104) whereas cis- and trans-[PtC14(NH3)z] were only 
studied in 1.0 M HCl. With Fe(II) in HCl the absorbance of all three complexes 
increased over time to a different constant value for each complex. However a 
different pattern was seen for [PtC16f and Fe(II) in HC104, where the absorbance 
decreased over time. The second order rate constant, k2, for the reduction of Pt(IV) 
by Fe(II) can be found from the slope of the kobs vs [Fe(II)] plot ie. k2 = kobs[Fe(II)r 
1
• Data are presented in Table A4.4. The similarity of all activation parameters 
points to a common mechanism (Table 4.4). This could involve two one-electron 
transfer steps following the formation of a bridged species where, in the case of 
perchloric acid, x=O. Only a small variation in rate with [Cr] was observed. 
The rate law for the bimolecular process is: 
rate = k2[Pt(IV)] [Fe(II)] (4.19) 
Table 4.4: Activation parameters for the reduction of platinum(IV) by 
iron(II) (25 °C). 
Complex k2 L\H# L\S# 
(M-'s-1) (kJmor1) (JK1mor1) 
[PtC16]2- a 0.274 59 ±2 -59±6 
[PtC16]2- b 0.132 58 ±2 -67 ±6 
[PtC16f c 0.158 50±2 -91 ± 6 
cis-[PtCl4(NH3)2] a 1.21 xl0-3 82±3 -34±9 
trans-[PtCl4(NH3)z]a 1.54 xl0-3 79±2 -26±6 
a 0.1 M HCI. b 1.0 M HCl. c 1.0 M HCl04. 
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This is a mechanism similar to that proposed by Peloso for the reduction of Pt(IV) by 
ferrocene in methanolic solutions [175]. 
4.3.5 Thiosulfate 
There are a wide range of sulfur oxoanions, many of which are important in 
both the laboratory and industry. The sulfur in thiosulfate (S20?) has an oxidation 
number of two, but the environments of the two S atoms are quite different. 
s 2-
1 
,.s .. 
o'''l ''''1o 0 thiosulfate 
It is a mild reducing agent and generally reacts via two-electron transfer steps with 
an oxygen-transfer pathway. Likely reaction products from thiosulfate reduction will 
be the corresponding platinum(Il) product and dithionate (S40t). 
The model platinum(IV) complexes were reacted with thiosulfate in 0.1 M 
NaCL All three complexes showed a decrease in absorbance, reaching a constant 
infinity value (Figure 4.4). 
Figure 4.4: Absorbance vs time curve for the reduction of [PtCI6] 2" by 
thiosulfate (27.5 mM, 0.1 M NaCI, 390 nm, 25 °C). 
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The reduction of the three model platinum(IV) complexes by thiosulfate has 
the rate law 
rate kz[Pt(IV)][ SzOlJ (4.20) 
The rate of reduction of [PtC16]2- was considerably slower than the reduction of 
the neutral cis- and trans-[PtCl4(NH3)z] due to the less favourable reaction between 
two negatively charged species (Table 4.5). This electrostatic repulsion accounts for 
the more negative activation entropy associated with [PtC16f-. Data are presented in 
TableA4.5. 
The mechanism for thiosulfate reduction will most probably involve a two-
electron transfer step via an outer-sphere mechanism. The product will be the related 
platinum(II) species, the platinum(IV) having lost two chloride ions. 
Table 4.5: Activation parameters for the reduction of platinum(IV) 
complexes by S2ol· (0.1 M NaCI, 25 °C). 
Complex kz ilH# AS# 
(M-ls-1) (kJmor1) (JK1mof1) 
[PtCI6t 0.567 40±2 -117 ± 6 
cis-[PtCl4(NH3)2] 15.7 62± 1 -15 ± 3 
trans-[PtCl4(NH3)z] 11.7 59.7 ± 0.5 -24±2 
No chloride ion effect in the reduction of [PtCI6] 2- was found, but a positive salt 
effect was observed, as expected for a reaction between ions of the same charge. 
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4.3.6 Correlation with reduction potential 
The rate of a reaction can often be correlated with the reduction potential for 
the reaction. It was decided to compare the rate of reduction of hexachloroplatinate 
with the reduction potential of three of the reducing agents to see if there are any 
trends in reactivity. 
Table 4.6: Correlation of rate constant with reduction potential. 
kred (25 oc) Reduction potential 
308 M-1 s-1 Sn4+ + 2e ---7Sn2+ 0.151 v 
0.567 M-IS-I s4ot + 2e ---7 2s2ol- 0.08V 
0.274 M-1 s-1 Fe3+ + e 
---7 Fe2+ 0.771 v 
As can be seen from Table 4.6, there appears to be no correlation between rate and 
redox potential. If the two-electron transfer agents are considered (Sn2+ and S2032-) 
the order holds ie. Sn(II) is a 'better' reducing agent and it has the higher reduction 
potential. Fe(II) is a one-electron reducing agent and this may be one reason why the 
correlation does not hold for all complexes. 
4.3.7 Other reductants 
Other unsuccessful reductants investigated included hydroquinone, r, oxalate 
and sulfite. Cysteine was also evaluated as a reducing agent without success. This is 
thought to be due to the pH (0.1 M NaCl, pH= 7.45) at which the reaction was 
studied. After this work was completed two papers by Elding et al [89 - 90] were 
published detailing the reduction of platinum(IV) by R -( + )-(L )-cysteine, glutathione, 
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penicillamine, L-methionine and thioglycolic acid. These reaction rates were found 
to be very sensitive to acid conditions. This provides an explanation as to why no 
reaction was observed. In fact, the reaction was very fast and thus had instantly gone 
to completion under the conventional mixing techniques used. 
4.4 CONCLUSIONS 
There is much speculation in the literature as to the role of platinum(III) in the 
two-electron transfer Pt(II) I Pt(IV) redox system. The reductants and oxidants used 
in this study have been either one-electron (non-complementary) or two-electron 
(complementary) acceptors. The reducing agents Sn(II), ascorbic acid, 
hydroxylamine hydrochloride and thiosulfate are all two-electron donors and no 
reason is seen to postulate any mechanism other than direct two-electron transfer 
except for the reduction of hexachloroplatinate by Sn(II). The other systems do 
however differ in detail, as the Sn(II) and Fe(II) reductions are proposed to proceed 
via [PtC16t substitution into the labile reductant coordination sphere ie. an inner-
sphere mechanism. An outer-sphere activated complex is proposed for the ascorbic 
acid and hydroxylamine reductions of inert platinum(IV). 
The in vivo reduction of platinum(IV) anti-tumour drugs is thought to be their 
primary mode of action. This study measured the rates of reduction of platinum(IV) 
complexes to attempt to determine if in vivo reduction is a viable pathway. Only one 
biological reducing agent (ascorbic acid) was used, other reductants were used to 
explore mechanistic differences. Ascorbic acid effects reduction of platinum(IV) at a 
rate that would allow in vivo reduction to proceed. However there are other, more 
plentiful biological reductants (ie. glutathione, cysteine) which have been studied by 
other groups. Results from these studies show that ascorbic acid and thiol-containing 
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complexes are effective reducing agents and thus it seems likely, considering all the 
chemical and biochemical research, that platinum(IV) compounds may act as 
prodrugs for the anti-tumour active platinum(II) complexes. 
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CHAPTERS 
THE OXIDATION OF PLATINUM(II) 
COMPLEXES 
5.1 INTRODUCTION 
Since the discovery of the anti-tumour activity of cis-diamminedichloro-
platinum(ll), there has been significant interest in the chemistry of simple four-
coordinate square-planar platinum(II) complexes [21, 36, 179]. 
Several thousand potentially active platinum(ll) complexes have now been 
tested for anti-tumour properties [21]. It has been established that the early stmcture-
activity relationships which were developed to correlate biological success and 
stmcture, do not always apply [21]. For example, the ligands on carboplatin, 
diammine( cyclobutane-1, 1-dicarboxylato )platinum(II), are many orders of 
magnitude more inert [145, 180 181] than those for cisplatin [44- 51], yet both are 
successful anti-tumour dmgs. 
A further generalisation that has recently been challenged is that the platinum 
IV 
must be in the ll+ oxidation state. CHIP, cis, cis ,trans-[Pt Cl2(iPrNH2)z(OH)2] [36, 
IV 
85, 93], tetraplatin, [Pt Cl4(chxn)] [21, 36], and JM-216, cis, trans, cis-
IV [Pt Clz(OAc)2(NH3)(cyclohexylamine)] [21, 170] all show particular promise as 
anti-tumour dmgs. The general route for the synthesis of these complexes involves 
the oxidation of a suitable platinum(II) precursor compound. It is thus important to 
understand the processes by which the oxidation occurs. 
92 
The oxidation of square-planar platinum(II) complexes can occur by two main 
mechanisms. The first is a simple two-electron transfer ie. a complementary redox 
process. The second mechanism proceeds by two successive one-electron transfers 
requiring the production of a platinum(III) intermediate. This species is unstable but 
has been detected by addition of a radical trapping agent (eg. galvinoxyl) to a 
reaction mixture [105]. This does not distinguish platinum(III) from any other 
radical and in this situation other radicals including the peroxydisulfate radical anion 
and the hydroxyl radical may be detected. 
In order to study reactions of platinum(IV) complexes it is necessary to prepare 
the compounds by the oxidation of platinum(II) complexes. Little work has been 
done on the kinetics of the oxidation process (Ref. [105 113, 115- 116, 172]) and 
so this research has measured kinetic data for the oxidation of platinum(II) 
complexes using potassium permanganate, potassium dichromate, hydrogen peroxide 
and sodium peroxydisulfate as oxidising agents. 
5.2 EXPERIMENTAL 
5.2.1 Materials 
The platinum(II) complexes were either commercially available from Strem 
Chemical Company (cisplatin, carboplatin, [PtC12chxn], K2[PtC14], ~[Pt(ox)2], 
K2[Pt(en)2], K2[Pt(NH3)4]) and used without further purification, or synthesised 
(K2[PtC12(ox)]) by known methods [107]. For the latter complex, a 195Pt NMR 
spectrum (o = -995 ppm, referenced to H2PtC16) was in agreement with the literature 
value (-1005 ppm [107]). All other chemicals used (KMn04, K2Cr207, NazSzOB, 
HzOz) were AnalaR or best reagent grade available. 
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5 .2.1.1 NazSzOs 
Solutions of cisplatin (25 mg/50 mL 1 M HCI, 1.67 mM), carboplatin 
(25 mg/50 mL H20, 1.35 mM), K2[PtC12(ox)] (3 mg/50 mL H20, 0.14 mM), 
K2[Pt(ox)2] (3 mg/200 mL H20, 0.03 mM), K2[PtC12(ox)] (25 mg/50 mL 1M HCl, 
1.20 mM), K2[Pt(en)z] (25 mg/50 mL 1M HCl, 1.29 mM) and Kz[Pt(NH3)4] (25 
mg/50 mL 1M HCI, 1.42 mM) were prepared. [PtC12(chxn)] (1 mg, 0.43 mM) was 
dissolved in three drops of DMF before addition of 10 mL S20{ solution (1 M 
HC1). Reactions involving DMF and S20 82- and DMF and platinum(II) were 
performed to confirm that DMF had no effect on the reaction rate. The NazSzOs 
solution was freshly prepared (in 1M HCl for cisplatin, [Pt(en)z]2+, [Pt(NH3)4]2+, 
[PtCI4t and in 2M HCl for [PtC]z(ox)]2-, carboplatin, [Pt(ox)2f) before each 
kinetic run. 
5.2.1.2 HzOz 
Solutions of carboplatin (50 mg/50 mL H20, 2.70 mM), K2[Pt(ox)2] (10 mg/25 
mL H20, 0.89 mM), Kz[Pt(en)z] (30 mg/50 mL 1M HCl04, 1.55 mM) and 
K2[Pt(NH3)4] (30 mg/50 mL 1 M HCI04, 1.70 mM) were prepared. HzOz was 
freshly prepared (in 2M HC104 for carboplatin, [Pt(ox)2] 2- and in 1 M HCI04 for 
[Pt(en)2] 2+, [Pt(NH3) 4] 2+) and the concentration determined by titration with 
potassium permanganate solution, standardised using AR sodium oxalate. Cisplatin 
(1 mg, 0.33 mM) and [PtC12(chxn)] (1 mg, 0.43 mM) were dissolved in three drops 
of DMF (it was determined that DMF had no effect on the reaction rate) before 
addition of 10 mL of H20 2 solution (1 M HC104). [PtC14]2- (1 mg, 0.24 mM) was 
dissolved in a drop of water before addition of 10 mL of HzOz (1 M HCI04). 
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5.2.1.3 
Solutions of [Pt(NH3)4f+, [Pt(en)2] 2+ and [PtC14]2- were prepared immediately 
prior to reaction by dissolving known amounts in 0.1 M HC104. Solutions of 
carboplatin were prepared in water. KMn04 solution (2 mg/100 mL, 0.126 mM in 
0.1 M HCl04 for [Pt(NH3)4]2+, [Pt(en)2]2+, [PtC14] 2- and in 0.2 M HCl04 for 
carboplatin) was used. 
5.2.1.4 
Solutions of carboplatin and [PtC14] 2- were prepared immediately prior to 
reaction in 1.0 M HC104. K2Cr20 7 solution (7.4 mg/250 mL 1M HCl04, 1.0 x 10-4 
M) was used. 
5.2.2 Oxidation kinetics 
The reactions in this chapter were monitored at fixed wavelengths using 
UV/Visible spectroscopy. All reactions except those involving permanganate, were 
followed using a Perkin Elmer /v-2 Recording Spectrometer. For low temperature 
reactions this was fitted with a 5 em pathlength jacketed cell attached to an external 
cooling (waterbath) system. A refrigerator unit immersed in the water bath allowed 
temperatures as low as 12 octo be reached. For systems requiring temperatures of 
greater than 30 oc an electrically heated cell unit, with a 4 em pathlength cell, was 
used. 
Due to the rapidity of the permanganate oxidation reactions, these were studied 
with an Applied Photo-Physics Biosequential SX-18MV Stopped-Flow Reaction 
Analyser. 
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In all cases the reactions were monitored at fixed wavelengths for 6 - 8 half-
lives and the appropriate rate constants calculated using at least 20- 30 data points 
over that time interval. The effect of temperature was studied to allow calculation of 
activation parameters. All rate data are presented in Tables A5.1 - A5.6. 
5.3 RESULTS AND DISCUSSION 
5.3.1 Peroxydisulfate Oxidation 
Peroxydisulfate, S20l , is a powerful oxidising agent in aqueous solution but, 
even with strong reducing agents, reactions are usually slow [182- 183]. In contrast, 
the S2ol- I [Pt(NH3) 4]2+ oxidation takes place in the stopped-flow time scale [105]. 
This oxidation work by Harrigan and Johnson [105] was repeated under different 
conditions, and the oxidation of [Pt(en)2]2+ studied using stopped-flow techniques. 
Neutral and negatively charged complexes were also studied to see the effect of 
charge on rate and mechanism. 
Peroxydisulfate oxidations of the neutral platinum(II) anti-cancer drugs, 
cisplatin, [PtC12(chxn)] and carboplatin, were followed using conventional mixing 
spectrophotometric techniques. As with [Pt(NH3)4] 2+, the absorbance of the reaction 
mixture ([Pt(II)] ~ 0.1 mM, [S20 82-] = 10- 50 mM, [H+] = 1.0 M) increased with 
time at all wavelengths below 350 nm to reach a stable final absorbance without the 
generation of isosbestic points (Figure 5.1). 
Figure 5.1: Repeat scans (180 s time interval) showing the increase in 
absorbance for the oxidation of carboplatin by peroxydisulfate 
(10 mM, 1 M HCI, 30 °C). 
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Absorbance vs time traces at fixed wavelengths followed pseudo-first-order kinetics 
and plots of kobs (s-1) vs [S20 82-] were linear with zero intercept (Figure 5.2). 
Values of k2 in the expression 
(5.1) 
were calculated from 
(5.2) 
and all k2 data at various temperatures were used to estimate the activation 
parameters (LlH# and ilS#) in Table 5 .1. 
Figure 5.2: kobs vs [S20{] for the oxidation of carboplatin by peroxydisulfate 
(22.5 oc, 1.0 M HCI04). 
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Table 5.1: Activation parameters for the oxidation of platinum(II) complexes 
by peroxydisulfate (25 °C). 
Complex k/ MI" As" 
(kJ mor1) (JK1 mor1) 
[Pt( ox)zf- b 1.94 s-1 85.7 ± 4 48± 12 
[PtCh(ox)f b 0.431 s-1 80.8 ± 6 19 ± 18 
[PtCl4f b 0.0056 s-1 105 ±3 66±9 
[PtCI4fc 28 M-1s-1 94.2 ± 3 66±9 
cis-(NH3)z b 0.028 M-1s-1 37.9 ±2 -147 ± 6 
chxn b 0.113 M-ts-1 53.1 ± 3 -85±9 
carboplatin d 0.205 M-1s-1 54.0± 3 -77 ±9 
[Pt(en)z]2+ b 10.14 M-1s-1 44.0±2 -78 ±6 
[Pt(NH3)4]2+ b 2.58 M-•s-1 28.0 ± 1 -143 ± 3 
[Pt(NH3)4]2+ e 4.23 M-1s-1 39.3 -101 
[Fe(OH2)6]2+ f 137 M-1s-1 48.0 -43 
• See text for rate laws. b 1.0 M HCI. c Data for the Cu2+ catalysed oxidation. d 1.0 M HCI04• e Ref. 
[105], I= 1.0 M HCI04. c Ref. [184], I 1.0 M. 
With the anionic complexes [PtC14f, [Pt(ox)z] 2- and [PtClz(ox)] 2-, the 
absorbance (250- 400 nm) of the reaction mixture (Pt(Il) - 0.01 mM, [PtCl{] - 1 
mM, [S2ol-J = 0.2 - 50 mM, [HCl] = 1.0 M) again increased to a constant value 
without isosbestic points. However, absorbance vs time plots at fixed wavelengths 
were linear indicating the reaction is pseudo-zero-order in platinum(II) (Figure 5.3). 
Experiments varying the [Pt(II)]initiai showed that the reaction was independent of the 
initial [Pt(ll)]. The end point times of the reactions were proportional to [SzOlJ 
and so rate law (5.3) is followed for these anionic systems. 
(5.3) 
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Values of k0 (s-1) were calculated from the expression (5.4). 
(5.4) 
Activation parameters were estimated from the variation of k0 with temperature 
(Table 5.1). 
The changing reaction order between S20 82- and platinum(II) complexes of 
differing charge suggests that electrostatic interactions are significant. Neutral and 
positively charged platinum(II) complexes exhibit rates that depend on both [Pt(II)] 
2-
and [S20 8 ], while anionic platinum(II) complexes react at rates independent of 
[Pt(II)]. 
Figure 5.3: Absorbance vs time scan for the oxidation of [PtCI4] 2" by 
peroxydisulfate (20 mM, 1 M HCI, 340 nm, 35.5 °C). 
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Equations (5.5) and (5.6) provide mechanisms which generate the observed 
reaction order but involve a direct two-electron transfer. While two-electron transfer 
processes are not common, the Pt(II)/Pt(IV) redox couple may be one situation where 
this mechanism is plausible, as the Pt, en and Cl- exchange rates between [Ptii(en)2]2+ 
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and [PtiV Ch( en)zf+ all proceed with similar values for the third order rate constant 
[185]. 
The proposal for the hydroxo sulfato platinum(IV) product follows from the 
work of Harrigan and Johnson [105]. In the presence of 1M HCl, cis-[PtiVCI6f is 
the most likely final product. 
The [Pt(II)]2+ I S20 82- reactions are quite rapid for peroxydisulfate but are still 
not as fast as the [Fe(Il)]2+ I S20 82- system [184]. Nevertheless, the activation 
enthalpies for both [Pt(Il)]2+ and [Fe(OH2) 6] 2+ are similar (Table 5.1) suggesting that 
most of the energy barrier in the oxidation takes place in forming the encounter 
complex. However, in the post-encounter electron transfer reaction, [Fe(OH2)6] 2+ 
only requires a one-electron transfer process. This may allow for a more rapid 
reaction. 
For the [Pt(Il)] 2- complexes that are oxidised at rates independent of the 
reductant concentration, it is difficult to avoid a mechanism that does not involve 
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Pt(III), ie. a series of one-electron transfers. Equations (5.7)- (5.11) outline one 
possible mechanistic scheme via a radical chain process. 
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Both [Pt1vC16] z- and [PtNCI5(0H)]- are detected as reaction products by 195Pt 
NMR (8 = 0.4 ppm, -280 ppm, respectively, relative to H2PtC16). In HCl04 one 
major peak is observed. This has been tentatively assigned as [PtCl4(0H)(S04)]2-
(961 ppm). If the NMR solution is left for a longer period of time (two weeks) 
further peaks are observed. One of these (1076 ppm) is assigned to the 
dihydroxoplatinum(IV) complex, formed by substitution of S04 by OH. Assuming 
a steady state concentration of SO/, OH' and Pt(III) [182], the mechanistic scheme 
(5.7- 5.11) gives: 
(5.7) 
(5.8) 
(5.9) 
(5.10) 
(5.11) 
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(5.12) 
Activation parameters for the S20 82- oxidation of [Pt(II)]2- complexes follow a 
different pattern from those observed for the cationic and neutral platinum systems. 
These cannot be compared as the reaction orders are different. However, the first 
three entries in Table 5.1 (negatively charged platinum(II) complexes) have less-
favourable electrostatics with which to form any encounter complex and therefore 
their oxidations occur by a different mechanism. In contrast, the much lower 
activation enthalpy and significantly more negative activation entropy for the neutral 
and positively charged complexes are consistent with the association step (5.5) prior 
to the electron transfer process (5.6). This latter process should not have a high 
activation barrier and thus is not expected to show a significant entropy effect. So 
reaction (5.5) is mainly responsible for the activation parameters in the lower part of 
Table 5.1. 
The oxidation of the negatively charged platinum(II) complexes shows a small 
[H+] effect (non-linear increase in rate as the concentration increases). Varying the 
amount of chloride ion in the reaction mixture has no effect on the rate. 
For the first-order oxidations (the neutral and positively charged complexes) 
there is a very slight increase in rate as the [H+] increases. A chloride ion effect is 
observed. There is a large decrease in rate when one goes from 0.0 M to 0.1 M cr, 
but with further increases in [Cr] the effect is negligible. 
Oxidations involving peroxydisulfate are often subject to trace metal catalysis 
so it was decided to study the effect of Cu2+ on the rate of oxidation of [PtCl4f. 
Zero-order reactions were again observed and it was found that copper(II) does have 
an acceleratory effect on the rate of oxidation. Plots of kobs vs [Cu2+] were linear 
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with a positive intercept corresponding to the uncatalysed rate (Figure 5.4). 
Activation entropy calculated from this data is in agreement with that for the 
uncatalysed rate (Table 5.1). The exact mechanism of catalysis is unknown but is 
thought to occur by the initial oxidation of Cu2+ to Cu3+ 
(5.13) 
which then oxidises the platinum(II) complex. Thus there is competition between 
Cu3+, 01:(, SO/ and S20 82- for the reductants, with Cu3+ and OH' being the most 
favourable, having the least electrostatic repulsion. For this situation kcu is defined 
as the zero-order rate constant divided by the [Cu2+] which is then all divided by 
[SzOt] ie. (kobsi[Cu2+])/[ SzOlJ. Raw data are presented in Table A5.5. 
Figure 5.4: Effect of [Cu2+] on the rate of oxidation of [PtCI4] 2- by 
peroxydisulfate (20 mM, 1.0 M HCl, 340 nm). 
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5.3.2 Hydrogen peroxide oxidations 
The redox chemistry of hydrogen peroxide can be summarised by the following 
redox potentials: 
E0 = 1.76 V 
E0 = 0.68 V 
E0 0.87 V 
These show that H20 2 is a strong oxidising agent in either acidic or basic solution. It 
can behave as a reducing agent but only towards very strong oxidising agents eg. 
permanganate. Indeed, in this work the concentrations of the peroxide solutions 
were determined by titration with standardised potassium permanganate solution 
prior to each reaction. 
Dilute ( < 30 %) H20 2 solutions are widely used as oxidants. Its reactions are 
generally slower in acidic solution than in basic solution. The occurrence of the 
disproportionation of H20 2 to H20 and 0 2 means that solutions are unstable and 
therefore fresh solutions were prepared prior to each reaction. 
Hydrogen peroxide is often used as an oxidising agent in the synthesis of 
platinum(IV) complexes [186]. It is a very effective oxidising agent and it produces 
the trans dihydroxo complex. If the reaction is performed in concentrated HCI, then 
generally the trans dichloro complex is formed. Although it is widely used in 
synthetic work there have been very few studies on the kinetics of oxidation of 
platinum(Il) by HzOz [105]. 
The platinum(II) complexes carboplatin, cisplatin, [PtCl2(chxn)], [Pt(en)z]2+, 
[Pt(NH3)4]2+, [Pt(ox)z]2-, [PtCI4f, were oxidised by H20 2 in 1.0 M HCl04 under 
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pseudo-first-order conditions ([f{z02];:::: 10[Pt(ll)J). Kinetic data were obtained using 
the conventional spectrophotometric mixing technique described previously. In all 
cases, except for [Pt( ox)2f, the absorbance of the solution increased with time 
(Figure 5.5) without the generation of isosbestic points. For [Pt(ox)2] 2- a general 
decrease in absorbance was observed. Plots of kobs vs [H20 2] were linear with a zero 
intercept and the second-order rate constant, k2, in the rate law (5.14) was calculated 
from the expression (5.15). 
rate= kz[Pt(II)][HzOz] (5.14) 
where (5.15) 
All k2 data were used to estimate the activation parameters 8.S# and 8.H# (Table 5.2). 
Raw rate constant data are listed in Table A5.3. 
Figure 5.5: Absorbance vs time scan for the oxidation of carboplatin by H20 2 
(112.5 mM, 1.0 M HCI04, 315 nm, 26 °C). 
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It is interesting to note that many reactions involving hydrogen peroxide in 
solution involve free radicals. This indicates that the oxidation of platinum(II) may 
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occur by two one-electron transfer steps with the production of the unstable 
platinum(lll) intermediate. However, another possibility is the one-step two-electron 
transfer and this has been observed in some cases (ie. an encounter complex is 
formed between the platinum(Il) complex and the H20 2 , followed by a two-electron 
transfer step). 
The product formed is exclusively trans and the oxidation occurs via a 
tetragonally distorted octahedral intermediate with the sixth coordination site 
associated with a water molecule from the solvent. Studies by Dunham et al [107] 
on the H20 2 oxidation of [Pt(ox)2f using 195Pt NMR techniques showed that the 
oxidation product is consistent with a platinum(IV) complex with six bonded 
oxygens. In this research the 195Pt NMR was used to identify the product for both 
the [Pt(oxht and [PtC14]2- complexes. A chemical shift of 2910 ppm was found for 
the oxidation product for [Pt( ox)2f which agrees with the value quoted by Dunham 
et al (2873 ppm) [107]. A chemical shift of 1078 ppm was found for the oxidation 
product for [PtC14]2-. This is the same value as that obtained for the peroxydisulfate 
oxidation of the same complex. Another peak was found in an aged solution at -284 
ppm. This has been assigned as the platinum(IV) tetrachlorodiaqua complex. 
Harrigan and Johnson [105] also studied the oxidation kinetics of [Pt(NH3)4]2+ 
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by H202 and their activation parameters are comparable to those obtained in this 
study (Table 5.2). They proposed a two-electron transfer step in their paper detailing 
peroxydisulfate and peroxide oxidations. Their reasoning was based on the 
observation that the peroxide oxidations were slower than for the peroxydisulfate 
reactions, whereas for other systems (where peroxide is known to oxidise in two one-
electron steps) their rates are similar. 
Table 5.2: Activation parameters for the oxidation of platinum(II) complexes 
by hydrogen peroxide (25 °C). 
Complex l03k2u AH# AS# 
(M-ls-1) (kJ mor1) (JK1 mor1) 
cis-(NH3)2 8.99 47±2 -125 ± 6 
carboplatin 18.2 52±2 -102 ± 6 
chxn 33.6 58 ±3 -78 ± 9 
[Pt(en)2f+ 3.70 70±3 -58±9 
[Pt(NH3)4]2+ 3.15 66±2 -71 ± 6 
[Pt(NH3)4]2+ a 0.46 58±2 -117±8 
[Pt(ox)2]2- 155 53.5 ± 1.4 -81 ± 4 
[PtCl4]2- 4.25 76 ± 3 -35 ± 9 
a Ref. [105], I= 1.0 M. 
5.3.3 Permanganate oxidation 
Potassium permanganate is a very powerful oxidising agent and is also used in 
the synthesis of platinum(IV) complexes [116]. The rates of oxidation of 
carboplatin, [Pt(NH3)4f+, [PtCI4f- and [Pt(en)2]2+ were measured using an Applied 
Photo-Physics Biosequential SX-18MV Stopped-Flow Reaction Analyser (Table 
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5.3). Reactions were monitored at 520 nm where the large decrease in absorbance 
observed corrresponds to the loss of the characteristic purple permanganate colour. 
The reaction was studied under pseudo-first-order conditions with [Pt(II)] ~ 
10[Mn04-] due to the high molar absorptivity of permanganate (£520 = 7500 M-1cm-1). 
Plots of kobs vs [Pt(II)] were linear with zero intercept and the second-order rate 
constant, k2, in rate law (5.17), was calculated from expression (5.18). 
(5.17) 
where (5.18) 
The comparability between activation parameters (Tables 5.3) for all 
complexes indicates a similar mechanism occurs for neutral, anionic and cationic 
platinum(II) complexes. Raw data are listed in Table A5.4. 
Table 5.3: Activation parameters for the oxidation of platinum(II) complexes 
by permanganate (0.1 M HC104, 25 °C). 
Complex 10-4kza ilifF ilS# 
(M-ls-1) (kJ mor1) (JK1 mor1) 
carboplatin 10.5 16.9 ± 0.7 -92±2 
[Pt(en)z]2+ 3.24 27.3 ± 0.6 -48 ±2 
[Pt(NH3)4]2+ 1.94 24.8 ± 0.7 -60±2 
[PtCl4]2- 3.44 29.5 ± 1.0 -59± 3 
The proposed product is again the dihydroxyplatinum(IV) complex with a two-
electron transfer (as for oxidation by H20 2). 
oHI 2-
Cl"'- l~ctl 
Pt (5.19) 
c1/ I "'-ct 
OH 
Evidence for this product identification is that Zemskov et al were able to 
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isolate trans-dihydroxotetrachloroplatinate (as the silver salt) after the oxidation of 
[PtCl4]2- by permanganate [116]. 195Pt NMR was not used to identify the reaction 
product due to the interference of Mn2+. 
5.3.4 Dichromate oxidation 
Chromium(VI) has a wide and varied chemistry depending on pH and other 
factors. Many species are produced including the chromate ion (Cro/-), and 
Potassium dichromate used in this study has a high molar absorbance in the 
UV (£350 = 2521 M-1cm-1). In order to monitor the reaction spectrophotometrically 
platinum(II) was in excess over dichromate, with [Pt(II)];:::: 10[Cr20l-]. Repeat 
absorbance scans at fixed time interval showed a decrease in absorbance at 350 nm 
due to the loss of orange-red dichromate. This was observed for both complexes so 
all reactions were monitored at this wavelength. 
The oxidation of [PtC14]2- was studied in l.OM HCl04. Plots of kobs vs 
[PtCll-l were linear with zero intercept (within experimental error) and data are 
presented in Table A5.6. It can be seen from the activation parameters (Table 5.4) 
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that the reaction has a low activation enthalpy. This manifests itself in the reactions 
not having a great dependence on temperature. For this reason the individual rate 
constants calculated were plotted against concentration and the least-squares fitted 
slopes used to calculate L\W and L\S#. 
Dichromate was also used to oxidise carboplatin. As for [PtC14]2- the plots of 
kobs vs [Pt(Il)] were linear with zero intercept. The reaction was not greatly 
influenced by temperature thus the method above was used to calculate the activation 
parameters (Table 5.4). 
Table 5.4: Activation parameters for the oxidation of platinum(II) by 
dichromate (1.0 M HCI04, 25 °C). 
Complex k2 L\H# L\S# 
(M-Is-1) (kJ mor1) (JK1 mor1) 
[PtCl4t 14.91 17.3 ± 0.7 -164 ± 2 
carboplatin 4.37 32.0 ± 1 -125 ± 3 
The most probable mechanism for dichromate oxidation will involve the 
formation of an encounter complex followed by electron transfer giving the 
dihydroxo platinum(Il) product. Before oxidation platinum(II) has two spare 
coordination sites. Upon oxidation one of these will be coordinated to an oxygen 
originating from the dichromate and the other will coordinate a solvent molecule. It 
is not possible to verify the product using NMR due to the paramagnetic nature of the 
Cr3+ oxidation product. 
(5.20) 
A small negative salt effect was observed when the [Cl04-] was varied and 
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the rate of oxidation increased as [H+] increased. 
5.3.5 Correlation with reduction potential 
It was thought that the order of reactivity of the three oxidising agents might 
mirror their respective reduction potentials. As seen in Table 5.5 this does not 
appear to be the case. 
Table 5.5: Comparison between rate of reaction and reduction potential for 
the oxidation of carboplatin. 
kox (25 °C, M-ls-1) Reduction potential [123] 
20.5 X 10-2a S20s2- + 2e 
---7 2sol- 1.96V 
1.82 X 10-3 a H202 + 2H+ + 2e ---7 H20 1.763 v 
10.5 X 104 b Mn04- + 8H+ + 5e ---7 Mn2+ +4H20 1.51 v 
4.37 Cr20l + 14H+ + 6e ---7 2Cr3+ + 7H20 1.38 v 
" 1.0 M HC104. b 0.1 M HCl04. 
There are no clear correlations between the oxidants but once again, it is difficult to 
compare the systems due to the variable number of electrons transferred. 
5.4 CONCLUSIONS 
The oxidations of platinum(II) complexes by hydrogen peroxide, potassium 
permanganate and potassium dichromate appear to proceed via direct two-electron 
transfers. However, the oxidation by peroxydisulfate results in two different 
processes. For neutral and positively charged complexes (eg. carboplatin and 
[Pt(en)2]2+) the mechanism involves one two-electron transfer step as above, but for 
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the negatively charged complexes (eg. [PtCI4f) a radical mechanism with two one-
electron transfer steps is most likely. 
The mechanism for the one-step process probably involves the formation of an 
'encounter' complex between the oxidising agent and the platinum(II) complex. 
Once formed, the two-electron transfer can take place via 0-atom transfer and the 
encounter complex breaks into the appropriate products. This model would predict 
one 0-atom in the dihydroxo product to come from the oxidising agent .and the other 
from the solvent water (Equations (5.16) and (5.19)). Indeed, Dunham et al [106] 
have used 0 isotopic labelling studies to show that the mechanism begins with the 
addition of H2160 2 to a vacant coordination site. An H2160 or H2180 from the solvent 
fills the other vacant coordination site. The above scenario is less likely for the 
reaction between peroxydisulfate and negatively charged complexes due to 
electrostatic repulsion, and a radical mechanism dominates. 
The suggested mechanisms for all oxidants are consistent with those expected 
on the basis of the thermal activation parameters for both the oxidation and reduction 
reactions (Chapter 4). The large negative activation entropy values are indicative of 
an associative-interchange mechanism (see Chapter 2, Section 2.7). This is in accord 
with the proposed mechanism involving 0-atom transfer. 
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CHAPTER6 
BASE HYDROLYSIS OF PLATINUM(IV) 
6.1 INTRODUCTION 
The base hydrolysis of inert coordination compounds has been extensively 
studied for cobalt(III), rhodium(III), chromium(ID), iridium(ID) and platinum(ll) (eg. 
Equation (6.1)) [188]. 
(6.1) 
For the chloroamminecobalt(lll) system a first-order dependence in [OH-] 
was found. 
-d[Co(III)]/dt = koH[Co(III)][OH-] (6.2) 
The kinetics of this process were explained in terms of an acid-base pre-
equilibrium, followed by dissociation of the conjugate base of the complex (SN 1 CB 
mechanism) [189]. This is now the accepted mechanism for base hydrolysis [190]. 
(6.3) 
(6.4) 
(6.5) 
Compared with all other nucleophiles the hydroxide ion falls into a special 
category. Even low concentrations of OH- can affect the release of halide ions (or 
other labile ligands) from octahedral metal centres. Other nuclephiles eg. N3, N02 
have no effect on reaction rates as it is thought that the complexes undergo an 
aquation reaction prior to substitution. This is one piece of evidence as to why an 
SN 1 CB mechanism is likely for base hydrolysis. 
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The SN1CB mechanism was proposed by Garrick [191] who based his ideas 
on work by Br¢nsted and Erlenmeyer [192]. SN1CB stands for substitution, 
nucleophilic, unimolecular, conjugate base. It was first proposed for the base 
hydrolysis of cobalt complexes (as in equations (6.3)- (6.5)). Equation (6.3) must 
occur but only to a small extent otherwise all the complex will be converted to the 
conjugate base form. Then, as the concentration of hydroxide increases there will be 
no further change in rate ie. saturation kinetics are observed. 
(6.6) 
Another possible reason for saturation kinetics is ion-pair formation. Saturation 
kinetics have previously only been observed by Chan [193]. 
The SN1CB mechanism is essentially a dissociative process stereochemically, 
indicating a trigonal bipyramidal intermediate structure for both cis and trans 
isomers. 
For several metal ammine complexes (M = Co, Cr, Ru) the base hydrolysis 
reactions have been found to be first-order in hydroxide and first-order in complex 
(Equation (6.2)). Platinum(IV) complexes are known to be very inert and the few 
earlier studies of their base hydrolysis have given ambiguous results [188, 194- 196] 
with variable reaction orders. It was thus decided to reinvestigate the base hydrolysis 
of selected platinum(IV) complexes. One requirement for base hydrolysis is that 
there must be a moderately acidic proton with which to form the conjugate base and 
the complexes chosen for this study all meet this requirement. 
The earlier work on base hydrolysis came from two research groups; 
Grinberg in Russia and Johnson in the USA. 
Grinberg found that the rate for the substitution of the pentaamminechloro-
platinum(IV) complex ([PtCI(NH3)s]3+) was first order in both hydroxide and 
platinum(IV) [195] as expected for an SNlCB mechanism. In his paper in 1964 
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[ 187] he studied the aquation of the cis- and trans-[PtC14(NH3) 2] isomers. He 
measured this by two methods- titration of the aquation products with 0.01 N NaOH 
and by measuring the rate of change in electrical conductivity and pH. He found that 
the trans complex aquated faster than the cis complex (2 X 10-5 S-I VS 6.1 X 10-6 S-l, 
[OH-] = 0.25 mM, T =50 °C) and he attributed this to the trans complex having two 
Cl-Pt-Cl axes. In his work in 1966 [194] when studying the base hydrolysis of these 
complexes he found that the rate of reaction was proportional to [OH-] for the cis 
complex giving an SNlCB mechanism, but [OH-]0·35 for the trans complex with a 
complex mechanism. 
Work by Johnson andBasolo [188] found that the chloroammineplatinum(IV) 
complexes studied released chloride by at least three different processes. One 
reaction involved the simple replacement of coordinated chloride by hydroxide 
([PtCl(NH3)5]3+ and cis-[PtCh(NH3)4] 2+). For all cis complexes there were no 
platinum(II) products detected and the rate of hydrolysis was not affected by addition 
of [Pt(NH3) 4] 2+. However, for all trans complexes some reduction of platinum(IV) 
occurred. For trans-[PtCh(NH3) 3t and trans-[PtCh(NH3)4]2+ the reduction pathway 
was thought to be responsible for 10 %of the chloride lost. Trans-[PtCh(en)z]2+ was 
a more extreme case with up to 90 % of the cr being lost through a reduction 
pathway. 
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These very early studies leave a unclear picture of base hydrolysis and it was 
hoped reinvestigation using spectrophotometric techniques would clarify some 
mechanistic details. 
6.2 EXPERIMENTAL 
6.2.1 Materials 
The platinum(IV) complexes cis-[PtCl4(NH3)2] and trans-[PtCl4(NH3)z] were 
commercially available (Strem) and used as supplied. Trans-[PtC}z(en)z](ZnC14) and 
trans-[PtC}z(NH3)z]C}z were synthesised as described below. [PtCl(NH3)s]Cb was 
prepared by Professor D.A. House. Sodium hydroxide and sodium perchlorate were 
of the best reagent grade available. 
All complexes except cis- and trans-[PtC14(NH3)z] were studied over a 
hydroxide range of 0.2 - 1.0 M with ionic strength maintained at 1.0 M by addition of 
sodium perchlorate. NaOH (6 mL) was heated to the desired temperature in the 
4 em pathlength cell. Approximately 1 mg of complex was added. In all cases 
(except cis-[PtC14(NH3)z]) the complex dissolved upon gentle shaking and the cell 
was then placed in the electrically heated cell block unit (as described in Chapter 2). 
This procedure was used for trans-[PtC14(NH3)2] but with hydroxide concentrations 
of 10- 100 mM. For cis-[PtC14(NH3)2] a stock solution was prepared (7.4 mg/20 
mL, 9.97 x 10-4 M, in water). 3 mL of the platinum(IV) solution and 3 mL NaOH 
were mixed and then transferred to the 4 em pathlength cell as for the other 
complexes. For these reactions the final concentrations of NaOH ranged from 15.0-
45.0mM. 
For all complexes, repeat scans (Figures 6.1 and 6.3) showed a decrease in 
absorbance at A < 400 nm without the generation of isosbestic points. The reactions 
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were then monitored at fixed wavelength (trans-[PtCh(NH3)4]2+ 340 nm, trans-
[PtClz(en)z]2+ 350 nm, cis-[PtCl4(NH3)z] 330 nm, trans-[PtCl4(NH3) 2] 330 nm and 
[PtCl(NH3) 5] 3+ 310 nm) for at least 6 - 8 half-lives and the observed rate constant 
kobs, calculated from the usual absorbance vs time expression (see Chapter 2). 
6.2.2 Synthesis of trans-[Pev C}z(NH3)4]Clz 
[Ptn(NH3)4]Ch (250 mg) was dissolved in 5 mL H20. 5 mL concentrated 
HCl was added and the mixture stirred. 2 mL H20 2 (30 %) was added and a pale 
yellow solid formed immediately. This was filtered using a sintered glass crucible 
giving 269 mg (89.8 %) of trans-[PtrvClz(NH3)4]Ch. 
6.2.3 Synthesis of trans-[Pev C}z( en)z](ZnCI4) 
[Ptn( en)2]Clz (250 mg) was dissolved in 5 mL H20. 5 mL concentrated HCl 
was added and the mixture stirred. 2 mL H20 2 (30 %) was added. The solution 
changed from colourless to pale yellow but no formation of solid occurred. After 
three days the solution was heated on a steam bath to 40 oc and 0.5 g ZnCh added. 
A white crystalline solid formed immediately. This was filtered using a sintered 
glass crucible giving 340 mg (98.9 %) of trans-[PtrvClz(en)z](ZnC14). An X-ray 
crystal structure of this complex confirmed the expected structure and selected 
crystal data are presented in Table A6.3. 
6.3 RESULTS AND DISCUSSION 
6.3.1 [PtCI(NH3) 5] 3+ 
With just one chloride ion to be substituted by hydroxide it was expected that 
the reaction would obey simple first-order kinetics. Repeat scans (Figure 6.1) 
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showed a decrease in absorbance without generation of isosbestic points. Plots of 
kobs vs [OK] (Figure 6.2) were linear with zero-intercept giving rise to the expected 
rate law 
(6.7) 
which is second-order overall. The mechanism in this reaction will involve a simple 
replacement of coordinated chloride by hydroxide. This was also observed in the 
early work by Johnson et al [188]. Raw data are presented in Table A6.1. 
Figure 6.1: Repeat scans (180 s time interval) showing a decrease in 
absorbance for the base hydrolysis of [PtCl(NH3)5]3+ (0.1 M 
NaOH, 32.2 °C). 
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Figure 6.2: Linear plot of [OH"] vs kobs for the base hydrolysis of 
[PtCl(NH3)5] 3+ (I = 1.0 M). 
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6.3.2 trans-[PtCh(en)z]2+ and trans-[PtCh(NH3)4]2+ 
Absorbance vs time scans repeated at 3 minute intervals showed one reaction 
for both complexes, which was assumed to be the removal of the first chloride 
ligand. Free chloride ion titrations [144a] confirmed this assumption, with only one 
free chloride ion detected. Due to the trans effect, where OK has less of an effect 
than cr, substitution of the second chloride ion is expected to be slow. This was 
qualitatively observed with further small changes in absorbance occurring at the end 
of the initial reaction. Plots of kobs vs [OH-] were linear with zero intercept (within 
experimental error). The second order rate constant koH was calculated from the 
expression koH = kobs[OHT1• Activation parameters are listed in Table 6.1 and raw 
data in Table A6.1. 
Repeat absorbance vs time scans showed a decrease in absorbance (Figure 
6.3). However when observing this at single wavelengths two reactions were seen. 
Figure 6.3 shows that the process is not "clean". 
Figure 6.3: Repeated spectra (180 s time interval) showing the 'unclean' 
repeat absorbance scans for the base hydrolysis of cis-
[PtCI4(NH3)z] (0.1 M NaOH, 44.6 °C). 
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The first reaction resulted in a small increase in absorbance, followed by a 
slower decrease for the second. Attempts to monitor the first reaction were 
unsuccessful due to the small absorbance change, ie. scans were very noisy, and thus 
only the second reaction was monitored. It is thought that this second reaction will 
be the substitution of a second chloride ion. No other subsequent reactions were 
observed. Free chloride ion titrations [144a] on a freshly prepared solution ([OH-] = 
0.1 M) indicated one chloride ion released, but a solution subjected to reaction 
conditions (ie. one hour reaction time at 80 oq showed two chloride ions released. 
These results are in agreement with the spectrophotometric results ie. one chloride 
substituted rapidly and the next more slowly. The slow reaction is that measured. 
When cis- and trans-[PtCl4(NH3)z] complexes were studied in the [OR] range 
0.2- 1.0 M, plots of kobs vs [OH-] were non-linear and showed saturation kinetics. It 
was decided that other processes were swamping the reaction under study eg. 
possibly other chloride ions being replaced by the hydroxo ligand. Another 
explanation for the saturation kinetics is based on the conjugate base mechanism as 
discussed earlier (Section 6.1). This mechanism suggests that at a sufficiently high 
concentration of hydroxide, a stage could be reached where all the original complex 
has been converted into the conjugate base form so that further increases in 
hydroxide concentration have no effect on the rate. Reactions were therefore studied 
at a lower hydroxide concentration over which plots of kobs vs [OR] were linear with 
zero intercept. Raw data are tabulated in Table A6.2. 
Under identical conditions the cis isomer reacts slightly slower than the trans 
isomer. For the second chloride release, the trans complex still has one Cl-Pt-Cl axis 
while the cis isomer has none and therefore it is expected that the trans isomer will 
react faster. As NH3 and NH2- have stronger trans effects than OH, it is likely that 
the second chloride (on the cis isomer) replaced will be trans to a NH3. 
A similar diagram for trans complexes is: 
NH3 
Cl" I /OH 
Pt -~,...,.._ 
c1/ I "cl 
NH3 
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Ionic strength effects were measured for cis-[PtCl4(NH3)z] and [PtCl(NH3)s]3+. 
No effect was found for the neutral complex, but a negative salt effect was observed 
for [PtCl(NH3) 5] 3+. This is expected for a reaction between ions of different charges. 
6.3.4 Mechanistic interpretation 
The most likely mechanism for the base hydrolysis of platinum(IV) complexes 
is an SN1CB type mechanism (Equations (6.8)- (6.10)). This would involve the 
initial formation of a conjugate base species before hydrolysis occurs. Evidence for 
the formation of a conjugate base species comes from the absorbance spectra of the 
platinum(IV) complexes. When in acidic or neutral media the absorbance spectra are 
the same, but when in base the spectrum changes. This alone does not necessarily 
mean a conjugate base is formed, but the only other explanation is ion-pair 
formation. This can be discounted as the formation of ion-pairs would give rise to 
saturation kinetics [193]. 
[PtCl(NH2)(NH3)4]2+ + H20 
[Pt(NH2)(NH3)4]3+ + Cr 
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(6.8) 
(6.9) 
(6.10) 
Another mechanism may involve a preliminary aquation step. Studies on the 
complex hydrolysis in water and acid showed that this pathway is not likely due to 
the extreme slowness of the reaction and as the diammines are weakly acidic [190], 
the SN 1 CB mechanism discussed above may be the most applicable. 
Further to this, qualitative experiments found that acid hydrolysis for these 
platinum(IV) complexes is very slow (no reaction was observed over 10 hours at 
40 °C). This is in contrast to platinum(II) complexes where base hydrolysis is much 
slower than acid hydrolysis. An explanation for the slowness of platinum(II) base 
hydrolysis may be due to the possible stabilisation of the transition state due to 
hydrogen bonding between an ammine ligand and the hydroxo oxygen. However, as 
platinum(II) complexes base hydrolyse by a completely different mechanism [51] it 
is difficult to compare the two different oxidation states. 
Some of the earlier studies have indicated that the trans platinum(IV) 
complexes are partially reduced during the base hydrolysis process [188]. To 
investigate this a 195Pt NMR spectrum of the final reaction mixture was run for trans-
[PtC14(NH3)2]. No peaks were observed at -2854 ppm, the chemical shift for the 
most likely platinum(II) reduction product [Pt(NH3)4]2+ [196]. From this it is 
assumed that extensive reduction is not occurring. 
Table 6.1: Activation parameters for the base hydrolysis of platinum(IV) 
complexes (25.°C). 
Complex koH ~H# ~s# 
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(104M-1s-1) (kJ mort) (JKt mort) 
[PtCl(NH3)s]3+ a 0.308 123 ±2 80.0 ± 6 
trans-[PtCh(NH3)4]2+ a 0.327 84.6 ± 3 30± 9 
trans-[PtCh(en)z] 2+ a 1.12 102±4 21.6 ± 12 
cis-[PtCb(OH)(NH3)z] b 6.07 108 ± 5 55.4 ± 15 
trans-[PtCb(OH)(NH3)2] b 7.41 101 ± 5 35 ± 15 
"I= 1.0 M. b I= 0.1 M 
Consideration of the data in Table 6.1 show that platinum(IV) complexes 
undergo base hydrolysis at a slow rate. The positive activation entropy for all five 
complexes is another indication of an SN 1 CB mechanism. The large positive 
activation entropy value is due to charge neutralisation. If a direct displacement 
reaction were to take place a negative activation entropy would be expected [197]. 
The first step in this type of mechanistic scheme requires the formation of a 
conjugate base. Stereochemical results support the conclusion that formation of an 
amido group cis rather trans to the leaving group leads to the trigonal bipyramidal 
intermediate [198]. It is thought that this intermediate is stabilised by 1t donating 
groups. This stabilistion is not possible for a trans amido group [197]. 
Table 6.2: 
M 
Cr(III) 
Co(III) 
Ru(III) 
Rh(III) 
Pt(N) 
a Ref. [189]. 
Comparison of rate parameters for the base hydrolysis of 
[MCI(NH3)s] 11+ complexes.a 
koH (25 °C) ~H# ~s# 
(M-Is-t) (kJ mor1) (JK-1 mor1) 
4.9 112 143 
1.58 114 140 
1.85 x w-3 109 69 
4.1 x w-4 117 82 
3.1 x w-s 123 80.0 
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The data in Table 6.2 show that the platinum(N) complex hydrolyses slower 
than the other metal complexes. All five metal centres have similar activation 
enthalpies and large positive entropies for their base hydrolysis. The latter suggests 
that they all hydrolyse by the same mechanistic process SN 1 CB. 
6.3.5 X-ray crystal structure of trans-[PtC}z(en)z](ZnCI4) 
During the synthesis of trans-[PtCh(en)2](ZnCl4) white crystals suitable for 
an X-ray crystallographic study formed (Figure 6.4). The structure was determined 
by Professor Ward Robinson in the same way as the structures discussed in Chapter 
3. The average Pt(IV)-N and Pt(N)-Cl bond lengths were 2.05 A and 2.30 A 
respectively. The torsion angles indicate that the en rings have a A,() configuration. 
Further details are given in Table A6.3. 
CI6A 
CI3A 
Figure 6.4: X-ray crystal structure oftrans-[PtC}z(en)z](ZnC:4). 
....... 
N 
+>-
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6.4 CONCLUSIONS 
To date there have been very few studies on the base hydrolysis of 
platinum(IV) complexes- the last being in the 1960's. Because of this, a study was 
undertaken to reinvestigate the base hydrolysis of platinum(IV)-amine complexes. 
The base hydrolysis of five chloroammineplatinum(IV) complexes has been 
studied over a range of hydroxide ion concentrations. Results indicate an SN 1 CB 
mechanism as found for other octahedral complexes eg. cobalt(III). The mechanism 
was assigned by considering the activation entropy and the absorbance spectra. A 
mechanism of this type requires the initial formation of a conjugate base species 
which is only possible if there is an acidic proton in the complex. 
Therefore, from the work in this chapter it seems likely that an SN 1 CB 
mechanism occurs for the base hydrolysis of platinum(IV) chloroammine complexes. 
CHAPTER 7 
CONCLUSIONS 
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The introduction to this thesis gave a summary of the discovery, use, DNA 
interactions, redox and hydrolysis chemistry of cisplatin. The fact that cisplatin is 
such a successful anti-cancer drug, with a cure rate of over 90 % for testicular cancer, 
has meant that many research groups have focussed their efforts into probing the 
chemistry and biochemistry of this, and other related complexes. Expected 
outcomes from this large body of research have been to improve the efficiency of 
cisplatin treatment protocols and to find more successful platinum-based drugs. In 
order to achieve these outcomes it is necessary to have an understanding of the 
fundamental chemistry of cisplatin. The aim of this thesis was therefore to expand 
the simple chemical knowledge about cisplatin, carboplatin and related platinum 
amine complexes (for both +II and +IV oxidation states). 
The work presented in this thesis further investigates some of the simple 
chemistry of cisplatin and other related complexes. This includes the platinum(II) 
complexes and platinum(IV) complexes which have been shown to be effective anti-
tumour agents. Although there has been a lot of research into the chemistry of 
cisplatin, it is necessary to extend this for chemically related (but not necessarily 
biologically active) platinum(II) complexes in order to better understand why 
cisplatin is a most effective anti-cancer drug. It is also necessary to investigate the 
chemistry of the newer platinum(IV)-based complexes (eg. JM-216). This will 
provide information about their chemistry from which it is hoped a better 
understanding of the mechanism of action in vivo will arise. 
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Chapter 3 of this work describes the chloride and bromide anation reactions 
for a range of platinum(II) amine complexes in 1.0 M HCI04 (Equations (3.1) and 
(3.2)). It is important to understand the hydrolysis/anation chemistry of these 
complexes due to the suspected in vivo mode of action of cisplatin. The chloride 
anation of the diaqua (cis-[Pt(N)2(0H2) 2] 2+) complexes (k_2, equation (3.2)) was 
initially investigated. The rate of chloride anation of these complexes was 10 15 
times faster than the monoaqua anation. This ratio increased to 94 for transplatin due 
to a decrease in activation enthalpy. All complexes (except transplatin) have similar 
activation parameters and an associative-interchange mechanism for the anation 
process is most likely. The reaction showed a negative salt effect as expected for 
reactants of differing charge. 
The equilibrium constant, K2, associated with the anation/hydrolysis of the 
diaqua was determined by Hg2+ titration. Values for k2 (k2 = K2k_2) calculated were 
of similar magnitude("" w-5 s-1) to previously determined values for kt. 
Consideration of the equilibrium constants K1 and K2 indicate that the second 
hydrolysis reaction (ie. K2) is less favourable, and in the biological situation, 
cisplatin is unlikely to hydrolyse in any great amount to the diaqua complex. 
In acid solution, cisplatin hydrolyses more slowly than any of the other 
dichloro-platinum(II) complexes studied in this work. This may be significant in 
terms of its anti-tumour activity. When crossing from the plasma to the cell, the 
intact cisplatin undergoes the first hydrolysis reaction (Equation (3.1)) due to a 
change in the chloride ion concentration gradient. The long aquation time and 
unfavourable equilibrium for the second hydrolysis means that the drug, once in the 
biologically active monoaqua form, is more likely to react with biomolecules (eg. 
DNA) than form the diaqua species. The inertness of cisplatin both to anation and 
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aquation, compared to the other non-biologically active platinum amine complexes, 
may be one reason why it is such an effective anti-tumour drug. 
The bromide ion anation of platinum(II) amine complexes was also 
investigated. In these cases values for k1, k_h and k_2 were measured. Stopped-flow 
techniques were necessary to determine k_2 due to the rapidity of the reaction. The 
bromide anation of the bromoaqua was 2 - 5 times faster than the equivalent chloride 
anation of the chloroaqua with relatively constant activation enthalpy values. A 
similar trend was seen with the bromide anation of the diaqua, which was 5 fold 
greater than the analogous chloride anation. Again, for all complexes the activation 
entropy was negative, indicating the likelihood of an associative-interchange 
mechanism - the most common mechanism for substitution reactions of square-
planar complexes. The effect of the non-replaced amine ligands on the order of 
reaction rate (for k_2) was identical for both chloride and bromide ion anation, 
probably due to simple steric effects. 
A further aspect to this work was a high-pressure stopped-flow study. The 
sign and magnitude of activation volumes can also be used (along with activation 
entropy) as an indicator of reaction mechanism. The technique used allowed 
calculation of the activation volume for selected reactions. The small, negative 
values calculated for AV# are indicative of an associative-interchange mechanism as 
predicted by the activation entropy values. 
Single crystal X-ray studies of the products resulting from the evaporation of 
residues from the bromide ion anation studies, showed that tetrabromoplatinum(IV) 
complexes were produced. The platinum(II) residues were oxidised, either 
atmospherically or by bromine produced in the residue containers, to platinum(IV) 
tetrabromodiamine complexes. A 195Pt NMR investigation on these and chxn and 
Me2tn crystals (unsuitable for X-ray study) seemed to indicate a similar structure, 
with all four complexes having similar chemical shifts. 
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It is often discussed why cisplatin shows anti-tumour activity whereas its 
isomeric trans form is inactive. In fact, transplatin is active, but a higher dosage is 
required which can exacerbate the undesirable side-effects associated with cisplatin. 
The basis for the difference can be attributed to the difference in reactivity - the 
diaqua for of transplatin anates faster than the diaqua form of cisplatin. The trans 
effect can be used to explain this feature as cr has a stronger effect than water, and 
thus hydrolysis trans to a chloride (ie. transplatin) is more likely. NH3 is also 
involved in directing, but to a lesser extent than cr. However, the aquation of 
transplatin is slower than that for cisplatin which is in disagreement with the trans 
effect. 
Thus Chapter 3 extends the available knowledge on the simple reaction 
chemistry of cisplatin and other related platinum amine complexes. This knowledge 
may prove useful in aiding the development of new, improved anti-tumour platinum 
drugs. 
The more recent development of platinum(IV) based anti-tumour drugs has 
led to an increase of interest in the redox chemistry of platinum(II) and platinum(IV). 
The platinum(IV) drugs are thought to be reduced in vivo to the corresponding 
platinum(ll) complex and biological studies seem to confirm this mechanism. 
Information on the rate of reduction of platinum(IV) model complexes is important 
for the development of new drugs and treatment protocols eg. the activity of a drug 
may be enhanced by co-administration of a reducing agent. 
Chapter 4 studied the reduction of three model platinum(IV) complexes with 
ascorbic acid, Sn(ll), Fe(II), S20 32- and hydroxylamine. Reductions by Sn(ll) and 
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Fe(II) appear to proceed by a chloride bridged mechanism while the other reductants 
may react via the formation of an outer-sphere encounter complex prior to electron 
transfer. 
The most effective (ie. fastest) reductant was ascorbic acid, the biological 
reducing agent. It seems likely, considering work by others [89- 90], that there are 
many possible in vivo reducing agents that can reduce platinum(IV) anti-cancer 
drugs. Of these, it is expected that the sulfur containing complexes eg. glutathione 
and methionine will be the most prevalent reductants, but ascorbic acid may also 
play an important role. If the complex is reduced too quickly there may be an 
increase in side-effects due to extraneous reactions between the platinum(II) complex 
and other biological nucleophiles. In such a situation it is necessary to have an 
effective, but not too powerful, reducing agent. In order to gain more insight into 
these reactions they must be studied under strict biological conditions ie. pH = 7 .4. 
The other reductants, although not biologically relevant, were selected to 
provide mechanistic comparisons. Of all chosen, Fe(II) is the only non-
complementary reductant. The mechanism for this, though, is similar to that 
proposed for Sn(II), where a chloride-bridged structure is formed prior to electron 
transfer. Thiosulfate and hydroxylamine reductions appear to involve the formation 
of an electrostatic encounter complex before electron transfer. Ascorbic acid 
reductions may be more dependent on electrostatics. The large difference in 
activation parameters between the negatively charged [PtC16]2- and the neutral cis-
and trans-[PtCl4(NH3) 2] may be attributed to electrostatic effects. At pH 4 (ie. 
reaction pH), the main reactant is likely to be HA-. The proposed mechanism 
involves the formation of an ascorbate radical anion and the formation of transient 
platinum(III). 
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The main route for the preparation of platinum(IV) complexes is via the 
oxidation of platinum(II) compounds. Very few studies have measured the kinetics 
of oxidation of platinum(II) and thus it was decided to study the oxidation kinetics of 
platinum(II) using hydrogen peroxide, peroxydisulfate, permanganate and 
dichromate as oxidants. For peroxide, permanganate and dichromate, reactions may . 
proceed by one two-electron transfer involving an oxygen-transfer pathway. The 
most probable final product for all oxidants will be the trans-dihydroxo complex. It 
is likely that one oxygen will come from the oxidant and the other from the solvent. 
195Pt NMR has provided evidence for this when H20 2is the oxidising agent, however 
due to the production of paramagnetic Mn2+ and Cr3+ NMR could not be used for 
permanganate and dichromate. 
The kinetic pattern observed in peroxydisulfate oxidations is highly 
dependent on the charge of the platinum(II) complex. Positively charged and 
neutral complexes are oxidised in a two-electron transfer pathway, similar to the 
other oxidants described above. Negatively charged complexes, eg. [PtCl4]2-, 
proceed by a one-electron transfer mechanism involving the production of 
platinum(III) and S04-· radicals. The rate law for these oxidations is independent of 
platinum concentration and thus the reaction is zero-order in platinum(II). This 
completely alters the absorbance vs time spectra, giving a linear increase in 
absorbance with time before a sharp levelling off at the end of the reaction. 
Mechanisms of this type are not common, but have been previously observed for the 
acetone/iodine reactions [122]. 
The penultimate chapter in this thesis describes a study on the base hydrolysis 
of platinum(IV) chloroammine complexes. [PtCl(NH3)s]3+, trans-[PtCb(en)zf+ and 
trans-[PtCb(NH3)4]2+ hydrolyse in basic solution releasing just one chloride ion. 
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The neutral complexes cis- and trans-[PtC14(NH3) 2] release two chloride ions under 
the selected reaction conditions and for these complexes the rate of hydrolysis was 
calculated for the second hydrolysis reaction. It is proposed that all five complexes 
react with the same SN 1 CB mechanism. This mechanism applies to the base 
hydrolysis of many octahedral metal centres and evidence such as positive activation 
entropy values and absorption spectral changes also indicate the applicability of this 
mechanism for platinum(IV) complexes. 
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APPENDIX 
APPENDIX 1: Derivation for the calculation of activation volume (L\ y#). 
Pressure is a fundamental physical property that can influence both 
thermodynamic and kinetic parameters. The relationship between pressure and these 
parameters can be found by considering the pressure dependence of a chemical 
potential Jli of a solute species i for an ideal dilute solution. 
Jli = Jli + + RTlnxi = Jli 0 + RTlnMi (where x =mole fraction, M =molarity) (Al.l) 
The pressure dependence of Jli at constant temperature and composition equals the 
partial molar volume vi of species i. 
(Al.2) 
but for molarity, Mi will change with pressures in the same way as the density of the 
solution cp thus: 
(A1.3) 
where K is the compressibility of the solution. 
Now consider a general chemical reaction of the form 
aA + bB ¢::::> cC + dD (A1.4) 
The overall chemical potential at equilibrium should be zero thus 
(Al.S) 
which gives 
(Al.6) 
h . K c d/ a b W Cie x = Xc Xo XA XB (expressed in terms of mole fraction). 
Applying the pressure derivative in (A1.2) gives 
-RT(dlnKxf()P)T =eVe+ dVn- aV A- bVB 
= !':3.V (A1.7) 
where V is the reaction volume or partial molar volume change for the 
reaction. 
Or, in the case of molarity 
-RT(()lnKM/()P)T = 11V- RTK(c +d-a-b) (Al.8) 
These thermodynamic expressions can be converted to the equivalent kinetic 
expressions. 
aA + bB <=> [ aA ......... bB ]# ---7 cC + dD (A1.9) 
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K# obeys the normal thermodynamic relationships above and the experimentally 
measured rate constant, k, is assumed to be proportional to K#T. Since k then has the 
same concentration dimensions as K# the activation volume can be given by 
11 V# = -RTln(dlnkxldP)T 
So that, in terms of molarity, 
= 
= 
/), V# - R TK(l - a - b) 
11V# - RTK(l- n) 
(Al.lO) 
(Al.ll) 
where n is the kinetic order of the reaction. Thus for a first-order process the 
expressions are identical for mole fraction and molarity. 
The temperature dependence on the reaction rate gives rise to the activation 
enthalpy (11H#) and the activation entropy (11S#). The mechanistic interpretation of 
these, together with 11 V#, is most important for any kinetic investigation. 
APPENDIX 2: Derivation of Equation (3.4). 
Now: 
cis-[PtCl(OH2)(NH3)zt 
cis-[PtC12(NH3)z] == a - x - y 
K2 = y(x + 2y) 
X 
= 
X 
== yT 
T- 2y 
yT = (T 2y)K2 
K1 = xT 
a-x-y 
so 
also 
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cis-[PtCl(OH2)(NH3ht + Cr 
cr = x + 2y == T 
y = T- X 
2 
K2 = (T- x)T 
2x 
T2 = x(2K2 + T) 
X := _::;;____ 
2K2 +T 
T2 - K2T ) 
T+2K2 T+2K2 
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APPENDIX3: Supplementary Tables 
Table A3.1: Observed and calculated rate constants for the first step in the 
chloride anation of some [Pt(N)z(OH2)z]2+ complexes (I = 1.0 M). 
(Nh T [Cr] 104kobs l02k_za 102k} 102k_2c 
(OC) (mM) (s-1) (M-1s-1) (M-1s-1) (M-1s-1) 
cis-(NH3h 20.5 18 11.7 6.50 6.28 6.06 
33 17.3 5.24 
43 30.5 7.09 
25.0 18 17.3 9.61 9.11 9.27 
23 20.1 8.74 
33 29.6 8.97 
30.0 23 35.1 15.3 14.1 14.7 
33 45.4 13.8 
43 57.2 13.3 
35.0 18 40.6 22.6 23.3 22.8 
23 53.0 23.4 
33 79.7 24.2 
43 98.4 22.9 
40.0 18 63.5 35.3 35.2 35.0 
23 79.2 34.4 
33 119 36.0 
cis-(pyh 13.6 2.65 1.71 6.50 6.65 6.05 
5.20 3.90 7.50 
7.55 4.40 5.80 
10.2 6.90 6.80 
20.5 2.65 2.90 10.9 11.4 12.6 
5.20 6.30 12.1 
7.55 8.50 11.3 
10.2 11.4 11.1 
26.0 2.65 6.10 23.0 21.0 22.1 
5.20 11.2 21.5 
7.55 16.3 21.5 
10.2 21.3 20.9 
21.3 20.9 
13.2 25.9 19.6 
25.8 19.5 
32.6 2.65 17.0 32.6 40.1 42.1 
12.4 46.8 
5.20 20.2 38.8 
7.55 32.7 43.3 
10.2 45.2 44.3 
34.2 33.5 
13.2 55.0 41.7 
40.0 2.65 24.3 91.7 80.1 84.4 
5.20 41.8 80.3 
36.0 69.2 
7.55 63.0 83.4 
10.2 78.1 76.0 
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en 18.0 23 32.8 14.3 13.7 13.5 
33 44.7 13.5 
43 57.5 13.4 
23.2 18 38.5 21.4 20.9 21.1 
23 46.8 20.4 
33 68.9 20.9 
30.0 18 67.2 37.3 35.9 36.8 
23 80.4 35.0 
33 117 35.5 
35.0 18 104 57.6 55.5 54.7 
23 121 52.7 
33 185 56.1 
39.4 23 181 78.8 77.2 76.6 
33 250 75.7 
chxn 15.5 18 13.5 7.50 7.95 8.6 
43 36.2 8.40 
20.5 23 31.6 13.7 14.5 14.0 
33 49.1 14.9 
43 65.1 15.1 
23.6 18 21.6 21.6 19.4 18.6 
23 20.7 20.7 
33 17.3 17.3 
43 18.3 18.3 
30.3 18 33.4 33.4 33.8 34.7 
23 34.2 34.2 
37.3 18 32.8 62.8 62.9 64.0 
23 63.9 63.9 
33 62.1 62.1 
tn 18.6 23 34.7 15.1 17.1 18.6 
33 36.6 15.9 
43 87.6 20.4 
22.5 18 50.8 28.3 29.6 27.2 
23 69.1 30.1 
33 101 30.6 
30.3 18 106 59.1 58.5 56.3 
23 135 58.5 
33 191 57.9 
35.0 18 150 83.5 87.5 85.8 
23 205 89.3 
33 296 89.6 
39.4 18 219 122 116 126 
23 255 110 
Me2tn 15.5 33 51.0 15.5 14.8 15.0 
43 60.9 14.2 
18.4 18 36.9 20.5 19.9 19.2 
23 44.5 19.4 
33 65.1 19.7 
23.5 18 53.4 29.7 29.9 29.4 
23 68.1 29.6 
33 101 30.5 
30.0 18 81.6 45.0 47.3 49.4 
')'1 1 1 t;: <;:(I A 
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trans-(NH3)2 11.8 9.5 50.6 53.0 57.0 56.3 
47.5 50.0 
11.5 71.4 61.2 
14.5 88.7 62.1 
17.0 100 58.8 
18.0 9.5 90.1 94.8 91.9 90.8 
11.5 104 90.6 
14.5 133 91.7 
17.0 154 90.5 
22.5 9.5 121 127 124 126 
11.5 141 122 
14.5 177 122 
181 125 
17.0 207 122 
220 129 
27.0 9.5 161 170 172 175 
11.5 195 170 
14.5 254 175 
17.0 298 175 
294 173 
a Calculated from the expression k_2 kohs[ClT1• b Mean for entries in Column 5. c Calculated from 
the activation parameters cited in Table 3.1. 
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Table A3.2: Effect of ionic strength on k.1 and k.2 for cis-(NH3)2 at 25 oc. 
I 104k_1a lOLk-2 
(M) (M-1s-1) (M-1s-1) 
0.05 79.7 20.5 
0.1 76.8 20.2 
0.5 - 10.7 
1.0 62.6 9.27 
a Ref. [49]. 
156 
Table A3.3: Observed and calculated rate constants for the bromide anation 
of some [PtBr(Nh(OH2)]+ complexes (I= 1.0 M). 
Complex T [Bn 104kobsa 1 04k( calc )0 
(°C) (mM) (s-1) (s-1) 
cis-(NH3)2 19.3 22.0 4.66 4.68 
36.5 5.31 6.75 
56.5 10.4 9.35 
25.3 22.0 10.2 8.77 
36.5 13.4 11.6 
66.5 15.9 13.4 
72.5 18.8 14.5 
86.5 24.1 17.2 
30.5 22.0 14.3 15.1 
36.5 18.6 19.3 
56.5 23.8 25.2 
66.5 27.7 28.1 
72.5 34.3 30.1 
36.0 36.5 36.4 35.9 
56.5 46.3 45.3 
66.5 52.3 50.5 
72.5 53.6 53.6 
86.5 57.4 60.8 
40.7 9.50 28.1 33.4 
22.0 42.0 41.9 
36.5 51.0 51.8 
66.5 70.3 72.1 
72.5 76.0 76.2 
86.5 86.0 85.7 
45.5 22.0 57.4 60.4 
36.5 71.2 73.9 
66.5 105 102 
86.5 125 120 
cis-(pyh 20.9 15.0 13.2 14.4 
40.0 17.3 18.1 
55.0 18.9 20.3 
70.0 21.1 22.5 
85.5 23.7 24.7 
28.8 15.0 26.1 24.7 
25.5 29.0 27.8 
55.0 38.0 32.1 
70.0 42.0 40.1 
85.5 46.7 45.6 
39.4 15.0 44.9 43.9 
25.5 49.5 50.0 
40.0 57.4 58.4 
55.0 66.3 67.0 
70.0 78.2 75.7 
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85.5 83.7 84.7 
46.0 15.0 62.2 61.2 
25.5 73.7 72.4 
40.5 93.6 88.4 
55.5 105 104 
70.0 126 120 
en 21.7 32.0 18.2 18.9 
67.0 35.3 35.7 
72.5 37.6 38.3 
86.5 45.1 45.0 
25.9 32.0 24.5 28.4 
42.0 33.1 35.4 
67.0 49.3 52.9 
72.5 55.7 56.7 
86.5 65.5 66.6 
31.6 32.0 43.3 45.2 
42.0 50.6 56.2 
67.0 84.9 84.0 
86.5 108 106 
40.8 32.0 87.2 101 
42.0 121 126 
67.0 190 188 
86.5 251 237 
chxn 12.3 10.0 10.5 10.1 
30.0 16.5 17.2 
41.5 21.5 21.3 
65.5 24.2 29.9 
19.2 10.0 15.1 16.4 
21.0 21.6 22.3 
30.0 27.2 27.2 
41.5 30.9 33.4 
65.5 44.5 46.4 
24.0 10.0 21.7 24.7 
21.0 34.9 34.8 
30.0 43.9 43.0 
41.0 53.5 53.1 
65.5 74.1 75.5 
29.0 10.0 41.3 37.4 
21.0 52.8 52.7 
30.0 65.6 65.2 
41.0 80.1 80.5 
65.5 115 115 
33.5 10.0 61.3 51.7 
21.0 71.1 72.4 
30.0 92.3 89.2 
41.0 112 110 
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Me2tn 13.4 32.0 11.1 12.2 
40.5 15.3 15.1 
55.0 20.5 19.9 
70.0 25.2 24.9 
85.5 30.0 30.1 
18.0 17.5 11.1 12.2 
32.0 19.9 19.4 
40.5 25.8 23.6 
55.0 31.9 30.9 
70.0 39.0 38.4 
85.5 45.8 46.2 
22.7 17.5 19.4 20.2 
32.0 30.1 31.0 
55.0 49.4 48.2 
70.0 60.7 59.4 
85.5 70.8 71.0 
28.0 17.5 37.6 36.7 
32.0 51.7 52.7 
55.0 77.0 78.0 
70.0 87.0 94.5 
85.5 108 117 
33.9 17.5 59.6 62.2 
32.0 85.2 86.4 
55.0 120 125 
70.0 146 150 
trans-(NH3)2 12.4 32.0 17.3 17.1 
43.0 20.6 20.7 
67.0 28.5 28.6 
86.5 35.4 35.1 
19.4 32.0 37.5 36.2 
43.0 45.8 45.3 
67.0 64.0 64.9 
72.5 72.1 69.5 
86.5 80.5 80.9 
25.2 32.0 59.5 59.6 
43.0 72.1 74.2 
67.0 106 106 
72.5 118 113 
86.5 130 132 
30.0 11.5 40.3 43.7 
22.0 57.8 62.6 
22.5 59.2 63.5 
43.0 104 100 
35.0 11.5 59.8 64.9 
22.5 102 102 
31.5 141 132 
43.0 174 170 
67.0 267 251 
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trans-(NH3) 2 c 35.5 21.5 10.3 12.9 
36.5 21.9 18.7 
51.5 23.5 24.6 
67.5 31.2 30.8 
82.0 38.7 36.5 
40.5 21.5 21.1 21.9 
36.5 32.6 32.0 
51.5 44.7 42.0 
67.5 50.7 52.7 
82.0 59.6 62.4 
43.8 21.5 27.5 30.7 
36.5 49.3 45.0 
51.5 59.4 59.2 
67.5 73.5 74.4 
82.0 98.6 88.2 
46.5 21.5 31.0 40.3 
36.5 61.1 59.0 
51.5 81.2 77.8 
67.5 99.6 97.8 
82.0 117 116 
51.5 21.5 52.2 65.4 
36.5 91.4 96.9 
51.5 122 128 
67.5 148 161 
82.0 186 191 
82.0 185 191 
"Based on the mean value from 20- 30 point-by-point calculations over 2- 3 half lives. The standard 
deviation from the mean was usually less than 2 %. b Calculated using the expression 
kobs = k1 + k_ 1[Br-] using the data from Table A3.4. c cr anation of trans-[PtCI(OH2)(NH3ht at 
235 nm, I= 0.1 M. 
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Table A3.4: Derived and calculated rate constants for the bromide anation of 
[PtBr(Nh(OHz)t (I= 1.0 M). 
(N)2 T 104lqa 104k1(calc)b l02k_1a 102k_1(calct 
(°C) (s-1) (s-1) (M-1s-1) (M-1s-1) 
cis-(NH3)2 19.3 2.0 2.1 1.30 1.25 
25.3 4.5 4.4 1.94 2.04 
30.5 8.6 8.2 2.94 3.10 
36.0 16 15 5.18 4.74 
40.7 27 26 6.78 6.74 
45.5 40 44 9.29 9.54 
cis-(py)2 20.9 12 13 1.46 1.48 
28.8 20 20 2.97 2.52 
39.4 35 34 5.78 6.32 
46.0 45 47 10.7 10.2 
en 21.7 3.5 3.7 4.80 4.76 
25.9 6.0 5.6 7.00 6.95 
31.6 9.6 9.6 11.1 11.4 
40.8 22 22 24.8 24.5 
chxn 12.3 6.5 6.4 3.57 3.36 
19.2 11 11 5.40 6.06 
24.0 16 16 9.14 8.79 
29.0 24 23 139 13.3 
33.5 33 32 18.7 18.8 
tn 18.6 2.0 2.2 5.60 5.67 
24.1 6.0 5.3 8.70 8.65 
31.5 16 16 15.2 14.9 
40.7 60 62 27.9 28.3 
Me2tn 13.4 1.5 1.5 3.35 3.37 
18.0 3.4 3.4 5.00 4.99 
22.7 7.8 8.0 7.47 7.33 
28.0 21 20 11.0 11.2 
33.9 33 37 16.7 17.0 
trans-(NH3h 12.4 6.5 6.6 3.2 3.5 
19.4 10 11 8.4 7.3 
25.2 17 16 13.3 12.9 
30.0 23 21 18.0 20.3 
35.0 27 29 33.4 32.1 
trans- 35.5 0.6 0.6 4.70 4.90 
(NH3)2 d 40.5 1.0 1.0 8.00 8.00 
43.8 1.6 1.5 12.0 11.1 
46.5 
51.5 
2.0 
3.0 
1.9 
3.2 
14.6 
21.8 
161 
14.4 
22.9 
"Estimated from the expression kobs = k1 + k_1[BrT b Calculated from the activation parameters cited 
in Table 3.5. c Calculated from the activation parameters cited in Table 3.4. d Data for the chloride 
anation of trans-[PtCl(OH2)(NH3ht (I = 0.1 M). 
Table A3.5: Kinetic data for the bromide anation of [Pt(N)z(OH2)z]2+ 
complexes (I = 1.0 M). 
(N)z T [B{] 10Lkobs k_za k_zo k_zc 
(oC) (mM) (s-1) (M-1s-1) (M-1s-1) (M-ls-1) 
cis-(NH3)2 18.4 50 1.20 0.24 0.23 0.24 
70.5 1.61 0.23 
90.5 2.04 0.22 
107.5 2.43 0.23 
120 2.84 0.24 
25.0 50 2.28 0.46 0.45 0.45 
70.5 3.14 0.45 
91.5 4.10 0.45 
107.5 4.83 0.45 
34.5 50 5.72 1.14 1.12 1.07 
70.5 7.74 1.10 
91.5 10.4 1.13 
107.5 12.4 1.15 
120 13.1 1.09 
43.9 50 11.4 2.28 2.33 2.41 
70.5 16.2 2.30 
91.5 21.1 2.30 
107.5 25.9 2.41 
120 28.1 2.34 
en 24.9 10 1.31 1.31 1.28 1.28 
20 2.57 1.28 
30 3.8 1.27 
40 5.17 1.29 
50 6.34 1.27 
34.4 10 3.13 3.13 3.17 3.19 
20 6.38 3.19 
30 9.49 3.16 
40 12.7 3.19 
50 16.0 3.19 
43.8 10 7.09 7.09 7.38 7.46 
20 14.8 7.40 
30 22.2 7.39 
40 29.9 7.47 
50 37.8 7.56 
50.4 10 13.2 13.2 13.3 13.2 
20 26.6 13.3 
30 39.2 13.1 
40 53.6 13.4 
50 67.7 13.5 
tn 24.7 10 1.82 1.87 1.82 1.81 
20 3.56 1.78 
30 5.45 1.82 
40 7.34 1.83 
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50 9.04 1.81 
34.4 10 4.71 4.71 4.46 4.44 
20 8.92 4.46 
30 13.1 4.37 
40 17.1 4.28 
50 22.5 4.50 
43.9 10 9.49 9.49 9.75 10.1 
20 20.7 10.4 
30 27.2 9.06 
40 38.5 9.62 
50 51.2 10.3 
51.4 10 18.9 18.9 19.2 18.8 
20 38.5 19.2 
30 57.7 19.2 
40 78.3 19.6 
50 96.2 19.2 
Me2tn 24.9 11 1.76 1.58 1.55 1.52 
20 3.12 1.56 
30 4.66 1.55 
40 6.13 1.53 
50 7.77 1.55 
34.5 11 3.74 3.40 3.39 3.55 
20 6.77 3.38 
30 9.93 3.31 
40 13.1 3.27 
50 18.0 3.60 
43.9 10 8.41 8.41 7.92 7.75 
11 9.25 8.15 
20 16.3 7.38 
30 22.2 7.29 
40 29.2 7.88 
50 39.4 8.41 
chxn 24.9 10 1.16 1.16 1.12 1.12 
20 2.21 1.11 
30 3.31 1.10 
40 4.44 1.11 
50 5.64 1.13 
34.5 10 3.05 3.05 2.80 2.78 
20 5.53 2.77 
30 8.42 2.81 
40 11.1 2.78 
50 13.0 2.61 
43.0 10 5.59 5.59 5.74 5.94 
20 10.8 5.41 
30 16.4 5.48 
40 24.5 6.13 
50 30.5 6.09 
50.0 10 11.4 11.4 11.1 10.8 
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20 21.5 10.7 
30 33.7 11.2 
40 44.7 11.2 
trans-(NH3)z 16.6 10 2.05 2.05 2.00 2.12 
20 3.95 1.98 
30 5.75 1.92 
40 8.00 2.00 
50 10.34 2.05 
24.9 10 4.74 4.74 4.50 4.19 
20 9.31 4.65 
30 13.46 4.49 
40 16.67 4.17 
50 22.15 4.43 
34.5 10 8.72 8.72 9.20 8.80 
20 18.4 9.22 
30 28. 9.59 
40 34.0 8.51 
50 49.9 9.98 
43.5 10 15.1 15.1 16.1 16.9 
20 31.3 15.7 
30 49.8 16.6 
40 66.0 16.5 
50 82.7 16.6 
"Calculated from the expression k_2 = kobs[BrT1• b Mean value of the data in Column 5. c Calculated 
from the activation parameters cited in Table 3.6. 
Table A3.6: Crystal data and structural refinement for [PtBr4(en)] (I) and 
[PtBr4(tn)] (II). 
Crystal Data 
(I) (II) 
Empirical formula C2HsBr4N2Pt C3HwBr4N2Pt 
Formula weight 574.83 588.86 
Crystal system monoclinic orthorhombic 
Space group C2/c Pnma 
Unit cell dimensions a= 10.414(3) A a= 12.666(4) A 
b = 8.356(2) A b = 9.789(5) A 
c = 11.651(9) A c = 8.352(3) A 
a= 90 o a= 90 o 
b = 112.77(3) 0 b = 90 ° 
c = 90 ° c = 90 ° 
Volume 934.8(8) A3 1035.5(7) A3 
z 4 4 
Density (calc) 4.084 g/cm3 3.777 g/cm3 
F(OOO) 1008 1040 
Linear absorption coefficient 32.035 mm-1 28.924 mm-1 
Temperature (K) 158(2) 158(2) 
Data Collection 
(I) (II) 
Diffractometer Siemens P4 Siemens P4 
Absorption correction From \jf scans From redundant 
(semi -empirical) data 
Max. and min. transmission 0.7470 and 0.3654 0.8433 and 0.1581 
Reflections collected 1085 1761 
Independent reflections 783 527 
e range 3.23-24.99 2.92-22.48 
Range of h, k and l -12~h~3 -10~h~ 10 
O~k~9 -10~k~ 10 
-13~1~13 0 ~ ~~ 5 
Refinement 
(I) (II) 
Method Full matrix least- Full matrix least-
squares on F2 squares on F2 
Data/restraints/parameters 783/12/42 527/18/52 
H -atom refinement no ref no ref 
Goodness-of-fit on F2 1.052 1.017 
Final R indices [I> 2cr(I)] R1 = 0.0680 R1 = 0.0669 
wR2 = 0.1534 wR2 = 0.1621 
R indices (all data) R1 = 0.0761 R1 = 0.0872 
wR2 = 0.1569 wR2 = 0.1709 
Largest diff. of peak and hole 7.155 2.051 
-5.721 e A-3 -3.479 e A-3 
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Table A3.7: Kinetic data for the pressure dependence on the anation of 
[Pt(N)z(OH2)z]2+ complexes (25 oc, I= 0.1 M). 
Reaction p 10Lkobsa, c lnkobs 
(MPa) (s-I) 
en+Cr 10 2.27 -3.785 
(283 nm) b 1.97 -3.925 
30 2.45 -3.709 
50 2.55 -3.669 
2.40 -3.729 
87.5 2.59 -3.655 
2.50 -3.688 
115 2.63 -3.640 
120 2.75 -3.594 
en+ Br- 10 10.1 -2.290 
(290 nm) b 25 10.7 -2.237 
50 11.5 -2.159 
75 12.3 -2.095 
100 12.7 -2.067 
120 13.1 -2.035 
cis-(NH3)2 + B{ 25 4.97 -3.003 
(300 nm)b 50 5.34 -2.929 
75 5.49 -2.903 
100 5.96 -2.821 
125 6.01 -2.812 
tn+B{ 10 13.2 -2.029 
(280nm)b 25 15.8 -1.843 
42 18.0 -1.715 
72.5 18.5 -1.687 
102.5 19.8 -1.618 
130 20.8 -1.571 
tn+Cr 25 3.31 -3.410 
(273 nm)b 52.5 3.59 -3.328 
75 3.87 -3.251 
100 4.19 -3.172 
127.5 4.46 -3.110 
a Mean of at least 4 kinetic traces. b Wavelength used to monitor the reaction. 
c [Cr] = [Br-] =50 mM. 
l:iV# 
(cm3 mor1) 
-5.27 ± 1.2 
-5.70 ± 0.5 
-5.08 ± 0.6 
-5.82 ± 1.0 
-7.41 ± 0.3 
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Table A3.8: Data for the pressure dependence on the anation of 
[Pt(N)zX(OH2)t complexes (25 oc, 0.1 M HC104). 
Complex p 102kobs (s-1) 102k_1a 
(MPa) [X-]= 0.5 0.75 1.0 1.25 (M) (M-1s-1) 
en+ crb 10 2.49 2.61 2.72 2.07 2.09 
(300 nmt 25 2.25 2.72 3.63 5.41 2.24 
50 2.44 3.00 4.95 5.95 2.42 
75 2.64 3.08 5.29 6.90 2.62 
100 2.74 3.14 5.56 8.35 2.70 
120 3.22 3.36 5.87 8.77 3.30 
en+Bf 10 - 5.08 6.67 8.46 4.67 
(315 nmt 25 4.04 5.69 7.29 8.47 4.97 
50 4.37 5.97 8.42 9.34 5.55 
75 4.73 6.38 8.81 10.4 6.00 
100 4.98 6.81 9.22 10.9 6.50 
120 5.23 6.91 9.51 11.4 7.20 
cis-(NH3)z + 25 1.38 2.14 2.47 2.55 1.47 
Br- 50 1.48 2.32 2.84 3.48 1.65 
(320 nmt 75 1.56 2.34 2.87 3.60 1.86 
100 1.63 2.52 2.95 3.70 2.10 
120 1.69 2.62 3.27 3.99 2.24 
tn + Br- 10 5.43 7.12 9.95 20.5 9.34 
(315 nm)c 25 6.59 11.1 11.9 21.1 12.0 
50 7.50 12.4 14.0 23.4 13.5 
75 8.58 12.6 16.6 26.2 14.7 
100 9.41 13.2 17.5 27.6 15.2 
120 9.75 14.3 18.6 29.5 16.4 
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11V# 
(cm3 mor1) 
-9.4 ± 0.5 
-7.43 ± 0.3 
-10.16 ± 0.4 
-10.4±0.8 
"Estimated from the slope of kobs vs P. b Measured at 304 K. c Wavelength used to monitor the 
reaction. 
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Table A4.1: Kinetic data for the reduction of platinum(IV) complexes by 
Sn(II) (1.0 M HCl). 
Complex T [Sn(II)] kobs kza k2b (calc) 
(oC) (mM) (104s-1) (M-1s-1) (M-1s-1) 
[PtC16]2- 14.2 0.36 650 181 190 
(330 nm) c 0.42 791 188 
0.48 975 203 
18.3 0.24 529 220 225 
0.31 709 229 
21.4 0.16 425 266 255 
0.22 556 250 
0.35 874 250 
cis- [PtCl4(NH3)z] 14.4 0.29 241 83.1 90.5 
(275 nm) c 0.38 300 78.9 
0.45 374 83.1 
0.49 408 83.3 
19.3 0.19 225 118 123 
0.31 332 107 
0.34 390 115 
23.6 0.24 396 165 160 
0.28 476 169 
0.38 618 163 
trans- [PtCl4(NH3)z] 14.8 0.38 261 68.7 62.6 
(275 nm) c 0.53 278 52.5 
0.78 480 61.5 
20.0 0.41 395 96.3 92.1 
0.46 454 98.7 
0.56 450 96.4 
30.0 0.23 376 164 186 
0.41 761 186 
0.56 1120 200 
a Calculated from the expression k2 = kobs[Sn(II)r1. b Calculated from the activation parameters cited in 
Table 4.1. cwavelength used to monitor the reaction. 
169 
Table A4.2: Kinetic data for the reduction of platinum(IV) complexes by 
ascorbic acid (0.1 M NaCl, pH=4.0). 
Complex T [HzAh kobs k(calc) a ket b 103Kos c 
(°C) (mM) (104s-J) (104s-t) (103s-1) 
[PtC16f 14.4 0.78 179 161 50.7 0.61 
(350 nm) d 1.5 260 239 
2.4 257 297 
19.5 0.78 405 329 96 0.67 
1.5 530 481 
2.4 529 592 
23.2 0.68 431 447 140 0.69 
1.5 667 712 
2.3 774 859 
26.9 0.68 605 629 210 0.63 
1.5 1040 1020 
2.9 1230 1360 
trans-[PtCl4(NH3)z] 14.2 0.4 30.9 31.4 5.1 4.0 
(350 nm)d 1.35 42.5 43.0 
2.16 50.9 45.7 
2.64 58.1 46.6 
19.0 1.35 54.3 50.2 6.0 3.8 
2.16 58.4 53.5 
2.64 66.0 54.6 
22.8 0.8 45.0 52.3 6.9 3.9 
1.5 57.6 58.9 
2.25 53.0 61.9 
3.0 57.0 63.6 
26.4 1.5 75.0 80.6 9.6 3.5 
2.25 90.0 85.2 
3.0 80.3 87.7 
30.5 0.78 96 93.7 11.5 5.7 
1.49 100 103 
2.25 103 107 
cis- [PtCl4(NH3)z] 14.3 0.78 36.2 34.7 5.7 2.0 
(330 nm) d 1.49 41.4 42.7 
2.25 47.9 46.6 
25.8 1.49 84.6 83.3 10 2.7 
2.25 84.6 89.3 
3.00 93 92.6 
30.5 0.78 85 85.4 13 2.3 
1.49 104 103 
2.25 110 111 
3.00 115 116 
"Calculated from llkobs llket + llketKos. b From the reciprocal plot (interceptr'. c From the 
reciprocal plot Kos ket (sloper'. d Wavelength used to monitor the reaction. 
Table A4.3: Kinetic data for the reduction of platinum(IV) complexes by 
hydroxylamine (0.1 M NaCl). 
Complex T [hyd] kobs k (calc) a ket b Kos c 
(oC) (mM) (104s-l) (104s-l) (103s-1) 
[PtC16]2- 35.0 10 6.12 5.92 1.04 132 
(350 nm) d 27 8.04 8.13 
6 4.70 4.59 
30 9.11 8.31 
6 4.47 4.59 
15 6.00 6.90 
21 7.38 7.65 
11.5 6.83 6.27 
46.5 62 25.9 23.3 1.53 111 
46 24.5 22.4 
36 23.2 21.5 
30 20.3 20.7 
25 18.8 19.8 
14 15.6 16.6 
7 15.9 12.1 
40.0 10 8.65 8.06 2.63 123 
22 11.2 11.3 
21 10.8 10.7 
14 8.47 9.34 
41 12.1 12.6 
58.5 12.2 13.3 
14 8.73 9.34 
41 11.7 12.6 
trans- [PtCl4(NH3)z] 31.0 46 12.7 5.92 7.66 74.0 
(325 nm) d 6.5 2.45 2.49 
56 11.7 6.17 
25 13.8 4.97 
12 3.67 3.60 
20 5.12 4.57 
70 6.27 6.27 
37.9 12 6.08 6.48 11.9 99.6 
26 9.15 8.58 
40 9.48 9.51 
17 7.46 7.48 
11 5.70 6.22 
8 4.92 5.28 
44.0 19 12.6 12.5 17.4 131 
22.5 14.3 13.0 
43 14.2 14.8 
32 12.9 14.0 
170 
9.5 9.90 9.63 
cis- [PtCl4(NH3)2] 36.0 7 1.13 1.14 3.58 66.5 
(270 nm) d 15 1.82 1.79 
40 2.73 2.60 
24 2.10 2.20 
20 20.6 2.04 
11 1.50 1.51 
46.0 20 5.56 5.68 8.90 88.2 
12 4.96 4.58 
14.5 4.77 4.99 
50 7.55 7.25 
19.5 5.49 5.63 
52.0 11 9.06 8.08 15.2 104 
30 17.1 17.5 
15 10.4 9.23 
12.5 8.96 8.56 
20 10.9 10.2 
40 10.9 12.2 
25 11.1 10.9 
" Calculated from 1/kobs = llket + llketKos· b From the reciprocal plot ket = (interceptY1. c From the 
reciprocal plot Kos ket = (slopeY1• d Wavelength used to monitor the reaction. 
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Table A4.4 Kinetic data for the reduction of platinum(IV) complexes by 
iron(II). 
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Complex T [Fe(II)] kobs 10Lk2° 10L 2 (calc) e 
coq (mM) (104s-1) (M-1s-1) (M-1s-1) 
[PtC16]2- a 14.9 5.5 5.9 10.7 11.5 
(355 nm) f 10.5 10.2 9.7 
15.5 16.5 10.6 
20 23.9 12.0 
20.5 5.5 11.7 21.3 18.7 
10.5 20.2 0.19.2 
15.5 30.5 19.8 
20 39.6 19.8 
25 50.3 20.1 
27 5.5 20.0 36.4 32.3 
10.5 32.3 30.8 
15.5 50.2 32.4 
20 66.3 33.2 
25 83.0 33.2 
35 5.5 31.1 56.5 61.0 
10.5 58.9 56.1 
15.5 93.2 60.1 
[PtC16]2- b 20 15.5 13.4 8.6 8.7 
(355 nm) f 20.5 17.6 8.6 
25.5 22.5 8.8 
31.0 28.3 9.1 
35.5 30.4 8.6 
25.5 15.5 20.2 13.0 13.7 
20.5 28.2 13.8 
25.5 35.2 13.8 
31.0 42.0 13.5 
35.5 50.0 14.1 
32 5 13.4 26.8 23.1 
15.5 34.8 22.4 
20.5 45.3 22.1 
25.5 58.3 22.9 
37 5.0 19.0 38.0 .34.0 
10.0 32.1 32.1 
15.5 48.8 31.4 
[PtC16]2- c 20 15.5 17.8 11.5 11.0 
(355 nm) f 20.5 22.6 11.0 
25.5 25.9 10.2 
30.5 33.9 11.1 
35.5 37.8 10.6 
26.5 10.5 18.3 17.4 17.5 
15.5 28.7 18.5 
20.5 36.5 17.5 
25.5 44.7 17.5 
30.5 54.9 18.3 
33.5 10.5 25.5 24.3 28.1 
15.5 50.9 32.8 
20.5 58.9 28.7 
25.5 71.9 28.2 
30.5 79.6 26.1 
cis-b [PtCl4(NH3)z] 40.0 38.5 2.17 56.4 59.8 
(380 nm) f 46.5 2.81 60.4 
56 3.28 58.6 
67 4.12 61.5 
77.5 4.81 62.0 
47.0 38.5 5.0 130 126 
46.5 6.34 136 
56 7.8 139 
67 9.34 139 
55.5 36 9.87 274 285 
48 13.4 279 
60 16.47 275 
76.5 20.76 271 
trans-[PtC14(NH3) 2]b 40.7 35.5 2.64 74.4 79.5 
(380 nm) f 43.5 3.82 87.8 
50 3.53 70.6 
59.5 4.63 77.8 
47.9 59.5 10.5 180 160 
51 8.51 170 
69 11.0 160 
35 6.23 180 
75 11.1 150 
54.7 36 10.87 300 301 
50 14.25 290 
64 18.4 290 
31 9.5 310 
26 7.2 280 
"0.1 M HCl. b 1.0 M HCl. c 1.0 M HC104• d Calculated from the expression k2 = kobs[Fe(II)r1• 
e Calculated from the activation parameters cited in Table 4.4. f Wavelength used to monitor the 
reaction. 
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Table A4.5: Kinetic data for the reduction of platinum(IV) complexes by 
thiosulfate (0.1 M NaCl). 
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Complex T [Sz032-] kobs l02kza 102kz (calc) b 
(°C) (mM) (1 04s-1) (M-ls-1) (M-ls-1) 
[PtC16]2- c 12.0 8 20.1 25.1 26.0 
(390 nm)c 12.5 29.9 23.9 
17.5 47.5 27.1 
22.5 62.2 27.6 
27.5 78.5 28.5 
18.5 8 26.4 33.0 38.8 
12.5 49.2 39.4 
17.5 72.0 41.1 
22.5 91.4 40.6 
27.5 107 39.0 
25.0 8 46.3 57.9 56.7 
8 41.4 51.7 
12.5 71.1 56.9 
17.5 100 57.4 
27.5 150 54.5 
30.0 8 60.9 76.1 75.1 
12.5 101 80.8 
cis- [PtCl4(NH3)z] 17.8 10 771 771 828 
(320 nm) c 20 1570 783 
30.5 2504 821 
40.5 3330 822 
51.5 4370 849 
24.9 10 1606 1610 1560 
20 3255 1630 
30.5 5098 1670 
40.5 6835 1690 
51.5 8343 1630 
32.4 10 2853 2850 2950 
20 5801 2900 
30.5 8592 2820 
40.5 11600 2870 
51.5 14700 2860 
40.9 10 5821 5820 5860 
20 11900 5960 
30.5 17900 5870 
40.5 23900 5900 
trans- [PtCl4(NH3)z] 25.0 10 1191 1190 1170 
(350 nm) c 20 2214 1110 
30.5 3726 1220 
40.5 4762 1180 
175 
51.5 6002 1170 
32.6 10 2114 2110 2180 
20 4464 2230 
30.5 6501 2130 
40.5 8918 2200 
51.5 11000 2140 
40.8 10 4086 4090 4120 
20 8198 4100 
30.5 12600 4140 
40.5 16600 4110 
51.5 21500 4180 
47.5 10 6849 6850 6770 
20 13600 6810 
40.5 27500 6790 
"Calculated from the expression k2 = kobs[S20 3 2T1• b Calculated from the activation parameters cited 
in Table 4.5. c Wavelength used to monitor the reaction. 
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Table A5.1: Kinetic data for the oxidation of neutral and positively charged 
platinum(II) complexes by peroxydisulfate. 
Complex T [S2ol-J kobs 102k2a 1 02k2( calc )b 
(OC) (mM) (1 04s-1) (M-1s-1) (M-1s-1) 
cis-(NH3)2 c 36 10 5.3 5.3 5.1 
(350 nm)e 20 10.6 5.3 
30 15.1 5.0 
40 20.1 5.0 
50 23.1 4.6 
42.8 10 7.12 7.1 7.1 
20 14.0 7.0 
30 20.9 7.0 
40 29.4 7.4 
50 36.1 7.2 
30.5 10 3.68 3.7 3.8 
20 7.38 3.7 
30 11.38 3.8 
40 16.8 4.2 
50 19.1 3.8 
chxnc 25.0 10 11.9 11.9 11.3 
(331 nmt 20 24.1 12.1 
30.8 37.2 12.2 
19.5 10 7.5 7.5 7.4 
30 21.7 7.2 
40 28.9 7.2 
20 13.8 6.9 
30.5 25 39.0 15.6 16.9 
8.4 13.6 16.2 
20 33.5 16.8 
30 51.5 17.2 
carboplatin d 22.5 10 16.9 16.9 16.9 
(350 nm) e 20 32.2 16.1 
30 50.6 16.9 
40 70.0 17.5 
17.5 10 12.2 12.2 11.4 
20 21.5 10.8 
30 35.6 11.9 
12 20 14.0 7.0 7.3 
30 21.0 7.0 
40 31.3 7.8 
50 39.3 7.9 
[Pt(NH3)4]2+ c 10.8 42.5 564.7 133 140 
(275 nm) e 50 692.6 138 
61 760.3 125 
74 1156 156 
82.5 1257 148 
18.4 10 188.6 189 196 
20 400.3 200 
40 689.4 174 
60 1270 212 
80 1668 209 
23.2 7 155.1 221 240 
10 257.6 258 
25 610.1 244 
50 1208 241 
70 1637 234 
[Pt( en )zf+ c 12.3 12.5 526.3 421 440 
(275 nmt 22 992.7 451 
30 1445 482 
43 1920 446 
60 2704 451 
18.0 10 595.2 595 646 
20 1276 638 
30 1980 660 
40 2564 641 
50 2887 577 
25.1 10 1059 1060 1020 
20 1965 983 
30 3247 1080 
40 3976 994 
50 5401 1080 
a Calculated using Equation (5 .2). b Calculated from the activation parameters cited in Table 5 .1. 
c 1.0 M HCl. d 1.0 M HC104• e Wavelength used to monitor the reaction. 
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Table A5.2: Kinetic parameters for the oxidation of negatively charged 
platinum(II) complexes by peroxydisulfate (1.0 M HCl). 
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Complex T [SzOs'"-] kobs 10'"koa 10Lk0(calc) 0 
(oC) (rnM) (104Ms-1) (s-1) (s-1) 
[Pt(ox)2]L- 13 0.67 2.54 37.9 43.0 
(285 nrn)c 1.0 4.95 49.5 
1.5 5.72 35.1 
17 0.25 2.48 99.2 73.0 
0.58 4.61 83.7 
1.0 6.8 68.2 
1.5 12.6 83.8 
22.6 0.25 4.53 181.0 145 
0.5 6.65 133.0 
1.0 14.0 140.0 
1.5 24.4 163 
[PtC}z(ox)f- 13.0 2 1.8 9.1 10.5 
(305 nrn)c 3.8 3.7 9.7 
5 6.0 12.0 
6.5 7.7 11.8 
17.7 2.5 4.87 19.5 18.6 
4.1 7.1 18.5 
5.5 10.2 17.3 
22.5 1.33 4.0 30.1 32.4 
5.4 19.1 354 
[PtCI4f 30.5 10 1.0 1.0 1.2 
(340 nrn)c 20 2.0 1.1 
30 4.1 1.4 
40 5.7 1.4 
50 6.6 1.3 
36 10 2.2 2.2 2.7 
20 5.8 2.9 
30 9.0 3.0 
40 11.5 2.9 
45 13.2 2.9 
50 14.0 2.8 
42.5 10 5.7 5.7 6.3 
15 8.9 6.0 
20 12.6 6.3 
25 16.4 6.6 
35 23.0 6.6 
40 28.7 7.1 
"Calculated using Equation (5.4). b Calculated from the activation parameters cited in Table 5.1. 
c Wavelength used to monitor the reaction. 
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Table A5.3: Kinetic data for the oxidation of platinum(II) complexes by H20 2 
(1.0 M HCl04). 
Complex T [H202] kobs 103k2a 103k2 (calc) b 
CO C) (mM) (104s-I) (M-Is-1) (M-Is-1) 
carboplatin 25.0 35 7.50 21.4 18.0 
(315 nm) c 55 10.5 19.1 
83 15.7 18.9 
98.5 18.7 19.0 
112.5 20.9 18.6 
31.5 45.5 13.4 29.5 28.9 
60 17.6 29.3 
82.5 23.1 28.0 
105 29.6 28.2 
130 36.7 28.2 
38.0 38.5 18.7 48.6 45.6 
59.5 27.3 45.9 
89 35.4 39.8 
100 45.1 45.1 
19.5 49 5.50 11.0 11.8 
111 12.9 11.6 
170 19.3 11.4 
63.5 7.00 11.0 
[PtCl4]2- 28.5 50 3.24 6.48 6.14 
(380 nm) c 60 3.90 6.50 
98 6.10 6.22 
115 7.33 6.37 
135 8.00 5.90 
35.5 40 4.71 11.8 12.5 
60 8.10 13.5 
80 9.70 12.1 
88 9.65 11.0 
132 14.6 11.1 
42.0 33 7.80 23.6 23.6 
42 10.5 25.0 
50 12.8 25.6 
70 16.3 23.3 
98 21.2 23.6 
[Pt(en)2]2+ 30.0 50 2.91 5.82 5.97 
(335 nm) c 55 3.01 5.47 
77 4.96 6.44 
82.5 5.27 6.39 
115 7.34 6.38 
35.0 50 4.37 8.73 9.51 
55 5.18 9.42 
180 
87 7.90 9.08 
116 10.8 9.31 
40.5 51.5 8.33 16.1 15.6 
65.5 10.8 16.5 
85.5 13.3 15.5 . 
100 15.5 15.5 
[Pt(NH3)4]2+ 30.0 60 3.03 5.05 4.98 
(335 nm) c 83.5 3.9 4.70 
117.5 5.71 4.86 
140 7.33 5.24 
143.5 7.63 5.10 
36.5 80.5 6.95 8.63 8.83 
91 8.04 8.84 
128 11.4 8.93 
138 12.2 8.84 
146.5 12.74 8.64 
42.0 62 8.97 14.5 14.1 
79.5 10.3 30.0 
107.5 15.96 14.9 
131.5 18.75 14.3 
[Pt(oxhf 12 13.5 7.44 55.1 55. 6 
(360 nm) c 18.75 10.2 54.5 
27.5 15.2 55.3 
38.5 21.3 55.3 
17.3 15 13.5 90.0 85.5 
22 18.7 85.0 
30 25.2 84.0 
50 44.9 89.8 
22.1 14 17.5 125 125 
30 37.7 126 
35 42.0 120 
45 55.0 122 
cis-(NH3)2 42 35 9.30 26.6 26.6 
(350 nm) c 56 15.3 27.3 
80 20.8 26.0 
97 25.6 26.4 
113 30.6 27.0 
36 30 5.50 18.3 18.4 
50 9.70 19.4 
65 12.6 19.4 
75 13.1 17.5 
116 20.2 17.4 
31 40 5.61 14.0 13.4 
50 6.10 12.2 
80 10.7 13.4 
95 13.0 13.7 
105 14.3 13.6 
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120 16.2 13.5 
chxn 20.0 27.5 5.82 21.2 22.1 
(331 nm) c 45.5 9.96 21.9 
72.5 14.6 20.2 
90 19.7 21.9 
140 31.1 22.2 
15.0 30 4.58 15.3 14.4 
40.5 6.28 15.5 
64 8.88 13.9 
83 11.7 14.0 
25.0 28 10.3 36.8 33.6 
39 13.2 33.8 
51.5 16.6 32.2 
62 21.3 34.4 
" Calculated using Equation (5.14 ). b Calculated from the activation parameters cited in Table 5 .2. 
c Wavelength used to monitor the reaction. 
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Table A5.4: Kinetic data for the oxidation of platinum(II) complexes by 
permanganate (0.1 M HC104). 
Complex T [Pt(II)] kobs l0-3k2a 10-3 k2 (calc) 
(°C) (mM) (s-1) (M-1s-1) b 
(M-1s-1) 
[PtCl4]2- 15.6 3.44 77.1 22.4 22.6 
(520 nm) c 2.31 53.4 23.1 
1.88 40.4 21.5 
1.35 30.3 22.4 
0.96 20.5 21.3 
0.96 21.7 22.6 
24.9 0.70 26.7 38.2 34.3 
1.20 44.1 36.8 
2.19 77.5 35.4 
1.73 62.3 36.0 
3.32 109 32.8 
34.9 0.77 39.3 51.0 52.1 
1.30 65.8 50.6 
1.73 88.0 50.9 
2.22 116 52.1 
3.13 157 50.2 
[Pt(NH3)4]2+ 15.0 0.71 95.3 134 133 
(520 nm) c 0.71 95.9 135 
1.245 167 134 
1.245 168 135 
1.865 251 134 
1.865 250 134 
3.11 415 133 
3.11 418 134 
19.8 0.71 110 155 160 
0.71 110 155 
1.245 194 155 
1.245 194 156 
1.865 289 155 
1.865 290 156 
3.11 483 155 
3.11 485 156 
25.0 0.71 140 196 194 
0.71 140 196 
1.245 246 198 
1.245 244 196 
1.865 367 197 
1.865 368 197 
3.11 611 196 
3.11 614 197 
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[Pt(en)2]2+ 10.5 0.625 149 238 175 
(520 nm) c 1.25 219 175 
1.875 328 175 
3.125 550 176 
15.5 0.625 136 218 218 
1.25 286 229 
1.875 402 214 
3.125 676 216 
20.2 0.625 169 270 265 
1.25 325 260 
1.875 504 269 
3.125 826 264 
25.0 0.625 203 324 312 
0.625 198 316 
1.25 408 326 
1.875 615 328 
3.125 914 318 
carboplatin 11.0 0.63 35.5 71.1 71.8 
(520 nm) c 1.26 89.2 70.8 
1.89 135 71.2 
3.15 222 70.3 
14.5 0.63 50.6 80.3 79.3 
1.26 102 81.7 
1.89 152 80.4 
3.15 257 81.1 
19.0 0.63 56.3 89.4 89.8 
1.26 112 89.0 
1.89 170 89.7 
3.15 285 90.6 
23.0 0.63 60.4 95.9 100 
1.26 125 99.0 
1.89 192 101 
3.15 322 102 
"Calculated using Equation (5.17). b Calculated from the activation parameters cited in Table 5.3. 
cwavelength used to monitor the reaction. 
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Table A5.5: Kinetic data for the effect of copper(II) on the rate of oxidation of 
[PtCl4] 2" by peroxydisulfate (20 mM, 1.0 M HCI). 
T [Cu:t+] kobs kcua kcu0 kcuc 
(OC) (104M) (104Ms-1) (M-1s-1) (M-1s-1) (M-1s-1) 
30 0 2.2 - 52.5 51.9 
2.5 4.5 49 
3 5.8 55 
4 6.6 60 
5 7.1 46 
36 0 6 - 107 109 
1.25 9.7 124 
2 9.7 92.5 
2.5 11.8 116 
3 12.5 109 
4 13.9 99 
5 16.0 100 
43 0 13 - 255 252 
2.5 26 260 
3 28 250 
4 32 240 
5 40 270 
"Calculated from the expression kcu = ((kobs- intercept)/[Cu2+])/[S20 82T b Mean value of 
Column 4. c Calculated from the activation parameters cited in Table 5.1. 
Table 5.6: 
Complex 
Kinetic data for the oxidation of platinum(II) complexes by 
dichromate (I = 1.0 M HC104). 
T k2a k2 (calc)b 
(OC) (M-1s-1) (M-1s-1) 
carboplatin 14.8 2.63 2.67 
21.1 3.57 3.63 
25.0 4.74 4.37 
29.8 5.19 5.45 
[PtCl4} 2- 14.6 11.32 11.18 
18.7 12.24 12.55 
23.0 14.45 14.13 
28.0 15.98 16.15 
35.0 19.10 19.32 
39.0 21.60 21.33 
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" Calculated from the slope of kobs vs [Cr20 7 2-] plots. b Calculated from the activation parameters cited 
in Table 5.4. 
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Table A6.1: Kinetic data for the base hydrolysis of [PtCI(NH3) 5] 3+, trans-
[PtClz(NH3)4]2+ and trans-[PtC}z(enh]2+ (I= 1.0 M). 
Complex T [OH-] kobs koH koH(calc) 
(°C) (M) (104s-l) (103M-ls-I) (103M-ls-I) 
trans-[PtC!z(NH3)4]u 37 0.4 3.12 0.78 1.27 
0.6 4.15 1.04 
0.8 8.87 1.48 
1.0 12.6 1.26 
44.2 0.2 6.27 3.14 2.74 
0.4 11.2 2.80 
0.6 13.9 2.32 
0.8 23.6 2.95 
48.5 0.2 8.07 4.04 4.27 
0.6 25.1 4.18 
0.8 34.9 4.37 
1.0 43.0 4.30 
54.2 0.2 15.8 7.89 7.52 
0.4 34.0 8.49 
0.6 45.0 7.50 
0.8 60.2 7.52 
1.0 76.6 7.66 
59 1.0 83.3 8.33 9.87 
trans- [PtClz( en )zf+ 35.8 0.4 2.55 6.38 4.35 
0.6 2.69 4.48 
0.8 2.67 4.58 
1.0 3.38 3.38 
42.5 0.4 5.23 13.1 10.4 
46 0.4 7.03 17.6 16.2 
0.6 10.1 16.8 
0.8 12.4 15.5 
1.0 15.7 15.7 
54 0.4 21.8 54.5 56.6 
0.6 31.8 53.1 
1.0 51.4 51.4 
0.4 1.78 4.45 
[PtCI(NH3)s]3+ 41.5 0.6 2.41 4.02 4.34 
0.8 3.78 4.10 
1.0 4.49 4.49 
0.4 4.49 11.2 11.3 
47.9 0.6 8.10 13.3 
0.8 8.97 11.2 
1.0 10.8 10.8 
0.4 14.8 37.0 39.8 
56.8 0.6 24.9 41.5 
0.8 31.2 39.0 
1.0 39.8 39.8 
a 
-
- b Calculated from the expressiOn koH- kob/[OH ]. Calculated fiom the actlvatlon parameters c1ted 
in Table 6.1. 
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Table A6.2: Kinetic data for the base hydrolysis of cis- and trans-
[PtC14(NH3h] (I = 1.0 M). 
Complex T [OH-] kobs koHa koH (calct 
(oC) (mM) (104s-1) (103M-ls-I) (103M-1s-1) 
cis-[PtC14 (NH3)2J 39.9 35 1.86 5.31 5.05 
35 1.95 5.57 
45 2.07 4.61 
46.6 25 2.98 11.9 12.3 
34 4.16 11.9 
45 5.61 12.5 
50.0 15 2.46 16.4 19.0 
53.0 15 5.09 34.0 27.8 
25 7.59 30.4 
35 9.13 26.1 
45 11.4 25.3 
trans-[PtCl4(NH3)2J 32.4 70 1.53 2.18 2.04 
34.8 90 1.82 2.02 2.81 
38.5 100 2.93 2.90 4.45 
45.4 10 1.51 15.1 10.8 
30 4.01 13.4 
50 7.73 15.5 
70 8.74 12.5 
90 13.2 14.7 
50.5 100 23.7 23.7 20.1 
53.0 10 2.86 28.6 27.0 
30 9.47 31.6 
50 12.0 23.9 
70 16.1 23.1 
90 19.8 22.0 
55.6 10 4.93 49.3 36.5 
30 10.2 34.1 
50 18.1 36.2 
70 31.1 35.1 
90 22.4 32.0 
57.6 100 58.1 58.1 45.9 
61.5 10 5.08 50.8 71.3 
30 17.7 59.1 
a Calculated from the expression k0 H = kob/[OR]. b Calculated from the activation parameters cited 
in Table 6.1. 
Table A6.3: Crystal data and structure refinement for trans-
[PtCI2( en h] (Zn Cl4). 
Empirical formula 
Formula weight 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
z 
Density (calc) 
F(OOO) 
Linear absorption coefficient 
Temperature (K) 
Diffractometer 
Absorption conection 
(semi-empirical) 
Reflections collected 
Independent reflections 
e range 
Range of h, k and l 
Method 
Data/restraints/parameters 
H -atom refinement 
Goodness-of-fit on F2 
Final R indices [I> 2cr(l)] 
R indices (all data) 
Largest diff. of peak and hole 
Crystal Data 
Data Collection 
Refinement 
C4H14Cl6N4PtZn 
591.35 
monoclinic 
P21/c 
a 14.8584(3) A 
b = 7.48070(10) A 
c = 14.5118(3) A 
a= 90 ° 
~ = 108.2170(10) 0 
y=90 ° 
1532.16(5) A3 
4 
2.564 mg/m3 
1104 
11.712 mm·1 
-129 K 
Siemens P4 
From redundant data 
5900 
2166 
3.08 to 23.31 o 
-16shs 16 
-8 s ks 7 
-16 s l s 16 
Full matrix least-squares on F'" 
2166/0/133 
no ref 
1.216 
R1 0.0465 
wR2 = 0.1211 
R 1 = 0.0522 
wR2 = 0.1247 
2.998 and -3.178 e A"3 
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